The mechanisms and consequences of haemodialysis induced acute cardiac injury by Burton, James O.
Burton, James O. (2009) The mechanisms and 
consequences of haemodialysis induced acute cardiac 
injury. DM thesis, University of Nottingham. 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/10662/1/Thesis_-_final_draft_with_revisions.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
· Copyright and all moral rights to the version of the paper presented here belong to 
the individual author(s) and/or other copyright owners.
· To the extent reasonable and practicable the material made available in Nottingham 
ePrints has been checked for eligibility before being made available.
· Copies of full items can be used for personal research or study, educational, or not-
for-profit purposes without prior permission or charge provided that the authors, title 
and full bibliographic details are credited, a hyperlink and/or URL is given for the 
original metadata page and the content is not changed in any way.
· Quotations or similar reproductions must be sufficiently acknowledged.
Please see our full end user licence at: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf 
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
  
 
THE MECHANISMS AND CONSEQUENCES OF 
HAEMODIALYSIS INDUCED ACUTE CARDIAC 
INJURY 
 
 
James O Burton 
BA (Hons), MB ChB (Hons), MRCP (UK). 
 
 
Thesis submitted to the 
School of Graduate Entry Medicine and Health, 
University of Nottingham for the degree of 
DOCTOR OF MEDICINE 
 
 
 
January 2009 
 
  
 
 
 
µ7KHLPSRUWDQWWKLQJLVQRWWRVWRSTXHVWLRQLQJ¶ 
 
 
Albert Einstein (1879 ± 1955) 
 
  
 
 
 
For 
Hen, Felix and Charlotte. 
 
 
 i 
Table of Contents 
Table of Contents ..................................................................................... i 
Table of Figures..................................................................................... viii 
Abstract ................................................................................................. xiii 
Declaration ............................................................................................ xv 
Acknowledgements .............................................................................. xvii 
Publications and abstracts arising from this thesis ................................xix 
Peer reviewed publications .............................................................. xix 
Oral presentations ............................................................................. xx 
Poster presentations ........................................................................ xxi 
1 Introduction....................................................................................... 2 
1.1 End stage renal disease .......................................................... 2 
1.1.1 Background ........................................................................ 2 
1.1.2 Epidemiology ..................................................................... 3 
1.1.3 Health service implications ................................................ 7 
1.2 Renal replacement therapy ..................................................... 7 
1.2.1 Background ........................................................................ 7 
1.2.2 Haemodialysis ................................................................... 9 
1.3 Cardiovascular disease in dialysis patients ........................... 12 
1.3.1 Epidemiology ................................................................... 12 
1.3.2 Risk factors ...................................................................... 14 
1.3.3 Left ventricular hypertrophy ............................................. 17 
1.3.4 Myocardial ischaemia and haemodialysis ........................ 18 
1.3.5 Dialysis induced acute myocardial stunning .................... 21 
1.3.6 Myocardial hibernation and fibrosis.................................. 24 
 ii 
1.3.7 Ischaemic preconditioning ............................................... 26 
1.3.8 Cardiac troponins in haemodialysis patients .................... 27 
1.3.9 Haemodialysis and cardiac arrhythmias .......................... 29 
1.3.10 Intra-dialytic hypotension and ultrafiltration rate ........... 31 
1.3.11 Cardiac failure .............................................................. 35 
1.3.12 Summary ...................................................................... 36 
2 Thesis aims .................................................................................... 39 
2.1 Hypothesis ............................................................................ 39 
2.2 Research questions .............................................................. 39 
3 Methodology ................................................................................... 42 
3.1 Applications for ethical approval ............................................ 42 
3.2 Patient recruitment ................................................................ 43 
3.3 Non invasive haemodynamic measurements ........................ 45 
3.3.1 Continuous measurement of blood pressure (the 
Finometer®) ...................................................................... 45 
3.3.2 Serial measurements of blood pressure .......................... 48 
3.4 Echocardiography ................................................................. 48 
3.4.1 Measurement of intra-observer reliability ......................... 52 
3.5 Dialysis methodology ............................................................ 53 
3.5.1 Blood volume measurement ............................................ 53 
3.5.2 Conductivity measurement and ionic dialysance ............. 54 
3.5.3 Dialysis technique ............................................................ 55 
3.6 Positron emission tomography .............................................. 55 
3.6.1 Measurement of regional myocardial perfusion ............... 55 
3.6.2 Analysis of myocardial perfusion data.............................. 59 
 iii 
3.7 Continuous ECG recording ................................................... 61 
3.7.1 Holter monitoring.............................................................. 61 
3.7.2 Analysis of Holter data ..................................................... 62 
3.8 Haematological and biochemical assays............................... 63 
3.8.1 Cardiac troponin-T ........................................................... 63 
3.8.2 High sensitivity C-reactive protein .................................... 64 
3.8.3 Dialysis adequacy ............................................................ 65 
3.9 Statistical methods ................................................................ 65 
4 Results: Haemodialysis induced contractile dysfunction is 
associated with acute and reversible reduction in global and 
segmental myocardial blood flow. ................................................. 67 
4.1 Introduction ........................................................................... 67 
4.2 Methods ................................................................................ 68 
4.2.1 Patients ............................................................................ 68 
4.2.2 Study protocol .................................................................. 69 
4.2.3 Haemodialysis details ...................................................... 71 
4.2.4 Positron emission tomography (PET) .............................. 71 
4.2.5 Echocardiography ............................................................ 72 
4.2.6 Finometer ......................................................................... 72 
4.3 Statistical analysis ................................................................. 73 
4.4 Results .................................................................................. 74 
4.4.1 Echocardiographic Data ................................................... 74 
4.4.2 PET Data ......................................................................... 74 
4.4.3 Haemodynamic data ........................................................ 81 
4.4.4 Laboratory data ................................................................ 83 
 iv 
4.5 Discussion ............................................................................. 84 
4.6 Conclusions ........................................................................... 87 
5 Results: Haemodialysis induced cardiac injury: prevalence and 
associated factors.......................................................................... 90 
5.1 Introduction ........................................................................... 90 
5.2 Methods ................................................................................ 91 
5.2.1 Patients ............................................................................ 91 
5.2.2 Study protocol .................................................................. 92 
5.2.3 Haemodialysis details ...................................................... 93 
5.2.4 Echocardiography ............................................................ 93 
5.2.5 Blood pressure ................................................................. 94 
5.2.6 Haematological and biochemical variables ...................... 94 
5.3 Statistical analysis ................................................................. 95 
5.4 Results .................................................................................. 95 
5.4.1 Prevalence of regional wall motion abnormalities ............ 95 
5.4.2 Severity of regional wall motion abnormalities ................. 96 
5.4.3 Patient characteristics and dialysis related factors 
associated with the presence of myocardial stunning ...... 98 
5.4.4 Haematological and biochemical variables associated with 
the presence of myocardial stunning ............................. 101 
5.4.5 Intradialytic blood pressure and myocardial stunning .... 103 
5.4.6 Factors associated with severity of myocardial stunning 105 
5.4.7 Multivariate analysis of factors associated with myocardial 
stunning ......................................................................... 106 
5.5 Discussion ........................................................................... 107 
 v 
5.6 Conclusions ......................................................................... 111 
6 Results: Haemodialysis induced left ventricular dysfunction is 
associated with an increase in ventricular arrhythmias. ............... 113 
6.1 Introduction ......................................................................... 113 
6.2 Methods .............................................................................. 114 
6.2.1 Patients .......................................................................... 114 
6.2.2 Study protocol ................................................................ 115 
6.2.3 Haemodialysis details .................................................... 116 
6.2.4 Continuous ECG monitoring (Holter) ............................. 116 
6.2.5 Echocardiography .......................................................... 117 
6.3 Statistical analysis ............................................................... 118 
6.4 Results ................................................................................ 118 
6.4.1 Haemodialysis induced echocardiographic dysfunction . 118 
6.4.2 Prevalence and associations of ventricular ectopy ........ 118 
6.4.3 Prevalence and associations of ventricular complexity 
(Lown Score) ................................................................. 125 
6.5 Discussion ........................................................................... 127 
6.6 Conclusions ......................................................................... 131 
7 Results: Haemodialysis induced repetitive myocardial stunning 
results in both global and regional reductions in left ventricular 
function ........................................................................................ 134 
7.1 Introduction ......................................................................... 134 
7.2 Methods .............................................................................. 135 
7.2.1 Patients .......................................................................... 135 
7.2.2 Study protocol ................................................................ 136 
 vi 
7.2.3 Haemodialysis details .................................................... 137 
7.2.4 Follow-up collection of study data .................................. 137 
7.2.5 Definitions of HD-induced cardiac dysfunction ............... 137 
7.3 Statistical analysis ............................................................... 138 
7.4 Results ................................................................................ 139 
7.4.1 Prevalence of regional wall motion abnormalities after 12-
months ........................................................................... 139 
7.4.2 Incidence of new regional wall motion abnormalities after 
12-months ...................................................................... 139 
7.4.3 Effect of myocardial stunning on global left ventricular 
function after 12-months ................................................ 140 
7.4.4 Effect of myocardial stunning on systolic blood pressure 
over 12 months .............................................................. 142 
7.4.5 Progression of myocardial stunning to fixed systolic  ........... 
 dysfunction (myocardial hibernation) ............................. 142 
7.5 Discussion ........................................................................... 149 
7.5.1 Study limitations ............................................................. 155 
7.5.2 Conclusions ................................................................... 156 
8 Results: Haemodialysis induced repetitive myocardial stunning is 
associated with an increased hazard of death and time to first 
cardiovascular event .................................................................... 158 
8.1 Introduction ......................................................................... 158 
8.2 Methods .............................................................................. 159 
8.2.1 Study protocol ................................................................ 159 
8.2.2 Haemodialysis details .................................................... 160 
 vii 
8.2.3 Collection of study data .................................................. 160 
8.3 Statistical analysis ............................................................... 160 
8.4 Results ................................................................................ 161 
8.4.1 Myocardial stunning is associated with a decreased 12 
month survival ................................................................ 161 
8.4.2 Myocardial stunning is associated with an increased 
cardiovascular event rate ............................................... 161 
8.4.3 Baseline troponin-T concentrations were associated with 
an increased mortality .................................................... 164 
8.5 Discussion ........................................................................... 166 
8.6 Conclusions ......................................................................... 168 
9 Conclusions .................................................................................. 171 
9.1 Limitations ........................................................................... 176 
9.2 Future work ......................................................................... 179 
10 Abbreviations ................................................................................ 183 
11 References ................................................................................... 189 
 
 viii 
Table of Figures 
Table 1.1.1a: The stages of chronic kidney disease ................................ 3 
Figure 1.1.2a: Prevalence of chronic kidney disease (stages 1-4) by age 
group in the National Health and Nutrition Examination Surveys .... 5 
Table 1.1.2a: Expected incidence and prevalence rates for ESRD in the 
United States up to 2020 ................................................................. 6 
Figure 1.2.1a: Patient numbers and modalities of treatment in ESRD 
patients requiring renal replacement therapy .................................. 8 
Figure 1.2.2a: A standard haemodialysis machine .................................. 9 
Figure 1.3.1a: The relative risk of cardiovascular events with respect to 
eGFR ............................................................................................. 12 
Figure 1.3.1b: Graph showing the cardiovascular mortality rates by age 
and ethnicity for dialysis patients and healthy controls .................. 13 
Figure 1.3.3a: LVH reduces survival in dialysis patients ........................ 18 
Figure 1.3.5a: The effect of brief coronary occlusion on systolic function21 
Figure 1.3.5b: The effect of repetitive myocardial stunning on contractile 
function .......................................................................................... 23 
Figure 1.3.8a: Kaplan-Meier survival plots for haemodialysis patients 
with normal (solid line) and clinically raised (dotted line) troponin-T 
levels ............................................................................................. 28 
Figure 1.3.10a: After adjustment for demographics (case-mix) and 
surrogates of malnutrition-inflammation complex syndrome 
(MICS), higher weight gain between HD sessions was associated 
with increased all-cause mortality .................................................. 32 
 ix 
Figure 3.2a: Patients recruited and their contribution to the collection of 
data and analysis of results in each chapter .................................. 43 
Figure 3.3.1a: The Finometer in isolation and connected to a subject... 46 
Figure 3.4a: Echo CMS software allows semi-automatic tracing of the 
endocardial border......................................................................... 49 
Figure 3.4b: The movement of the endocardial border is measured over 
100 chords around the left ventricle............................................... 51 
Figure 3.6.1a: Patient connected to the haemodialysis machine being 
studied in the PET scanner ........................................................... 58 
Table 3.7.2a: Lown Classification of ventricular arrhythmias ................. 62 
Table 4.2.1a: Patient demographics including angiographic indications 
and findings ................................................................................... 69 
Figure 4.4.2a: Mean global myocardial blood flow reduced significantly 
over time during dialysis compared to baseline ............................. 75 
Figures 4.4.2b and 4.4.2c: Regional myocardial blood flow is reduced 
over time on haemodialysis ........................................................... 76 
Figure 4.4.2d: Mean MBF during HD and BFD ...................................... 77 
Figure 4.4.2e: The development of RWMAs was associated with a 
greater reduction in MBF from baseline than those areas that 
maintained normal movement ....................................................... 78 
Figure 4.4.2f: The development of RWMAs was associated with a 
greater reduction in MBF at each timepoint than those areas that 
maintained normal movement ....................................................... 79 
 x 
)LJXUHJ$0%)UHGXFWLRQRIZDVDVVRFLDWHGZLWKDPHDQ
reduction in wall motion however a MBF reduction of <30% was 
associated with a mean increase in wall motion ............................ 81 
Figures 4.4.3a and 4.4.3b: A) Overall mean blood pressures between 
HD and BFD. BP was maintained higher on BFD (P<0.05). B) 
Heart rate increased similarly during both HD and BFD (P=ns) .... 82 
Table 4.4.4a: Laboratory data ............................................................... 83 
Figure 5.4.1a: Prevalence of haemodialysis induced left ventricular 
regional wall motion abnormalities (RWMAs) ................................ 96 
Figure 5.4.2a: Severity of regional wall motion abnormalities over time 
during haemodialysis ..................................................................... 97 
Figure 5.4.3a: Myocardial stunning and patient age .............................. 98 
Table 5.4.3a: Patient characteristics and dialysis related factors in all 
patients and in groups based on the presence (with) or absence 
(without) of dialysis induced regional wall motion abnormalities .... 99 
Figure 5.4.3b: Myocardial stunning and ultrafiltration volume .............. 100 
Table 5.4.4a: Baseline haematological and biochemical data stratified 
based on the presence (with) or absence (without) of 
haemodialysis induced myocardial stunning ............................... 101 
Figure 5.4.4a: Myocardial stunning and serum albumin ...................... 102 
Figure 5.4.4b: Myocardial stunning and cardiac troponin-T ................. 103 
Figure 5.4.5a: Reduction in systolic blood pressure (SBP) during 
haemodialysis (HD) in patients with and without HD-induced 
regional wall motion abnormalities .............................................. 104 
 xi 
Table 5.4.6a: Independent factors associated with the severity of 
myocardial stunning ..................................................................... 105 
Table 5.4.7a: The effect of increasing ultrafiltration (UF) volume and 
worsening intradialytic haemodynamics on the development of HD-
induced myocardial stunning ....................................................... 106 
Figure 6.4.2a: Frequency of premature ventricular complexes ............ 119 
Table 6.4.2a: Demographic characteristics of the patients .................. 120 
Table 6.4.2b: Biochemical data stratified according to frequency of 
PVCs ........................................................................................... 121 
Figure 6.4.2b: The effect of RWMA and HD on %PVCs ...................... 122 
Figure 6.4.2c:  The impact of IHD and LV morphology on PVCs ......... 124 
Figure 6.4.2a: Patients stratified according to Lown score .................. 125 
Table 4.3.3a: Biochemical data stratified according to Lown score ..... 126 
Figure 7.4.3a: Change in left ventricular ejection fraction at rest over 12 
months ......................................................................................... 140 
Figure 7.4.3b: Change in left ventricular ejection fraction during 
haemodynamic stress of HD over 12 months .............................. 141 
Table 7.4.5a: Demographics and dialysis related factors .................... 143 
Figure 7.4.5a: Change in regional SF over time .................................. 145 
Figure 7.4.5b: Change in EF at rest and during HD over 12 months in 
patients with fixed reductions in segmental function of >60% ..... 146 
Figure 7.4.5c: Changes in SBP during HD over 12 months ................. 147 
Table 7.4.5b: Pre- and Post-HD blood values ..................................... 148 
Figure 8.4.1a: The association of haemodialysis induced myocardial 
stunning with mortality ................................................................. 162 
 xii 
Figure 8.4.2a: The association of haemodialysis induced myocardial 
stunning with mortality and time to first cardiovascular event ...... 163 
Figure 8.4.3a: Cardiac troponin-T concentrations in patients with and 
without myocardial stunning at both baseline and after 12 months164 
Figure 8.4.3b: Baseline cardiac troponin-T levels were significantly 
higher in patients who died within 12 months (P<0.001) ............. 165 
 xiii 
Abstract 
Patients on dialysis are subject to a hugely elevated risk of 
cardiovascular mortality. Incidence and prevalence of, and mortality and 
morbidity from heart failure is significantly higher in the haemodialysis 
population than the general population as a whole. This thesis 
describes research work focusing on the large scale haemodynamic 
changes that occur during haemodialysis and how they may negatively 
impact on the cardiovascular system.  
Our results show that the haemodynamic disturbances which occur 
during haemodialysis are capable of causing a reduction in myocardial 
blood flow sufficient in magnitude to induce myocardial ischaemia. This 
is associated with a matched reduction in regional left ventricular (LV) 
function and is entirely in keeping with other published work describing 
haemodialysis induced myocardial stunning reflecting subclinical 
myocardial ischaemia (myocardial stunning).  
In addition, we now know that this phenomenon of haemodialysis 
induced myocardial ischaemia and stunning is common and associated 
with both short and long term complications including ventricular 
arrhythmias, left ventricular dysfunction, an increased hazard of death 
and time to first cardiovascular event. This is pertinent as in non-dialysis 
patients repeated episodes of myocardial stunning lead to chronic heart 
failure, and in dialysis patients the presence of LV dysfunction 
dramatically increases the risk of death.  
 xiv 
We also identified a number of factors associated with the presence of 
myocardial stunning including age, raised biochemical markers of 
cardiac damage (troponin-T), higher ultrafiltration volumes and lower 
intradialytic blood pressure. This is of crucial importance as 
ultrafiltration volumes and intradialytic haemodynamics are potentially 
modifiable risk factors that could provide targets for dialysis based 
interventions aimed at improving cardiovascular outcomes in the 
haemodialysis population. 
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Chapter 1 
 
Introduction 
 2 
1 Introduction 
1.1 End stage renal disease 
1.1.1 Background 
End stage renal disease (ESRD) is the final stage of chronic kidney 
disease (CKD) and is defined as the failure or near failure of the 
kidneys to perform their normal functions. These functions include: 
excretion; maintenance of acid-base, fluid and electrolyte balance and 
the synthesis of hormones such as erythropoietin and renin. 
ESRD usually results from a progressive and irreversible loss of renal 
function and is defined by a glomerular filtration rate (GFR) of less than 
15 ml/min. The Kidney Disease Outcomes Quality Initiative (K/DOQI 
2002) guidelines have CKD into five stages of which ESRD is the fifth 
(table 1.1.1a). 
When a patient reaches ESRD, renal replacement therapy (RRT) in the 
form of dialysis or transplantation must be considered as without 
treatment, symptoms will likely significantly deteriorate within weeks or 
months. 
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Table 1.1.1a: The stages of chronic kidney disease (CKD). 
 
1.1.2 Epidemiology 
Chronic kidney disease remains a significant health problem and it is 
now appreciated that it plays a significant role in increasing risk for 
many other disease processes. It is also apparent that the number of 
patients with CKD in the population is increasing year on year. The 
prevalence of CKD in the United States in 1999-2004 was significantly 
higher than it was in 1988-1994 with an increase in the total prevalence 
of CKD stages 1-4 from 10% to 13.1% over that time 1 (see figure 
1.1.2a). The same study also showed that a higher prevalence of 
diagnosed diabetes, hypertension and higher body mass index 
explained the entire increase in prevalence of albuminuria but only part 
of the increase in the prevalence of decreased GFR.  
Stage GFR Description 
1 90+ 
Normal kidney function but urine findings or 
structural abnormalities or genetic trait point 
to kidney disease 
2 60-89 
Mildly reduced kidney function, and other 
findings (as for stage 1) point to kidney 
disease 
3 30-59 Moderately reduced kidney function 
4 15-29 Severely reduced kidney function 
5 <15 Very severe, or established renal disease. 
 4 
Estimation of the prevalence of earlier stages of CKD in the population 
and understanding trends over time is central to disease management 
and prevention planning, particularly given the increase in the 
prevalence of obesity, diabetes and hypertension, the leading risk 
factors for CKD and cardiovascular disease.  
The early stages account for most of the individuals with CKD but 
because individuals with any stage of CKD have a higher risk of 
cardiovascular disease morbidity and mortality than their risk of 
progression to ESRD, cardiovascular risk factor management in this 
group is critical. The high prevalence of CKD overall, and particularly 
among older individuals and persons with hypertension and diabetes, 
suggests that CKD needs to be a central part of future public health 
planning. In addition, the increasing prevalence of diagnosed diabetes 
and hypertension may in turn lead on to higher rates of complications 
and ESRD requiring dialysis or transplantation.  
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Figure 1.1.2a: Prevalence of chronic kidney disease (stages 1-4) by age 
group in the National Health and Nutrition Examination Surveys 
(NHANES) 1988-1994 and 1999-2004 1. 
 
 
The projected number of ESRD patients is also expected to rise. In the 
United Kingdom, the incidence of ESRD, as measured by the number of 
patients commencing renal replacement treatment, varies between 80 
and 110 new patients per million of population (pmp) per year (UK 
Renal Registry 2002). In the United States, the incidence of ESRD is 
much higher at around 315 pmp in 1999 (USRDS 2001). In general, the 
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incidence of ESRD increases with age, reaching around 1300 pmp per 
year in patients aged over 65 years. 
 
Year Projected Incidence Projected Prevalence 
2005* 106,896 484,995 
2010 120,253 579,105 
2015 134,978 679,918 
2020 150,772 784,613 
 
 
Table 1.1.2a: Expected incidence and prevalence rates for ESRD in the 
United States up to 2020 (*Actual figures are quoted for 2005) 2. 
 
In 2001, a projected analysis undertaken in the United States suggests 
that the incidence of ESRD will continue to increase until 2010 at a rate 
of 6±7 per cent per year 3. More recent studies have put the projected 
number of ESRD patients at approximately 785,000 by 2020 ± an 
increase of 60 percent compared to the number of ESRD patients in 
2005 2 (see table 1.1.2a). Again, this takes into account the rising rates 
of a number of factors including obesity and diabetes. Given the costs 
associated with all treatment modalities for ESRD requiring renal 
replacement therapy, this has significant health service implications. 
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1.1.3 Health service implications 
The increase in the number of prevalent patients requiring renal 
replacement therapy (RRT) has a significant impact on the provision of 
services within a health service that has a limited budget.  
The cost of a kidney transplant is £20,000 per patient per transplant 
with immunosuppression costs of £6,500 per patient per year 
subsequently. The average cost of dialysis is £30,000 per patient per 
year. Despite the recognised health and social benefits of 
transplantation (which remains the gold standard for treating ESRD) 
dialysis remains the treatment for the majority of patients due to a 
shortage of donor kidneys and an increasingly older ESRD population, 
many of whom are unfit for transplantation surgery. 
In 2003, 67.5 per cent of RRT patients in the UK were receiving 
haemodialysis and 29.2 per cent peritoneal dialysis (3.3 per cent had a 
transplant). This large proportion of patients on haemodialysis (HD) has 
a significant impact on cardiovascular morbidity and mortality, which will 
form the basis of this thesis. 
1.2 Renal replacement therapy 
1.2.1 Background 
The basic principles of dialysis were described by Thomas Graham 
over 100 years ago. Even though the first treatments for acute renal 
failure were performed in the 1920s, chronic dialysis treatment for end 
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stage renal failure did not become a reality until 1960. In the following 
few years a series of breakthroughs, in both dialysis technology and 
vascular access, enabled chronic renal replacement therapy to be 
established in both the US and Europe by the mid 1960s. 
 
 
 
Figure 1.2.1a: Patient numbers and modalities of treatment in ESRD 
patients requiring renal replacement therapy. 
 
Chronic haemodialysis (HD) became widely available in the UK in the 
early 1970s (largely as a home based therapy) and continuous 
ambulatory peritoneal dialysis (CAPD) became increasingly popular 
during the early 1980s. There are now some 1.5 million patients 
receiving regular dialysis worldwide and around 25,000 in the UK alone 
(see figure 1.2.1a). 
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1.2.2 Haemodialysis 
Standard haemodialysis is performed three times a week, for 3±5 hours 
each session, with low-flux membranes (see figure 1.2.2a). Since the 
1960s there has been a general technical improvement in dialysis 
machines, dialysers, and dialysis solutions. These factors, as well as 
accurate control of the ultrafiltration rate by new dialysis machines and 
more precise control of electrolyte dialysate composition, have 
improved haemodynamic stability during treatment. The substitution of 
acetate as the dialysate buffer with bicarbonate has also improved 
vascular stability. 
 
 
Figure 1.2.2a: A standard haemodialysis machine 4 
 
 10 
The principle of haemodialysis is relatively straightforward. Blood flows 
on one side of a semi permeable membrane, and dialysis fluid, an 
osmotically balanced solution of electrolytes, buffer, and glucose in 
water, flows on the other. 
Haemodialysis (HD) was first described in the early 1900s. However, it 
was not until the 1960s that HD became a viable technique for the long-
term treatment of patients with ESRD. This was enabled by the 
development of a reliable and safe Teflon arteriovenous shunt that 
allowed adequate rates of blood flow, and also by the availability of 
heparin to prevent clotting in the extracorporeal circuit. 
Although viable, early HD was beset with problems. Poor predictability 
of the dialysers in terms of solute removal led to long treatment times. 
Ultrafiltration (UF) was controlled manually by adjustment of the blood 
and dialysate pumps to create a pressure gradient that led to 
unpredictable UF rates. Blood leaks in the dialysers and lines were 
common and there were concerns about bacterial contamination of the 
dialysate fluid. Also, it was not possible to produce a commercially 
viable dialysate solution that contained bicarbonate as a buffer because 
of bacterial contamination of the liquid bicarbonate. Therefore, non-
physiological acetate was employed as a buffer that diffused into the 
patient and was subsequently converted into bicarbonate by the liver. 
However, acetate transfer into the patient strongly predisposes to 
intradialytic symptoms, in particular hypotension (IDH), headaches and 
hypoxia 5. 
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Significant advances have been made over the subsequent years. The 
advent of hollow fibre dialysers greatly increased the efficiency of small 
solute removal and led to shorter treatment times, although shorter 
dialysis sessions with greater UF rates may themselves contribute to 
IDH. Dialysis membranes are now synthetic, which improves their 
biocompatibility. Bicarbonate-based dialysis became possible using dry 
bicarbonate concentrates that overcame the problems of precipitation 
and storage of large amounts of bicarbonate solution. In the 1980s, the 
concept of Kt/V, a measure of the amount of urea cleared by dialysis in 
relation to body size, became widely accepted. Importantly, it was 
shown that too little dialysis (as measured by a low Kt/V) was 
associated with increased mortality 6,7. Finally, various modifications of 
the dialysis technique have become common practice. The most 
widespread of these is haemodiafiltration (HDF), a technique based on 
additional convective clearance due to high UF volumes and 
subsequent fluid reinfusion. HDF may confer benefit in terms of stability 
on dialysis and greater clearance of some of the larger uraemic toxins. 
However, despite these technological advances HD remains an 
imperfect treatment. Dialysis only partially replicates the removal of fluid 
and uraemic toxins by the kidney, and does not replace any of its 
hormonal functions. The intermittent nature of dialysis dictates 
repeated, rapid shifts between fluid overload and euvolaemia, and IDH 
remains a complication of up to a third of treatments 8. In addition, the 
cardiovascular death rate of haemodialysis patients is extraordinarily 
high 9. 
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1.3 Cardiovascular disease in dialysis patients 
1.3.1 Epidemiology 
The frequency of fatal and non-fatal cardiovascular events is increased 
even in the earliest stages of chronic kidney disease 10-13 (see figure 
1.3.1a).  
 
Figure 1.3.1a: The relative risk of cardiovascular events with respect to 
eGFR. Those patients with CKD stages 4 or 5 have the highest risk 13. 
 
This risk is even higher within dialysis patients who display hugely 
elevated rates of cardiac mortality, at least thirty-times greater than age-
matched controls 9 (figure 1.3.1b).  
 13 
In the HEMO study, the most common cause of death in dialysed 
patients was ischaemic heart disease (20.4 per cent) followed by 
cardiac rhythm disorder (10.4 per cent), cerebrovascular disease (8.6 
per cent), and infections (7.7 per cent) 14. According to the Annual 
Report 2001 of the United States Renal Data System (USRDS), the 
incidence of new myocardial infarction in the first year of renal 
replacement therapy was 7.0 per cent, of cerebrovascular accidents 7.1 
per cent, and of surgery for peripheral vascular disease 8.4 per cent.  
 
 
 
Figure 1.3.1b: Graph showing the cardiovascular mortality rates by age 
and ethnicity for dialysis patients and healthy controls. The y-axis is a 
logarithmic scale, emphasising the huge excess of cardiovascular death 
seen with dialysis patients 9. 
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As a crude comparison, the Framingham Heart Study reported that the 
annual risk of re-infarction in subjects surviving a first recognised 
myocardial infarction was 4 per cent per year, almost half the risk of 
new myocardial infarction in HD patients 15 for whom the additional risk 
factor of uraemia is compounded by also being on dialysis. 
1.3.2 Risk factors 
Such high levels of cardiovascular disease in dialysis patients are in 
SDUW GXH WR WKH KLJK SUHYDOHQFH RI µWUDGLWLRQDO¶ ULVN IDFWRUV diabetes, 
hypertension, hyperlipidaemia, smoking, and physical inactivity). 
Unfortunately, aggressive management of these traditional risk factors 
in dialysis patients has failed to adequately control the progression of 
cardiovascular disease. For example, in uraemic patients, LV 
hypertrophy progresses with time on dialysis even when patients are 
kept normotensive 16,17. In the study of Parfrey, 71 per cent of non-
diabetic dialysis patients without dilated cardiomyopathy had LV 
hypertrophy and in the majority of patients this progressed over a period 
of 3±4 years. Progression was not predicted by blood pressure, 
hyperparathyroidism or anaemia (although these factors are definitely 
involved), suggesting that additional factors may play a part. Therefore 
this excess of cardiovascular disease in dialysis patients must be 
explained by the presence of other unique metabolic and 
haemodynamic derangements specific to the uraemic patient ± the so-
FDOOHGµXUDHPLF¶specific risk factors. These uraemic risk factors are less 
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well defined but are multiple, including some of those mentioned above 
already. 
It is not only systolic and diastolic blood pressures which determine LV 
work and LV mass. Vascular calcification with increased vessel stiffness 
is common, associated with the development of left ventricular 
hypertrophy (LVH) 18 and also independently predicts mortality 19. 
Stiffening of the aorta and the associated increased impedance play a 
major role in the development of LVH 20. High pulse pressure is a 
surrogate marker for aortic stiffness and pulse wave velocity is a potent 
predictor of LV mass and cardiovascular events 7,21,22. 
Diabetic patients with ESRD have particularly high cardiovascular 
morbidity and mortality 23. Even diabetic patients without nephropathy 
have major abnormalities of cardiac structure. In observational studies, 
when compared to non-diabetic individuals, diabetic patients have more 
severe LV hypertrophy and also develop ischaemic heart disease more 
frequently 24. 
Anaemia is a common consequence of ESRD. Sustained anaemia 
leads to vasodilatation, increased venous return, cardiac enlargement 
and increased cardiac output 25,26. Numerous observational studies 
documented that anaemia is associated with increased LV mass in 
patients with CKD 27 and this is true even for apparently trivial degrees 
of anaemia 28. Observational studies have also suggested that anaemia 
is an independent predictor of mortality 29,30. Partial correction of 
anaemia partly corrects LV hypertrophy 31-33 but there is little or no 
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controlled evidence that reversal of anaemia reduces cardiovascular 
mortality. In the Canadian Normalisation of Hemoglobin Trial, 
haemodialysis patients with asymptomatic echocardiographic 
enlargement were randomly treated to haemoglobin of 10 or 13.5 g/dl. 
The higher haemoglobin failed to show a regression in left ventricular 
dilatation but subsequent studies have shown that a normal 
haemoglobin will prevent the development of new LV dilatation 34. 
Recurrent volume overload with rapid fluid shifts (that occur on dialysis) 
increases cardiac filling pressures and venous return, imposing an 
increased work load on the left ventricle. Eventually this increase in 
preload results in LV dilatation and LVH. A correlation is found between 
LV volume and blood volume. In patients with fluid overload the heart 
diameters usually return to normal a few hours after ultrafiltration, but 
chronic overload may lead to eccentric LV hypertrophy and irreversible 
dilatation. The importance of hypervolaemia is illustrated by the 
observation of Ozkahaya et al. that volume control by low salt diet and 
aggressive ultrafiltration reversed LV dilatation and hypertrophy despite 
no administration of antihypertensive agents 35,36. 
Cardiac mortality in dialysis patients has also been linked to chronic 
inflammation, often manifest as hypoalbuminaemia and elevated C-
reactive protein (CRP) levels. Inflammation leads to accelerated 
atherosclerosis, vascular calcification and increased muscle catabolism 
37
. Certainly, the elevation of several cytokines (in particular CRP and 
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interleukin-6) have also been shown to be associated with an increase 
in mortality 38,39. 
1.3.3 Left ventricular hypertrophy 
The presence of LVH itself predicts a worse long term outcome, and is 
associated with an increased propensity to cardiac arrhythmias 40,41. 
LVH is more frequent in early stages of chronic kidney disease and 
increases progressively, so that it is found in approximately 70 per cent 
of patients starting renal replacement therapy 28. Initially concentric LVH 
is seen, while in later stages more frequently eccentric LVH prevails. 
LVH tends to be associated with hypertension, anaemia, high 
arteriovenous fistula flow and poor control of volume overload 31 as 
mentioned above. At an early stage, systolic function is usually normal 
or even increased, but evidence of diastolic malfunction ± including 
reduced compliance and abnormal passive filling of the LV ± can be 
found even in asymptomatic patients. LVH is not an innocent academic 
finding: Silberberg et al. had clearly documented that it was an 
independent predictor of death on dialysis 42 (figure 1.3.3a). 
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Figure 1.3.3a: LVH reduces survival in dialysis patients. Cumulative 
survival according to echocardiographic LV hypertrophy defined as LV 
mitral inflow greater than 125 g/m2. This cut-off point corresponds to 
the 95th centile of the normal population 42. 
 
1.3.4 Myocardial ischaemia and haemodialysis 
It has long been suspected that myocardial ischaemia may be 
precipitated by haemodialysis, with the first evidence of silent ST 
segment depression during dialysis reporting back to 1989 43. However, 
this concept of dialysis induced subclinical ischaemia (occurring without 
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acute atherosclerotic plaque rupture) has received remarkably little 
attention, despite its theoretical plausibility. 
Short intermittent haemodialysis treatments exert significant 
haemodynamic effects, and 20-30 per cent of treatments are 
complicated by intra-dialytic hypotension (IDH) 44-46. In conjunction with 
this, haemodialysis patients are particularly susceptible to myocardial 
ischaemia. In addition to the high prevalence of coronary artery 
atheroma 47,48, diabetic dialysis patients have been shown to have a 
reduced coronary flow reserve (CFR) ± the ability of coronary arteries to 
dilate when myocardial demand is increased ± even in the absence of 
coronary vessel stenoses 49.  
There is preliminary evidence that the same phenomenon is also seen 
in non-diabetic dialysis patients 50 which may be due to LVH, that leads 
to both structural and functional reductions in the myocardial 
microcirculation. The presence of LVH on its own reduces CFR even in 
the absence of large vessel coronary disease 51. Because of the 
increased extravasal resistance, coronary reserve is reduced as 
illustrated in the patient with aortic valve stenosis. They suffer from 
angina pectoris resulting from ischaemia despite patent arteries. This is 
particularly important in HD patients in whom ischaemia is often 
asymptomatic 52. 
Similarly the uraemic patient with LV hypertrophy may have ischaemia 
intolerance when oxygen demand is increased. In addition, the 
presence of concentric LVH renders the ventricle more sensitive to 
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acute changes in filling pressure, exactly as occurs during 
haemodialysis 53. Increased peripheral artery stiffness is also 
recognised to have an adverse effect on myocardial perfusion and 
reduces the ischaemic threshold 54; therefore, LVH in conjunction with 
increased vascular stiffness leads to a propensity to reduced 
subendocardial blood flow  55. 
Since the initial report by Zuber et al 43, there have been  further studies 
that have demonstrated silent ST segment depression occurring during 
dialysis 56-64. These studies report the occurrence of dialysis induced ST 
depression at rates that vary between 15 and 40 per cent. However, 
there has been ongoing debate as to whether these 
electrocardiographic abnormalities reflect silent ischaemia or changes 
in electrolyte concentrations. Other than this, there has been only one 
subsequent study that has demonstrated ischaemia using an alternate 
technique. Singh et al assessed dialysis induced ischaemia using 
sestamibi single photon emission computed tomography (SPECT) 65. In 
an unselected group of ten dialysis patients who were not known to 
have coronary artery disease, seven developed perfusion defects 
during dialysis. Importantly, concurrent ST depression occurred with the 
perfusion defects in only 3 patients, suggesting that 
electrocardiographic assessment alone may underestimate the 
incidence of dialysis induced ischaemia.  
Unfortunately, none of these studies included an intervention to attempt 
to reduce the frequency of dialysis induced ischaemia, nor did any 
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search for potential long term sequelae on LV function. Also, no studies 
have, as yet, looked at the direct effect of haemodialysis on both 
myocardial perfusion and function. 
1.3.5 Dialysis induced acute myocardial stunning 
In patients with coronary artery disease but without chronic kidney 
disease, transient myocardial ischaemia may lead to LV dysfunction 
that can persist after the return of normal perfusion.  
 
Figure 1.3.5a: The effect of brief coronary occlusion on systolic function. 
The box µLVFK¶UHSUHVHQWVDVKRUWHSLVRGHRILVFKDHPLD7KH
myocardium rapidly becomes dyskinetic but there is a gradual return to 
normal function. This period between restoration of normal flow and 
recovery of function is known as myocardial stunning 66. 
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Animal models have shown that after a brief reduction in coronary blood 
flow caused by occlusion to the coronary vessels, myocardial 
contractility falls and becomes dyskinetic. After restoration of normal 
flow, there is a mismatch between flow and function and this prolonged 
dysfunction (which can take days to recover) is known as myocardial 
stunning 66 (figure 1.3.5a).  
Myocardial stunning has been demonstrated in humans after exercise 
and dobutamine stress in patients with coronary artery disease 67,68. It is 
thought that transient wall motion abnormalities occur in areas of the 
myocardium that are subtended by a coronary stenosis of <40% that is 
not severe enough to diminish resting myocardial blood flow but will 
impair coronary flow reserve. As a consequence, the myocardium may 
become ischaemic following exercise (or other haemodynamic stressor) 
and before it has had time to completely recover, another episode of 
ischaemia may occur. Such repeated episodes of ischaemia can be 
cumulative and result in an apparent chronic reduction in left ventricular 
function 69 (figure 1.3.5b). 
It has previously been demonstrated that myocardial stunning occurs as 
a direct consequence of haemodialysis (and can be ameliorated by 
improving systemic haemodynamics whilst on treatment) 70,71. 
Therefore, if myocardial ischaemia and stunning are induced by 
haemodialysis then the process of haemodialysis itself, repeated three 
times a week, may potentially contribute to chronic cardiac damage in 
this patient group. Myocardial stunning is therefore increasingly thought 
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to be an underappreciated causative mechanism for heart failure in the 
haemodialysis population. 
 
Figure 1.3.5b: The effect of repetitive myocardial stunning on contractile 
function. The black boxes indicate short episodes of ischaemia. After 
restoration of flow, function begins to improve but before returning to 
normal a further episode of ischaemia results in a further reduction in 
contractility. Repeated short ischaemic episodes may therefore result in 
a chronic impairment of myocardial function 72. 
 
Recent studies in the non-dialysis population have provided evidence 
that repetitive episodes of ischaemia can be cumulative and lead to 
prolonged left ventricular dysfunction  through the process of 
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myocardial hibernation 66,68,73-77. However, none of these mechanisms 
have been studied in the haemodialysis population. 
1.3.6 Myocardial hibernation and fibrosis 
So, standard conventional thrice weekly haemodialysis may cause 
repeated episodes of sub-clinical myocardial ischaemia and therefore 
be a potential cause of repetitive myocardial stunning leading to chronic 
myocardial hibernation and left ventricular dysfunction. In the non-
dialysis population, repeated episodes of demand ischaemia and 
stunning (before full recovery has taken place) can result in an apparent 
chronic reduction in left ventricular function 72,78.  
This led to the hypothesis that in areas with reduced CFR but normal 
resting myocardial blood flow, repeated episodes of demand associated 
myocardial ischaemia led first to stunning and then to chronic 
myocardial hibernation 79. Whilst in myocardial stunning there is a flow-
function mismatch (return to normal flow but delayed return to normal 
function), myocardial hibernation is characterised by a matched 
deterioration in flow and function. Unlike stunned myocardium which 
can respond to inotropes like dobutamine, hibernating myocardium has 
little or no response and continues to display fixed areas of systolic 
dysfunction. Fortunately, both of these adaptive processes are 
reversible and in patients with obstructive coronary artery disease, 
revascularisation can lead to restoration of varying degrees of 
ventricular function 80,81. 
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Although myocardial hibernation may represent a functional adaptation 
to chronic hypoperfusion that can be reversed with restoration of 
UHJLRQDO 0%) WKH µVPDUW KHDUW¶ K\SRWKHVLV 82, there is evidence to 
suggest that hibernating myocardium is still highly vulnerable to 
increases in demand or reductions in oxygen supply 83. Therefore, 
ongoing recurrent episodes of ischaemia precipitated by HD may have 
negative consequences on this adaptive balance. Hibernation then, in a 
clinical context is most likely caused by repetitive stunning and these 
two processes form a continuum on their way to eventual myocardial 
fibrosis and ventricular dysfunction. Although it is often difficult to 
distinguish practically between them, both respond to revascularisation 
and so it is crucial to identify patients at this stage of the pathological 
process so that they can be targeted for appropriate intervention. 
Interestingly, the withdrawal of haemodialysis as the method of renal 
replacement therapy after kidney transplantation was associated with 
an increase in left ventricular ejection fraction, an improvement in 
functional status of congestive heart failure and increased survival 84. 
This is similar to the improvement seen in patients with congestive heart 
failure after coronary revascularisation and lends credence to the 
argument that it is the process of haemodialysis itself that causes 
repetitive myocardial ischaemia that in turn may contribute to the 
increased incidence, prevalence and mortality from heart failure in HD 
patients. 
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1.3.7 Ischaemic preconditioning 
Interconnected with the processes of stunning and hibernation is the 
concept of ischaemic preconditioning. This was originally defined as a 
short period of ischaemia that protected the myocardium from a 
subsequent, more prolonged and potentially catastrophic period of 
ischaemic damage 85. Initially it was believed that there had to be a 
period of reperfusion between the preconditioning ischaemia and the 
subsequent, more prolonged episode. This would fit with the idea of 
repetitive stunning leading to the adaptive process of hibernation 
through the mechanism of ischaemic preconditioning.  
Subsequent studies have shown however that a period of reperfusion is 
not always necessary and that the protective / adaptive phenomenon of 
preconditioning can also occur if the onset of lethal ischaemia is more 
gradual (sub-OHWKDO UDWKHU WKDQ VXGGHQ VR FDOOHG µLQWUD-ischaemic 
SUHFRQGLWLRQLQJ¶ 86. This model is less like the mechanism of repetitive 
stunning described above but could still be induced if the ischaemic 
insults were close enough together that full restoration of flow and 
recovery of function were never attained. 
What is clear is that both of these models could potentially result from 
haemodialysis induced repetitive cardiac injury and, whilst initially being 
protective, may eventually lead to maladaptive processes resulting in 
fibrosis and ventricular dysfunction due to the inexorable nature of 
current dialysis treatment regimes.  
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There is some preliminary data into the therapeutic effects of pre-
ischaemic conditioning in donor kidneys prior to renal transplantation 87 
however, as yet there is no research into the effects (positive or 
negative) of ischaemic myocardial preconditioning in dialysis patients. 
1.3.8 Cardiac troponins in haemodialysis patients 
It is well reported that cardiac troponins are elevated in haemodialysis 
patients, and that these elevated levels predict mortality 88,89. 
Interestingly, HD patients have an increased mortality not just from 
cardiovascular death but also all cause mortality including infections 90 
(see figure 1.3.8a). This may suggest that those patients with more 
severe cardiovascular disease (as evidenced by significant troponin 
leak) have insufficient cardiovascular reserve to cope with additional 
insults such as sepsis.  
Although both troponin T (cTnT) and troponin I (cTnI) levels are raised 
in dialysis patients, there is more data with respect to troponin T due to 
the uniformity of assays and greater homogeneity of cut off points 
employed. In addition, cTnT is elevated more frequently than cTnI, 
suggesting this molecule may be a more sensitive marker 88,91 and 
although the exact origin of elevated troponins in renal disease was 
initially unclear, it is now well established that the troponins are cardiac 
in origin 92. 
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Figure 1.3.8a: Kaplan-Meier survival plots for haemodialysis patients 
with normal (solid line) and clinically raised (dotted line) troponin-T 
levels. Cardiovascular and non cardiovascular mortality was raised in 
both diabetic and non-diabetic patients 90. 
 
There is however still some continuing uncertainty as to whether 
troponin rises acutely following dialysis.  Several authors have reported 
significant rises in cTnT post dialysis 91,93-95, whereas others have found 
no difference in pre- and post- dialysis cTnT or cTnI levels, or found that 
any difference disappears after correction for haemoconcentration 96-98. 
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However, measuring post dialysis troponin levels to look for dialysis 
induced ischaemia may be flawed; it is well recognised that plasma 
troponin levels may only become elevated after 6 to 12 hours following 
an episode of ischaemia. Therefore, the studies that found no difference 
in pre- and post-dialysis troponin levels do not refute the development 
of dialysis induced myocardial cell damage. 
Higher cardiac troponin T levels have been reported in patients prone to 
intradialytic hypotension as compared to stable patients 99. However, 
this does not necessarily reflect dialysis induced cTnT release and 
alternatively could be explained by a greater cardiac disease burden in 
those unstable patients 94. However, it has been demonstrated that cTnI 
rises significantly when measured 44 hours after dialysis sessions 
complicated by intradialytic hypotension (i.e. measured at the 
subsequent dialysis session) as compared to sessions in which patients 
were stable 100. This provides additional evidence that subclinical 
myocardial injury does occur during dialysis complicated by 
hypotension and haemodynamic instability. 
1.3.9 Haemodialysis and cardiac arrhythmias 
Sudden cardiac death appears to correlate with the peri-dialytic period 
101
. Consequently, there have been a number of studies looking at the 
potential pro-arrhythmogenic effects of HD, which reported the 
frequency of dialysis induced arrhythmias as anywhere in the range of 5 
± 75% of treatments 102,103. The presence of both potentially life-
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threatening complex ventricular arrhythmias (CVAs) and premature 
ventricular complexes (PVCs) has been associated with increased 
morbidity and mortality. CVAs (defined as Lown score of 3 and above) 
are reported in up to 35% of HD patients during treatment 56 and 
associated with negative prognostic factors including new coronary 
events 104 and silent myocardial ischaemia 60. In the general population, 
people with PVCs are more than twice as likely to die from coronary 
artery disease (CAD) 105 and their presence may play a vital role in 
assessment of cardiovascular risk.  
The frequency and prevalence of intra- and post-dialytic ventricular 
arrhythmias are higher in patients with significant coronary stenoses 106, 
suggesting that myocardial ischaemia plays a direct role in the induction 
and persistence of ventricular arrhythmias during and after HD. 
Myocardial ischaemia is also known to lead to the development of 
regional wall motion abnormalities (RWMAs) and myocardial stunning 
as a direct consequence of HD 70,71. This arises secondary to ischaemia 
caused by a reversible reduction in myocardial blood flow during the HD 
treatment session even in the absence of significant CAD 107. In 
addition HD patients have been shown to have  reduced coronary flow 
reserves 49, increased prevalence of left ventricular hypertrophy and 
impaired microcirculation 108, all of which predispose to demand 
myocardial ischaemia. 
A number of therapeutic strategies directly targeting the increased 
incidence of CVAs and PVCs in HD patients have been utilised.  
Unfortunately the majority of these involve additional pharmacological 
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agents that may be poorly tolerated and have undesirable side-effects 
109
.  
No evidence currently exists that myocardial ischaemia may contribute 
to the development of both RWMAs and ventricular arrhythmias. As 
ischaemia induced RWMAs are potentially preventable 70,71, the 
identification of a common pathophysiological process connecting both 
sudden and ischaemic cardiac death in HD patients may offer single 
therapeutic targets to reduce both causes of mortality. 
1.3.10 Intra-dialytic hypotension and ultrafiltration rate 
Intra-dialytic hypotension (IDH) is a very serious clinical problem and 
remains a significant cause of morbidity in the haemodialysis 
population, occurring in 20-30 per cent of treatments 46. In addition, a 
fall in blood pressure during dialysis predicts mortality 109. Furthermore, 
IDH could potentially contribute to myocardial hypoperfusion during 
dialysis. The main mechanism of IDH is rapid reduction of blood volume 
owing to ultrafiltration and decrease in extracellular osmolarity during 
the dialysis session. If the ultrafiltration rate exceeds the plasma refill 
rate, this will lead to a reduction in circulating volume. Hypotension 
occurs when this reduction in blood volume surpasses the 
compensatory mechanisms of the cardiovascular system. Although no 
data currently exists as to the direct effect of cumulative ultrafiltration 
volumes over time on mortality there is evidence to suggest that 
patients greater fluid retention between two subsequent HD treatment 
sessions is associated with worse survival (figure 1.3.10a) 110. 
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Figure 1.3.10a: After adjustment for demographics (case-mix) and 
surrogates of malnutrition-inflammation complex syndrome (MICS), 
higher weight gain between HD sessions was associated with increased 
all-cause mortality 110. 
 
Coexisting illnesses, especially cardiovascular diseases, particularly 
common in older and diabetic patients play a significant role in the 
development of IDH. Efficient treatment of IDH is difficult as there are 
no universally accepted approaches to its management 111. Multilevel 
strategy of IDH management includes emergency replacement of 
intravascular volume in acute episodes of hypotension, accurate 
assessment of 'dry weight', education of the patient, adequate 
hypertension treatment, and assessment. 
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Methods related directly to the haemodialysis procedure may also play 
a role in reducing the incidence of IDH. UF rate is important in 
determining blood volume 112. Other than reducing the interdialytic 
weight gain, which to a large extent is patient-dependent, other 
strategies are being tested to reduce hypotension. Several studies have 
shown biofeedback dialysis to be effective in reducing IDH frequency in 
both IDH prone and resistant patients 113-115. 
Dialysis using a low dialysate temperature have been shown to be 
beneficial 116. Standard dialysis (with a dialysate temperature of 37°C) 
leads to an increase in patient body temperature 117. The reasons for 
this are not entirely clear, but may include heat transfer to the patient 
from warm dialysate (especially as many dialysis patients have low 
baseline core temperatures), reduced heat loss from the skin due to 
vasoconstriction or possibly increased thermogenesis from an 
inflammatory response to a blood-membrane reaction. Cooling the 
temperature of the dialysate has been shown to reduce the incidence of 
both IDH 117 and myocardial stunning 70. However, cooling the dialysate 
remains a relatively under utilised technique. In part this may be due to 
fears of causing unacceptable symptoms of cold and shivering, as 
empirical reduction of dialysate temperature may in some patients lead 
to excessive cooling. In addition, there has also been concern that 
cooling the dialysate will lead to a reduction in dialysis adequacy due to 
peripheral solute sequestration as a result of greater peripheral 
vasoconstriction.  
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Dialysis techniques that use proportionally greater degrees of 
convection to remove uraemic toxins (haemofiltration, HF or 
haemodiafiltration, HDF) have also been linked to improvements in 
stability during dialysis (in addition to their other potential advantages 
on solute clearance) 118. However, there is accumulating evidence that 
most, if not all of this benefit on stability is due to thermal effects 119.  
Short daily dialysis has a protective effect against IDH compared to 
conventional HD three times per week 120. This was thought to be due 
to a number of factors including lower ultrafiltration volumes from 
smaller interdialytic volume gain. The benefits of short daily dialysis can 
also be seen at a biochemical level. Keeping the total number of hours 
of dialysis per week constant, patients on short daily dialysis have a 
reduction in pre-dialysis brain natriuretic peptide (BNP) dialysis 121. 
Given the body of evidence that BNP levels correlate with LV 
dysfunction in dialysis patients (see below), short daily dialysis appears 
to result in less myocardial injury than conventional dialysis.  
There is also a possibility for pharmacological treatment with the use of 
such agents as the well described midodrine, or other drugs such as 
caffeine, effedrin, and vasopressin analogs. Besides the discussed 
strategies, efficient treatment of congestive heart failure, a common 
reason of hypotension in uraemic patients, should not be overlooked. 
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1.3.11 Cardiac failure 
The development of cardiac failure, which can occur in as many as 25-
50 per cent of haemodialysis patients, reflects a particularly poor 
prognosis 122. In a cross-sectional study congestive heart failure 
(defined by persistent or recurrent heart failure when patients were 
considered to be at dry weight), was found in 10 per cent of non-
diabetic dialysis patients 16,51,123. A third of the patients had developed 
their congestive heart failure before reaching end-stage renal disease; 
53 per cent of these had dilated cardiomyopathy and 47 per cent had 
hypertrophic hyperkinetic disease. The most common cause of 
congestive heart failure in these patients is ischaemic heart disease, but 
other factors for example; diabetic cardiomyopathy, myocardial 
calcification, iron overload, and thiamine deficiency may also be 
involved.  
Congestive heart failure carries a poor prognosis; records from the US 
Renal Data System have shown that HD is an independent risk factor 
for the development of both de novo and recurrent heart failure with a 
two-year mortality after a diagnosis of congestive heart failure as high 
as 51% 124 (as compared with 80 per cent in patients without congestive 
heart failure), making it the one of the most common causes of 
cardiovascular mortality in this patient group. In non-uraemic patients 
with congestive heart failure, cardiomyocyte drop (by apoptosis or 
necrosis) is an important element. It is therefore of interest that 
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cardiomyocyte loss has been documented in experimental uraemia as 
well 125.   
However, in addition to the direct effects of uraemia, as discussed 
above, if myocardial ischaemia is induced by haemodialysis then the 
process of repeated haemodialysis itself may well potentially contribute 
to the development of congestive cardiac failure. 
1.3.12 Summary 
Despite the well documented increase in cardiovascular morbidity and 
mortality in haemodialysis patients, very little is known about the exact 
effect that haemodialysis has on myocardial blood flow and myocardial 
stunning or their relative contribution to the development of 
complications including hibernation, fibrosis and heart failure. This is 
despite the fact that HD patients are subject to a grossly elevated rate 
of cardiovascular decline and that raised levels of the biochemical 
markers of cardiac damage support the hypothesis that haemodialysis 
induces some form of cardiac injury.  
It is becoming apparent that the current prevailing paradigm of 
considering this as a result of a particularly severe form of the 
cardiovascular risk factors seen in the general population is not true. 
This results in the well appreciated failure of Framingham risk models to 
predict events in this group, and the almost universal failure of attempts 
to successfully apply interventions that are well proven to be effective in 
the general population. There is an urgent need to enhance our 
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understanding of the actual pathophysiology at work in haemodialysis 
patients, and to utilise that knowledge to generate and apply novel 
therapeutic interventions, configured and conformed to those 
mechanisms. 
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2 Thesis aims 
2.1 Hypothesis 
This thesis has been planned to test the following hypothesis: 
 
Haemodialysis directly induces subclinical myocardial ischaemia and 
myocardial stunning, which may, over time, progress to myocardial 
hibernation and fibrosis. This could be a previously underappreciated 
(and potentially modifiable) pathophysiological process in the 
development of heart failure in haemodialysis patients. 
  
2.2 Research questions 
To test this hypothesis, the following interrelated research questions will 
be addressed: 
x Is it possible to confirm that haemodialysis induces myocardial 
ischaemia through a reduction in myocardial blood flow and if so, 
does this cause myocardial stunning as defined using current 
literature? 
x What is the prevalence of myocardial stunning in the general 
haemodialysis population and what, if any, are the factors 
associated with its development and severity? 
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x Is haemodialysis induced myocardial ischaemia and stunning 
associated with any acute electrophysiological complications? 
x What are the long term functional cardiovascular consequences 
of repetitive haemodialysis induced cardiac injury in the form of 
myocardial stunning? 
x Is there an association between myocardial stunning and an 
increase in morbidity and mortality? 
  
 
 
 
 
Chapter 3 
 
Methodology 
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3 Methodology 
All methods are dealt with in detail in this chapter and then referred 
back to for reference in the relevant results sections. Certain methods 
and techniques were used in more than one study outlined below. 
3.1 Applications for ethical approval 
Ethical approval was sought and granted for all aspects of the research 
detailed in this thesis. In the first instance, application was made to the 
Central Office of Research Ethics Committees (COREC) now the 
National Research Ethics Service. Multi-centre research ethics 
committee (MREC) applications were made for every study either 
because data collection or patient recruitment took place on (or was 
planned for) more than one site. Site specific assessments were 
undertaken and submitted for each of these areas. The author attended 
the meetings of the Committee to answer questions and address 
concerns. 
Approval from the Derby Hospitals NHS Foundation Trust Research 
and Development Department was also sought using the centralised 
research and development application form that was integrated into the 
COREC application system. Joint sponsorship was granted between 
the Hospital Trust and the University of Nottingham to allow for the 
collection, analysis and storage of data and pathological samples 
(plasma and serum) within both institutions. 
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3.2 Patient recruitment 
All patients were recruited from the haemodialysis unit at Derby City 
General Hospital where the average number of prevalent HD patients is 
around 200. Because of the limited number of patients within the cohort 
to be studied, some patients undertook several different measurements 
that have been reported in more than one chapter. This is outlined in 
Figure 3.2a. 
 
 
 
Figure 3.2a: Patients recruited and their contribution to the collection of 
data and analysis of results in each chapter. 
 
4 patients recruited to 
investigate effect of HD on 
myocardial perfusion 
(Chapter 4) 
70 patients recruited to 
investigate HD induced acute 
cardiac injury (Chapter 5) 
40 of these patients further 
phenotyped using continuous 
ECG monitoring (Chapter 6) 
51 patients entered follow up 
to investigate the long term 
effects repetitive injury 
(Chapter 7) 
9 patients died and 14 had 
CV events analysed for 
hazards (Chapter 8) 
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All patients were interviewed twice during the recruitment process. 
Inclusion and exclusion criteria for each study are included in individual 
chapters. At the initial visit, they were approached to gauge level of 
interest in study participation and given an approved patient information 
sheet. During the second visit, interest was confirmed and consent 
obtained from those individuals willing to take part. There was ample 
opportunity to ask questions during both visits and it was stressed that 
patients could withdraw at any time, without reason or detriment to their 
ongoing treatment. 
Four patients agreed to take part in the study to investigate the 
associations between HD induced contractile dysfunction and 
myocardial blood flow (chapter 4). The data collection from these 
individuals was separate and distinct from any other aspects of the 
research in this thesis. 
Seventy patients were recruited to investigate the prevalence, 
associated factors and long-term outcomes of HD induced cardiac 
injury (chapter 5). The demographical information for this cohort is 
detailed in table 5.4.3a below. A sub-set of these seventy were further 
analysed with continuous ECG Holter monitoring for any associations 
between functional and electrophysiological abnormalities during (and 
after) HD. These data are displayed in chapter 6. Fifty-one patients 
entered follow up after 12 months (details of those censored are given 
in section 7.2.1 below) and were further investigated for the long-term 
consequences of HD induced myocardial stunning (chapter 7). A further 
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subset of the original 70 patients were analysed: those who died (n=9) 
and those who suffered a cardiovascular event (n=14) in the proceeding 
12 months to quantify hazards associated with HD and myocardial 
injury (chapter 8). 
3.3 Non invasive haemodynamic measurements 
Two methods were employed to measure haemodynamic variables that 
were either continuous or intermittent at regular time intervals. 
Continuous measurements were undertaken using the Finometer. This 
was used in studies involving smaller numbers of patients to gain 
records for variables including blood pressure, cardiac output, stroke 
volume and total peripheral resistance. Intermittent readings for blood 
pressure alone were taken in studies with larger numbers of patients 
using an automated digital oscillometric device. Both of these individual 
methods are outlined in more details below. 
3.3.1 Continuous measurement of blood pressure (the 
Finometer®) 
The Finometer (Finapres Medical Systems, Arnhem, The Netherlands) 
is a tool for blood pressure and haemodynamic monitoring (figure 
3.3.1a).  
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Figure 3.3.1a: The Finometer in isolation and connected to a subject. 
 
The advantage of the Finometer is that it is accurate and robust and 
provides continuous measurement of multiple cardiovascular variables 
in one device. As a result, it is a versatile, non-invasive monitoring 
system that measures multiple haemodynamic variables on a beat-to-
beat basis. The accompanying BeatScope® software allows online 
monitoring, control, storage and offline review of all the data on a PC. 
The Finometer is particularly useful due to its non-invasive nature and 
ability to provide continuous readings over a period of several hours. 
The Finometer works by continuous pulse-wave analysis at the digital 
artery and utilises the finger-clamp method, in which changes in digital 
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arterial diameter are detected by means of an infrared 
photoplethysmograph 126 and opposed by an ultra-fast pressure servo 
controller that changes pressure in an inflatable air bladder, both 
mounted in a finger cuff. This generates an arterial waveform that is 
measured on a beat-to-beat basis and is used to reconstruct a central 
aortic waveform 127.  This allows calculation of a full range of 
haemodynamic variables on a continuous basis; these include heart 
rate (HR), blood pressure (BP), stroke volume (SV), cardiac output 
(CO) and total peripheral resistance (TPR). All data are subsequently 
downloaded to the PC based analysis program, allowing averaging of 
results over defined time periods. This technology provides 
unprecedented resolution of changes in the critical cardiovascular 
variables. Previous work has validated the Finometer against invasive 
haemodynamic measurements in normal individuals, unstable intensive 
care patients and in cardiac surgery patients, a proportion of whom had 
vascular calcification 127-129. This has shown the Finometer to be 
accurate in tracking relative change. Data are therefore presented as 
percentage change from baseline except for BP, which is calibrated 
against brachial readings using a return to flow method and absolute 
values can therefore be used 130. 
More recently, the Finometer has been increasingly used to assess 
chronic dialysis patients 44,45,131 and has now been validated within this 
patient group. 
 48 
3.3.2 Serial measurements of blood pressure 
For larger studies, blood pressure was measured pre-dialysis and then 
serially every 15 minutes during haemodialysis using an automated 
digital oscillometric device (Model UA-767, A&D Instruments, Japan) 
calibrated to research standards. For each time point, 3 measurements 
were obtained and the average of those readings was recorded. 
Haemodynamic instability was defined by the magnitude of reduction in 
systolic blood pressure (SBP) at each time point compared to the pre-
dialysis reading. Patients were defined as having intradialytic 
hypotension if they experienced as systolic blood pressure of <100 
mmHg even in the absence of symptoms, or a fall in systolic blood 
pressure of >10 per cent of the pre-dialysis reading in association with 
any of the classical symptoms of hypotension including: abdominal 
discomfort; yawning; sighing; nausea; vomiting; muscle cramps; 
restlessness; dizziness or fainting; and anxiety. 
3.4 Echocardiography 
We used two-dimensional echocardiography to assess regional LV 
function as a marker of ischaemia.  The development of new LV 
regional wall motion abnormalities (RWMAs) during physiological or 
pharmacological stress occurs in response to ischaemia and its onset 
precedes that of symptoms and electrocardiographical changes. This 
principle underlies dobutamine stress echocardiography 132.  
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Left ventricular regional wall motion was assessed by recording 
standard apical views (with the patient in the left lateral position) before, 
during and after dialysis procedures and then performing specialised 
semi-automated analysis on the images. Images were acquired using 
commercially available equipment (Sonos 5500; Hewlett Packard, 
Andover, Massachusetts, USA or Vivid 3® with 1.5-3.6 MHz 3S probe, 
GE medical systems, Sonigen, Germany).  
 
 
Figure 3.4a: Echo CMS software allows semi-automatic tracing of the 
endocardial border that can be manually corrected for anomalies. The 
movement of the endocardial border is then measured over 100 chords 
around the left ventricle. 
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A single experienced technician (the author) carried out all 
examinations and if alternate dialysis modalities were used, they were 
blinded to dialysis treatment. Timing of the echocardiography varied 
between studies but is stated in each relevant chapter. Standard apical 
2-chamber and 4-chamber views (to visualise the LV endocardial 
border in 2 planes at 90° to each other) were recorded. For the Sonos 
5500 (Hewlett Packard) ultrasound machine, images were recorded 
directly onto super-VHS videotape for off-line analysis. For the Vivid 3®, 
the images were saved onto the internal hard drive and subsequently 
recorded onto compact disc using the standardised digital imaging and 
communications in medicine (DICOM) format. This enabled more 
effective backup of patient data and maintained digital quality images 
for offline analysis using the PC based software program (see below). 
Videotaped and digitised image sequences were subsequently 
analysed using a personal computer based software programme (Echo-
CMS, MEDIS, Leiden, The Netherlands) as previously described 133. 
Three consecutive heartbeats were analysed for each time point 
(extrasystolic beats were excluded). Endocardial borders (excluding 
papillary muscles) were traced semi-automatically for each video frame 
of the 3-beat sequence, and any anomalies corrected manually (see 
figure 3.4a). Maximal displacement of the endocardial border from a 
centrepoint was then measured over each of 100 chords around the LV 
wall, corrected for end-diastolic LV circumference and expressed as 
percentage shortening fraction (SF), as shown in figure 3.4b. Each 
apical view was divided into 5 segments and SF for the chords in each 
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segment was averaged so 10 regions of the left ventricle were 
assessed at each time point. New RWMAs were defined as those 
segments that demonstrated a decline in SF of >20 per cent from 
baseline. This technique uses endocardial borders as the sole marker 
of abnormal contraction, and therefore could be criticised as it does not 
take account of wall thickening or transmyocardial heterogeneity. 
However, this method does have the advantage that it is repeatable and 
quantitative. 
 
Figure 3.4b: The movement of the endocardial border is measured over 
100 chords around the left ventricle with each red line representing an 
individual measurement. 
 
We also used echocardiography to assess measure cardiac dimensions 
and global LV function. Ejection fraction (EF) was calculated using LV 
volumes at end systole and end diastole, measured by the biplane disk 
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method. M-mode echocardiography using the para-sternal long axis 
view was utilised to measure LV dimensions and LVMI was calculated 
IURP HDFK SDWLHQW¶V RULJLQDO EDVHOLQH LPDJHV XVLQJ WKH 'HYHUHX[
formula corrected for height2.7. 
3.4.1 Measurement of intra-observer reliability 
Echocardiographical training was delivered by British Cardiac Society 
instructors and accuracy and quality of appropriate windows (apical two 
chamber, apical four chamber, para-sternal long axis and M-mode) was 
assessed by accredited examiners. These results were verified by a 
Consultant Cardiologist. Competency was reviewed annually thereafter. 
7HQSDWLHQWV¶ LPDJHVZHUHVHOHFWHGDW UDQGRPIRU UHDVVHVVPHQW7KLV
was done to test reliability of both the detection of regional wall motion 
abnormalities (numbers and position) and the severity in terms of 
reduction in %SF. There was a strong correlation with respect to the 
numbers of regions affected (r=0.94) with no patients being re-classified 
as !5:0$VRU5:0$V7KHFRUUHODWLRQZLWK6)ZDV OHVVEXW
still high (r=0.85). Despite the often subjective nature of 
echocardiographical assessment, the intra-observer reliability was 
good, meaning the results are reproducible and robust. As all 
echocardiographical images were analysed by a single operator, inter-
observer reliability is not discussed. 
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3.5 Dialysis methodology 
3.5.1 Blood volume measurement 
Blood volume measurement was performed by dialysis monitors in 
several of our experiments. Measurement of the change in the 
concentration of blood components (blood cells, proteins, haemoglobin) 
during dialysis reflects the balance between fluid removal from the 
circulation (ultrafiltration) and the plasma refill rate. There are two 
commonly available methods to measure blood volume - optical and 
ultrasonic. The optical method measures haemoglobin concentration by 
measuring the light absorbance of blood at two different frequencies. 
Measurement at two frequencies allows correction for the degree of 
oxygenation, which can alter the light absorbance characteristics of 
blood.  
The ultrasonic method calculates the total protein concentration in blood 
(plasma proteins and haemoglobin) by measuring the velocity of sound 
in blood (which is determined by protein concentration) and compares 
this to the velocity of sound in isotonic saline. For this method, the 
temperature of the blood and saline must be accurately fixed, and the 
haematocrit is deduced from the total protein concentration using 
simple formulae.  
In our experiments, we used the optical method that has been 
commercially developed and incorporated into dialysis monitors 134.  
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3.5.2 Conductivity measurement and ionic dialysance 
The conductivity of a substance is defined as the ability to carry 
electrical current. In dialysate fluid, the conductivity is determined by the 
concentration of ions capable of carrying electrical current, providing the 
temperature remains constant. This is almost entirely dependent on 
sodium concentration, although the other ions (such as potassium and 
calcium) that are present in much smaller quantities do also exert a 
small effect. Therefore, by measuring conductivity of the dialysate it is 
possible to derive a value for dialysate sodium concentration 135. This 
technique has a variety of applications. A conductivity monitor can be 
placed at the dialysate inlet and outlet ports of the dialyser and by 
changing the inlet conductivity by a set amount and measuring the 
resultant change in dialysate outlet conductivity, it is possible to 
calculate ionic dialysance (value representing the amount of electrolytes 
that have passed from plasma to dialysate). From the degree of ionic 
dialysance that occurs at a set dialysate conductivity, it is possible to 
calculate plasma conductivity and this can be used a surrogate for 
plasma sodium concentration. As the transfer characteristics of sodium 
and urea are similar, the ionic dialysance also reflects the clearance of 
urea. Therefore, using this technology it is possible to estimate from 
each dialysis session the ionic mass balance (amount of sodium 
removed), the dialysis adequacy for small solute removal (Kt/V, 
SURYLGLQJWKHSDWLHQW¶VYROXPHRIGLVWULEXWLRQLVNQRZQDQGWKHSODVPD
conductivity at the end of the treatment 135.  
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3.5.3 Dialysis technique 
All dialysis described in this thesis was performed using Hospal 
Integra£ monitors (Gambro-Hospal, Mirandola, Italy) unless otherwise 
stated. In all cases, we used low-flux polysulphone dialysers either 
1.8m2 or 2.0m2 DV SHU LQGLYLGXDO SDWLHQWV¶ XVXDO SUHVcription (LOPS 
18/20, Braun Medical Ltd, Sheffield, UK) unless otherwise stated. 
Dialysate contained sodium 138 mmol/l, potassium 1 mmol/l, calcium 
1.5 mmol/l, magnesium 5 mmol/l, bicarbonate 32 mmol/l, glucose 1 g/l 
and acetate 3 mmol/l. All treatments were of 4 hours duration and anti-
coagulation was achieved with unfractionated heparin. Dialysate flow 
was 500 ml/min, dialysate temperature was set at 37°C and blood flow 
was 250-460 ml/min. For paired sessions, care was taken to ensure 
blood flows were similar for each patient. Net fluid removal was set on 
an individual basis according to ideal dry weight. No patients underwent 
sodium or ultrafiltration profiling. 
3.6 Positron emission tomography 
3.6.1 Measurement of regional myocardial perfusion 
Positron emission tomography (PET) with H215O or 13NH3 is the only 
technique that allows the non-invasive measurement of regional 
absolute myocardial blood flow. 
PET is a nuclear medicine imaging technique which produces a three-
dimensional image or picture of functional processes in the body. It is 
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both a medical and research tool and is used heavily in clinical 
oncology for the imaging of metabolically active tissues such as 
tumours and metastases, and for clinical diagnosis of certain diffuse 
brain diseases such as those causing various types of dementias. PET 
is also an important research tool to map normal human brain and heart 
function. 
The system detects pairs of gamma rays emitted indirectly by a 
positron-emitting tracer, which is introduced into the body on a 
biologically active molecule. Images of tracer concentration in 3-
dimensional space within the body are then reconstructed by computer 
analysis. In this case, reconstruction was accomplished with the aid of a 
transmission scan performed on the patient during the same session, in 
the same machine. 
To conduct the scan, a short-lived radioactive tracer isotope (in this 
case H215O, see below) is injected into the SDWLHQW¶V circulation and 
becomes concentrated in tissues of interest. As the radioisotope 
undergoes positron emission decay (also known as positive beta 
decay), it emits a positron, a particle with the opposite charge of an 
electron. After travelling up to a few millimetres the positron encounters 
and annihilates with an electron, producing a pair of annihilation 
(gamma) photons moving in opposite directions. These pairs of gamma 
photons are detected in the PET scanner and converted into images of 
bioactive tissue, photons which do not arrive in pairs (i.e. within a timing 
window of few nanoseconds) are ignored. 
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Radionuclides used in PET scanning are typically isotopes with short 
half lives such as carbon-11 (~20 min), nitrogen-13 (~10 min), oxygen-
15 (~2 min), and fluorine-18 (~110 min). These radionuclides are 
incorporated either into compounds normally used by the body such as 
glucose (or glucose analogues), water or ammonia, or into molecules 
that bind to receptors or other sites of drug action. Such labelled 
compounds are known as radiotracers. For this study, we utilised 
oxygen-15 (H215O) for two main reasons: firstly the short half life 
enabled us to perform repeated scans within the time frame of the study 
session without confounding effect of residual radiotracer and secondly 
because it is more readily utilised in the myocardium compared to other 
radiotracers and therefore less likely to be affected by dialysis. Due to 
the short half lives of most radioisotopes, the radiotracers must be 
produced using a cyclotron and radiochemistry laboratory that are in 
close proximity to the PET imaging facility, hence the need to transport 
the patients from the local HD unit in Derby to the PET centre with an 
onsite cyclotron at the Hammersmith Hospital in London. 
The PET scans were performed in a three-dimensional imaging mode 
with a 962 (HR+) scanner (Siemens, Knoxville, TN, USA) (see figure 
3.6.1a). The scanner enables the acquisition of 15 planes of data over a 
10.5-cm axial field of view, allowing the whole heart to be imaged.  
 58 
 
 
Figure 3.6.1a: Patient connected to the haemodialysis machine being 
studied in the PET scanner. The Finometer and cardiac ultrasound 
scanner are also visible in this picture. 
 
All emission and transmission data were reconstructed with a Hanning 
filter with a cut-off frequency of 0.5 units of reciprocal of the sampling 
interval of the projection data, achieving an image resolution of 
8.4x8.3x6.6 mm3 full-width half maximum at the centre of the field of 
view. All subjects were asked to abstain from caffeine containing 
beverages for 24 hours before the scan.  
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Subjects were positioned in the scanner, and after exposure of a 
retractable 68Ge ring source, a 5 minute rectilinear transmission scan 
was acquired to determine the optimal imaging position of the left 
ventricle within the field of view. A 20 minute transmission scan was 
subsequently performed for the purpose of attenuation correction of all 
emission scans. To maintain the optimal imaging position of the subject 
within the scanner, a low power laser beam was superimposed on a 
cross-VKDSHGLQNPDUNRQWKHVXEMHFW¶VFKHVWDQGWKLVSRVLWLRQZDVNHSW
constant throughout all the emission scans. Starting after a 30 second 
background frame, a bolus of oxygen-15 labelled water H215O (185 
MBq) was injected intravenously over 20 seconds at an infusion rate of 
10 ml/min. The venous line was then flushed for another 2 minutes. The 
following scanning protocol was used: 1x30 seconds (background); 
1x20 seconds; 14x5 seconds; 3x10 seconds; 4x20 seconds and 4x30s 
for a total scanning time of 350 seconds. 
3.6.2 Analysis of myocardial perfusion data 
The acquired sinograms were corrected for attenuation and 
reconstructed on a Microvax II computer (Digital Equipment, Marlboro, 
MA, USA) using dedicated array processors and standard 
reconstruction algorithms. Images were then transferred to a Sun Sparc 
2 workstation (Sun Microsystems, Mountainview, CA, USA). Images 
were analysed with customised MATLAB software (The Math-works 
Natick, MA, USA. Myocardial images, for the definition of regions of 
interest, were generated directly from the dynamic H215O, as previously 
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reported 136. The creation of factor sinograms requires estimates of 
vascular (right and left heart) and myocardial tissue time-activity curves 
136,137
. Factor images describing tissue and blood distributions were 
generated by iterative reconstruction as previously described 138. Factor 
images were re-sliced into short-axis images in an orientation 
perpendicular to the long axis of the left ventricle.  
Sixteen regions of interest, corresponding to the territories of 
distribution of the 3 major coronary arteries, were drawn within the left 
ventricular myocardium on 10 consecutive image planes, according to 
the recommendations of the American Society of Echocardiography 139. 
The regions were drawn semi-automatically by use of a centre line 
within the myocardium. For our analysis, however, the original 16 left 
ventricular regions of interest were regrouped into 12 segments. A 
separate set of regions of interest was defined for the right ventricular 
cavity and the left atrium.  
Myocardial and blood time-activity curves were then generated from the 
dynamic image and fitted to a single±tissue compartment tracer kinetic 
model to give values of MBF (in millilitres per minute per gram) 137. 
Because resting MBF is determined by cardiac work-load 140, we also 
corrected resting MBF for the rate-pressure product (RPP), an index of 
myocardial oxygen consumption: MBF = (MBF/RPP) 104 141. 
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3.7 Continuous ECG recording 
3.7.1 Holter monitoring 
Continuous ECG (Holter) monitoring was performed using four 
Northeast Monitoring Inc, DR180+ Digital Recorders. After correct skin 
preparation, the Holter monitor was connected to the patient with ten 
leads for the conventional 12-lead configuration using lead RL as the 
reference and nine signal leads. This utilised nine channels for the 
highest possible quality data collection. Signal quality was visually 
verified for proper amplitude, electrode placement and lack of artifact in 
all channels by the operator using the Holter display. Lead quality was 
then further verified using built-in software that displayed signal 
condition for each lead based on impedance detected between the two 
electrodes for each channel. The best possible reading was five; any 
channel with a reading of less than four was reapplied. The sampling 
rate was set to the maximum of 720 samples per second. Interval 
between recordings and length of ECG recordings were both set to zero 
in order to obtain continuous data readings. 
Monitoring commenced immediately before the start of HD and 
continued for 24 hours subsequently. Patients were encouraged not to 
change their activities of daily living for the duration of the study time. 
Recording stopped automatically after the 24 hour period. Patients 
disconnected themselves and returned the units for data retrieval at 
their next dialysis session. 
 62 
3.7.2 Analysis of Holter data 
Data was stored and subsequently downloaded from compact flash 
digital storage cards for offline analysis (NorthEast Monitoring Inc Holter 
LX Enhanced Software) by a single, experienced technician who was 
blinded to echocardiographical and biochemical results. 
Frequency of ectopy was classified as a percentage of the total beats 
during the time period studied 142 UDUH  RFFDVLRQDO ! WR
1.0%), frequent (>1.0 to 10%) and very frequent (>10%). Ventricular 
arrhythmias were stratified according to the Lown classification 143 (see 
table 3.7.2a); classes 3 and above were taken as complex ventricular 
arrhythmias (CVA). All patients who were classified as having a class 3 
arrhythmia or above had all their abnormal complexes visually reviewed 
to exclude false positive results caused by artifact. 
 
Class Arrhythmia 
0 None 
1 Unifocal; <30/hour 
2 Unifocal; 30/hour 
3 Multiform 
4A 2 consecutive 
4B 3 consecutive 
5 R-on-T phenomenon 
 
Table 3.7.2a: Lown Classification of ventricular arrhythmias 
 63 
BVpost x (1 - Hctpost) 
BVpre x (1 - Hctpre) 
Adjusted cTnT = cTnTpost  x 
Beat-by-beat analysis of ST segment changes using the auto-detection 
software was impracticable due to the large volume of incorrectly 
identified significant beats. Consequently, 12-lead ECGs were recorded 
and subsequently analysed for significant changes from baseline every 
15 minutes during HD. 
3.8 Haematological and biochemical assays 
All pre-dialysis blood tests were drawn immediately after insertion of 
access needles, and post-dialysis levels were taken from the arterial 
line 10 seconds after reduction of blood pump speed to 50 ml/min. 
Biochemical analysis was performed on a multichannel autoanalyser. 
Full blood count measurements were performed using a compact 
analyser. Other assays and measurements are detailed below. 
3.8.1 Cardiac troponin-T 
Cardiac troponin-T (cTnT) analysis was performed using a third-
generation electrochemiluminescence assay (Roche Diagnostics, 
Lewes, UK). Postdialysis cTnT values were corrected individually for 
haemoconcentration with reference to percentage change in 
haematocrit and blood volume using the following formula: 
 
 64 
where cTnTpost is postdialysis cTnT, Hctpost is postdialysis haematocrit, 
Hctpre is predialysis haematocrit, BVpost is end dialysis blood volume, 
and BVpre is start dialysis blood volume. 
3.8.2 High sensitivity C-reactive protein 
High sensitivity C-reactive protein levels were measured using an 
enzyme linked immunosorbent assay (ELISA).  
Briefly, a monoclonal antibody against the molecule to be detected is 
adsorbed onto the surface of microwells. Samples or standards are 
then added to the wells and the molecule binds to these solid phase 
antibodies. A labeled antibody against the molecule is then also added 
and this also binds to the molecule to form a sandwich (solid phase 
antibody - test molecule - labeled antibody). After incubation, the wells 
are washed to remove unbound labeled antibody and a chromogenic 
reagent is added that reacts with the labeled antibody to produce a 
colour change. A stop solution is added to prevent excess colour 
development and the absorbance of each well is measured 
spectophotometrically. The absorbance is proportional to the 
concentration of test molecule present. A standard curve is drawn from 
the standards and values for the concentration of samples in each well 
can then be calculated. We used standard ELISA kits that provided pre-
coated 96 well plates (DRG diagnostics, Marburg, Germany). 
Serum was isolated from blood collected in plain tubes and immediately 
centrifuged at 3500rpm for 10 minutes. The plasma was then removed 
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and frozen at -80°C until time of assay. Samples were centrifuged again 
upon thawing at 17,000rpm for 3 minutes to remove particulates. Before 
assaying, the serum was diluted 100-fold. The C-reactive protein (CRP) 
high sensitivity ELISA uses monoclonal mouse antibody for the solid 
phase and a goat anti-CRP antibody labeled with horseradish 
peroxidase (HRP). 
3.8.3 Dialysis adequacy 
Dialysis adequacy was measured using single-pool Kt/Vurea values 
which were calculated from pre- and postdialysis urea levels, post 
dialysis weight and ultrafiltration volume based on the Daugirdas II 
formula 144. 
3.9 Statistical methods 
The exact statistical methodology varied depending on the individual 
analyses used and is dealt with in detail in the relevant results sections 
below. 
The author undertook all statistical analyses using the software 
packages Prism 5 for Windows (GraphPad Software Inc, San Diego, 
USA) and SPSS v10 (SPSS Inc, Chicago, USA). More complex 
multivariate analyses were verified by an independent statistician 
employed by Derby Hospitals NHS Foundation Trust Research and 
Development Department. 
 
 66 
 
 
 
 
 
Chapter 4 
 
Results: 
Haemodialysis induced contractile dysfunction is associated with acute 
and reversible reduction in global and segmental myocardial blood flow. 
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4 Results: Haemodialysis induced contractile 
dysfunction is associated with acute and 
reversible reduction in global and segmental 
myocardial blood flow. 
4.1 Introduction 
Previous small studies have shown that HD induces acute and 
reversible regional wall motion abnormalities (as measured using 
echocardiography). Such regional wall motion abnormalities are usually 
indicative of ischaemia however; for conclusive evidence of dialysis 
induced myocardial stunning, myocardial blood flow needs to be 
measured in conjunction with functional assessment of the left ventricle. 
This would allow demonstration of the initial ischaemic insult followed 
by persistent dysfunction upon resolution of flow 145. 
This study was designed to investigate whether haemodialysis directly 
induces myocardial ischaemia and myocardial stunning through a 
reduction in myocardial blood flow using PET scanning (to measure 
myocardial blood flow), echocardiography (to measure left ventricular 
regional wall function) and non-invasive haemodynamic monitoring. We 
also aim to compare the effects of standard dialysis and biofeedback 
dialysis. This is an entirely novel concept, and one with great clinical 
relevance. The work may potentially reveal an additional aetiological 
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factor in the development of cardiovascular disease in dialysis patients, 
which could be a target for future therapy or prevention. 
We hypothesise that observed reductions in segmental contractile 
function consistent with myocardial stunning are as a result of 
ischaemia. Furthermore, the repeated nature of this insult (thrice 
weekly) may be important in the development of dialysis associated 
heart failure. 
Additional aims included: the evaluation of the acute effects of both 
standard and modified (biofeedback controlled) dialysis on global and 
segmental myocardial blood flow utilising intradialytic H215O PET 
scanning (the most accurate dynamic measure of myocardial 
perfusion); and the effect of reduced myocardial blood flow on 
segmental function using echocardiography. 
4.2 Methods 
4.2.1 Patients 
Four patients on chronic haemodialysis who were recruited for a 
randomised cross-over study. All patients were male and all had been 
on dialysis for longer than six months. Angiograms had been performed 
as part of routine clinical care (e.g. for investigation of ischaemic heart 
disease or for work up for transplantation). Angiographic results and 
remaining characteristics are shown in table 4.2.1a. All patients dialysed 
via native arteriovenous fistulae and all were anuric. 
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Table 4.2.1a: Patient demographics including angiographic indications 
and findings. 
 
Patients were excluded if they had significant symptomatic cardiac 
failure (NYHA t 3) or experienced an acute coronary syndrome in the 
preceding four months, had previously received a cardiac transplant or 
if it was not possible to obtain echocardiographic images of sufficient 
quality to allow meaningful analysis. 
4.2.2 Study protocol 
8SRQ HQWU\ WR WKH VWXG\ SDWLHQWV¶ GU\ ZHLJKW DQG DQWL-hypertensive 
medications remained unchanged for the duration. Patients were then 
randomised to two groups. Group A patients were commenced on 
standard thrice weekly haemodialysis (HD); group B patients started 
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thrice weekly dialysis with the Hemocontrol ELRIHHGEDFN V\VWHP
(BFD). Patients, but not dialysis unit staff, were blinded to the 
intervention. Both groups underwent two weeks of the dialysis therapy 
at the HD unit in Derby after which patients attended their initial 
monitored dialysis session at the Hammersmith Hospital in London. 
Beta-blocking agents and calcium antagonists were withdrawn 72 hrs 
prior to the study (as they are known to protect against myocardial 
stunning), and other anti-anginal medication omitted on the day. 
Patients were asked to avoid activities that might precipitate their 
angina for 12 hours before the study and were excluded if they have 
suffered angina or used their GTN spray within 4 hours of 
commencement. After the conclusion of the first study, patients then 
crossed over to the other dialysis modality thereby acting as their own 
controls. After two weeks on the alternate modality, patients underwent 
a second monitored session on the same day of the week as the first 
study session. 
For each monitored dialysis treatment, myocardial blood flow was 
measured pre-dialysis, during treatment at two and four hours and 
again 30 minutes into the recovery using H215O PET scanning. Serial 
echocardiography was performed at the same time points and 
immediately prior to the PET scans. Non-invasive haemodynamic 
monitoring of blood pressure (BP) and heart rate was undertaken using 
a Finometer. To obtain baseline values, monitoring was started 30min 
prior to commencement of dialysis. Pre-dialysis blood tests were drawn 
immediately after insertion of access needles, and post levels were 
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taken from the arterial line 10sec after reducing blood pump speed to 
50ml/min. Single pool Kt/Vurea values were calculated from pre and post 
urea levels 144.  
The primary endpoint was the frequency of new LV regional wall motion 
abnormalities during HD in relation to global and regional MBF. 
All patients gave informed consent prior to commencement, and ethical 
approval for the project was granted by Derbyshire Local Research 
Ethics Committee. 
4.2.3 Haemodialysis details 
Dialysis was performed as described in chapter 3. For standard HD, 
dialysate sodium conductivity was set at 13.6 mS/cm. For biofeedback 
dialysis (BFD), conductivity limits were set at 13.0 mS/cm and 14.0 
mS/cm. Automatic adjustment of dialysate conductivity by the dialysis 
monitor during Hemocontrol has been shown to achieve equivalent 
overall dialysate conductivity and therefore equal change in plasma 
water sodium concentration 146. Limits for relative blood volume were 
set on an individual basis depending on measurements taken during the 
week prior to echocardiographic assessment. 
4.2.4 Positron emission tomography (PET) 
Measurement of myocardial blood flow (MBF) using H215O PET is 
described in detail in chapter 3. Initial transmission scans and baseline 
measurements of MBF were taken before the commencement of 
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haemodialysis. Subsequent scan were taken at 120 minutes and 240 
minutes into dialysis and still on treatment, each being done 
immediately after echocardiographical imaging for assessment of left 
ventricular regional wall motion abnormalities. 
4.2.5 Echocardiography 
Echocardiography and subsequent analysis were performed as 
described in chapter 3. Images were recorded prior to commencing 
dialysis (baseline); at 120 minutes and 240 minutes during dialysis and 
immediately prior to the measurement of myocardial blood flow using 
PET; and 30 minutes after dialysis was finished (recovery). Ten regions 
of the left ventricle were assessed for the development of new regional 
wall motion abnormalities (RWMAs) at each time point. We calculated 
mean SF for all ten segments (SF(mean)) and for those segments that 
developed new RWMAs (SF(WMA)). Peak stress was defined for each 
patient as the point during the first monitored dialysis session when 
most RWMAs were present (either 120 minutes or 240 minutes). When 
comparing dialysis modalities, the same time point was used in the 
second dialysis session. 
4.2.6 Finometer 
The Finometer was used as described in chapter 3 and connected up 
before the first measurement of MBF was taken. This enabled: correct 
calibration of the device before commencement of haemodialysis; for 
accurate measures of blood pressure and heart rate during the PET 
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scan to allow for exact correction of the rate pressure product; and 
allowed for measurements of baseline haemodynamic variables over 20 
minutes for comparison to be made at subsequent timepoints on HD. 
4.3 Statistical analysis 
This power calculation is based on detecting a significant change in 
myocardial blood flow from baseline during dialysis (primary objective) 
and does not calculate the numbers required to detect a difference in 
blood flow between the two dialysis types. Data on myocardial blood 
flow are currently only available from patients with known coronary 
artery disease without renal failure. These data indicate that myocardial 
blood flow changes by about 60-70% in response to a dobutamine 
stress. Using the standard deviation (SD) from these studies, a sample 
size of 6 would appear to be sufficient to detect a difference of 62% 
change from baseline. A sample size of 6 is also similar to other studies 
using similar techniques 67,147. However, although this power calculation 
is not aimed at detecting a difference between the 2 types of dialysis, 
previous work with 8 patients has shown that we can detect a difference 
in LV regional wall motion with these 2 types of dialysis. 
Results are expressed as mean ± standard deviation if parametric or 
median (interquartile range, IQR) if non-parametric unless otherwise 
stated. Echocardiographic, BP and haemodynamic data were analysed 
using one-way analysis of variance (ANOVA) with a design for repeated 
PHDVXUHVDQG%RQIHUURQL¶VWest to correct for multiple comparisons. For 
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other data, either the paired t-test or Wilcoxon rank sum test was used 
depending on normality of the distribution. Significant deviations from a 
normal distribution were excluded with the Kolmogorov-Smirnov test. 
An alpha error at P<0.05 was judged to be significant. 
4.4 Results 
4.4.1 Echocardiographic Data 
Throughout the study all patients were in sinus rhythm and none had 
significant valvular disease or pulmonary hypertension. 
At two and four hours a total of 39/130 (33%) RWMAs developed during 
both types of dialysis. There was no significant difference in the number 
of RWMAs that developed between two and four hours. At 30 minutes 
post dialysis (recovery period) compared to four hours, 81% of RWMAs 
had improved and 23% had regained normal function, confirming the 
presence of myocardial stunning in this group. There was no significant 
difference in either the number of RWMAs or their severity in terms of 
shortening fraction (SF) between HD and BFD during dialysis or after 
the recovery period (P>0.05 by ANOVA). 
4.4.2 PET Data 
All results were corrected for rate pressure product (RPP). However, no 
significant difference was observed between corrected and non-
corrected values at given time points. Previous studies have shown 
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reduced baro-reflex sensitivity and heart rate variability in this group so 
results shown are therefore non-corrected unless otherwise stated. 
Global, mean pre-dialysis MBF for both modalities was within the 
normal range. Global MBF was acutely reduced during dialysis and 
became progressively worse over time. There was some restoration of 
flow (but not complete) after the 30 minute recovery period (figure 
4.4.2a). 
 
Figure 4.4.2a: Mean global myocardial blood flow reduced significantly 
over time during dialysis compared to baseline with partial restoration in 
the recovery period. 
 
Segmental MBF was reduced in 67% and 90% of regions at two hours 
and at 4 hours respectively (figures 4.4.2b and 4.4.2c). Three of the four 
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patients had universal (100%) involvement with reduction of MBF in all 
segments during both dialysis modalities.  
 
Figures 4.4.2b and 4.4.2c: Regional myocardial blood flow is reduced 
over time on haemodialysis. Higher amounts of H215O tracer are 
present in the ventricular myocardium at baseline (b) compared to 4 
hours into dialysis treatment (c) indicating reduced blood flow to that 
area. 
 
Between dialysis modalities (HD and BFD) baseline MBF was 
compared on an individual basis for each. There were no significant 
differences in three of the four patients (P>0.05) however one patient 
showed a significant improvement in resting MBF after the two weeks of 
BFD. There were also no significant differences in MBF between 
dialysis modalities at two or four hours although when observing 
C B 
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individual patients, one had a significant improvement in MBF at four 
hours during BFD (P<0.001) without any significant difference in MBF at 
baseline. 
After the recovery period, there was an improvement in MBF in 85% of 
segments demonstrating partial but not complete restoration of blood 
flow after 30 minutes. There was a greater overall restoration of MBF 
after BFD compared to HD (P<0.001) (see figure 4.4.2d). 
 
Figure 4.4.2d: Mean MBF during HD and BFD. There was no significant 
benefit between dialysis modalities during treatment (P>0.05) however, 
there was an improvement in MBF in the recovery period after BFD 
(*P<0.001). 
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The development of RWMAs demonstrated by echocardiography was 
significantly associated with both: a greater overall percentage 
reduction in MBF (-30 ± 27.7% vs. -12.3 ± 12.3%) (P=0.001, see figure 
4.4.2e); and a greater reduction in MBF at each time point studied 
(P<0.001 by ANOVA, see figure 4.4.2f).  
 
 
 
Figure 4.4.2e: The development of RWMAs (abnormal regions) was 
associated with a greater reduction in MBF from baseline than those 
areas that maintained normal movement (normal regions) (P=0.001) 
 
Not all regions with reduced MBF were functionally affected; however a 
reduction in MBF 30% from baseline (mean reduction of MBF in all 
regions = 29%) was significantly associated with the development of 
RWMAs (P<0.01). Also, in areas where reduction in MBF was <30%, 
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there was actually a mean overall increase in percentage wall motion 
(see figure 4.4.2g). 
 
Figure 4.4.2f: The development of RWMAs (red bars) was associated 
with a greater reduction in MBF at each timepoint than those areas that 
maintained normal movement (grey bars) (P<0.001) 
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)LJXUHJ$0%)UHGXFWLRQRIZDVDVVRFLDWHGZLWKDPHDQ
reduction in wall motion of -15.2% however a MBF reduction of <30% 
was associated with a mean increase in wall motion of 5% (P<0.01). 
 
4.4.3 Haemodynamic data 
Haemodynamic data are summarised in figures 4.4.3a and 4.4.3b. 
Mean systolic BP was maintained slightly higher during BFD (127 ± 10 
mmHg) than HD (124 ± 12 mmHg) (P<0.05).  There were no significant 
differences between diastolic BP or mean arterial pressure (MAP) 
between HD and BFD. None of the patients had episodes of 
symptomatic or asymptomatic intra-dialytic hypotension. 
Heart rate increased throughout both modalities to a similar degree, 
with means of 6 ± 2% during HD and 6 ± 3% during BFD (NS). 
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Figures 4.4.3a and 4.4.3b: A) Overall mean blood pressures between 
HD and BFD. BP was maintained higher on BFD (P<0.05). B) Heart 
rate increased similarly during both HD and BFD (P=ns). 
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4.4.4 Laboratory data 
There were no differences in any of the biochemical parameters when 
the two types of dialysis were compared. Cardiac troponin-I (cTnI) 
levels were similar between the 2 modalities and did not change 
significantly after dialysis. Three of the four patients had normal cTnI 
levels of <0.032 (table 4.4.4a). 
Parameter 
Standard dialysis (HD)
 
Biofeedback dialysis (BFD)
 
Pre dialysis Post dialysis Pre dialysis Post dialysis 
Haemoglobin (g/dl) 12.10 (10.7 to 13.4) 12.5 (11 to 14.6) 11.9 (11.3 to 13.6) 12.9 (11.3 to 13.1) 
Haematocrit 0.36 (0.33 to 0.44) 0.37 (0.34 ± 0.43) 0.37 (0.35 to 0.4) 0.38 (0.35 to 0.4) 
Na+ (mmol/l) 137 (135 to 149) 137.5 (136 to 138) 137 (136 to 138) 137 (135 to 138) 
Corr. Ca2+ (mmol/l) 2.32 (2.22 to 2.39) 2.28 (2.15 to 2.35) 2.46 (2.36 to 2.46) 2.33 (2.33 to 2.33) 
Phosphate (mmol/l) 1.75 (1.49 to 2.05) 0.89 (0.77 to 0.99) 1.93 (1.49 to 3.1) 1.05 (0.77 to 1.13) 
Albumin (g/l) 32 (31 to 33.5) 36.5 (35 to 39) 32 (32 to 33) 34 (33 to 36) 
CRP (mg/l) 7.5 (3 to 12) 7.5 (2 to 13) 4 (3 to 9) 5 (4 to 10) 
cTnI (Pg/l)* <0.032 (<0.032 to 0.05) 
<0.032 (<0.032 to 
0.46) 
<0.032 (<0.032 to 
0.41) 
<0.032 (<0.032 to 
0.4) 
Kt/Vurea 1.32 (1.3 to 1.42)  1.44 (1.42 to 1.52)  
 
Table 4.4.4a: Laboratory data. Data are median (interquartile range). 
There were no significant differences between haemodialysis (HD) and 
biofeedback dialysis (BFD) for any parameters, including Kt/Vurea. CRP, 
C-reactive protein; cTnI, cardiac troponin-I; Corr. Ca2+, corrected 
calcium. *Lowest value quoted 0.032 (normal). 
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4.5 Discussion 
This study demonstrates for the first time that HD is associated with 
significant reductions in MBF and that HD stress±induced myocardial 
ischemia results in the development of RWMA. Furthermore, dialysis-
induced myocardial stunning occurs in the absence of large-vessel 
epicardial coronary disease. 
All of the patients in all of the HD treatments studied developed RWMA 
during HD. Both the pattern of abnormalities and the subsequent partial 
resolution after dialysis are in keeping with previous reports of small 
studies done in this area 70,71. In an additional cross-sectional study of 
70 unselected HD patients, we also found significant dialysis-induced 
RWMA in 63% of patients who were undergoing conventional thrice-
weekly HD 148. 
Cardiac PET scanning using H215O revealed significant dialysis-induced 
changes in global and segmental MBF. Resting values in these patients 
were broadly in keeping with published values in patients without CAD 
or uremia 149. This is expected because ischemic potential of 
myocardium is determined by reduced CFR rather than resting 
perfusion. The values were also consistent within an individual between 
two study sessions. All patients experienced global reduction of MBF, 
which increased during the HD session and was partially restored to 
normality 30 minutes after HD. This observed pattern of change is 
mirrored in the development of RWMA during HD, both within this study 
and in others 70,71 where the numbers of segments affected and the 
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severity (in terms of the magnitude reduction in percentage shortening 
fraction) are increased over time. The magnitude of the reduction in 
MBF at peak stress during HD is also broadly comparable with that 
observed in studies of pharmacologically stressed myocardial ischemia 
in patients with known significant CAD 67.  
The reduction of MBF was significantly more marked in segments of 
myocardium that also displayed significant dialysis-induced reduction in 
contractile function. This was true both globally and at each given time 
point measured. Regional subendocardial and transmural MBF has 
been well correlated to reduction in segmental ventricular function in 
studies in conscious dogs that were subjected to graded coronary 
restriction 150. We observed a similar scale of response in our patients 
who were subjected to HD.  
Uraemic patients have a high prevalence of coronary atherosclerotic 
lesions 47,48 but although these patients did not have angiographic 
evidence of significant CAD (indeed, two of the patients had entirely 
normal coronary angiograms), HD was still capable of inducing 
myocardial ischemia. Previous descriptions of dialysis-induced 
myocardial ischemia and, indeed, implied ischemia from dialysis-
associated RWMA, indicate that this is a common feature, with a 
prevalence well in excess of even the more pessimistic estimates of 
significant CAD in this patient group. As already discussed, patients 
with chronic kidney disease (especially those who receive HD) are 
uniquely well primed to experience demand ischemia as a result of a 
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variety of factors relating to structural and functional alterations in the 
cardiac microcirculation 151, as well as abnormalities in myocardial 
metabolism 1526SHFLILFDOO\D UHGXFWLRQ LQFDSLOODU\GHQVLW\ µP\RF\WH-
FDSLOODU\ PLVPDWFK¶ KDV EHHQ GHVFULEHG 153,154 which is, in part, 
explained by left ventricular hypertrophy. Myocardial perfusion reserve 
has been found to be decreased in patients with chronic renal failure 
155
, in diabetic HD patients 49 and in young adults after renal 
transplantation 156 in the absence of coronary artery disease. Even 
patients with mild renal insufficiency but without significant CAD have 
significantly reduced CFR measured at coronary artery catheterisation 
with adenosine challenge 155. Other factors also play a role. LVH 
renders the ventricle more sensitive to acute changes in filling pressure 
during UF-induced hypovolaemia 53. Increased peripheral artery 
stiffness also has an adverse effect on MBF and reduces the threshold 
for myocardial ischemia in patients with coronary artery disease 54. LVH 
together with increased vascular stiffness predispose to reduced 
subendocardial blood flow 55. Left ventricular hypertrophy, and 
peripheral arterial stiffness 157.  
The haemodynamic response to HD was typical of that reported 
previously. The relative lack of change in heart rate with ultrafiltration-
induced changes in BP is also typical. Baroreflex sensitivity is 
characteristically significantly impaired in this patient group 158 and may 
account at least in part for the cardiovascular response to HD 159. Such 
heart rate stability also brings into question the validity of correcting 
MBF for RPP. Such correction, however, does not alter the pattern or 
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significance of the results reported in this study. Patients who 
underwent dialysis using biofeedback control did demonstrate 
significantly higher recovery of MBF in the postdialysis period. The 
reduction in BP was more marked when patients underwent dialysis 
using conventional rather than biofeedback HD. Although these patients 
did not experience any episodes of intradialytic hypotension (IDH), such 
biofeedback treatment has been associated with improvement of clinical 
indices of treatment tolerability even in patients who were characterised 
as being IDH resistant 113. The difference in BP was significant only in 
the latter part of the HD treatment. This was in contrast to a previous 
study of biofeedback dialysis on the development of RWMA 71. 
Comparison of this study with subsequent reduction in dialysis-induced 
RWMA using cooling of dialysate 70 suggests that the degree of 
protection from dialysis-induced cardiac injury is at least in part 
proportional to the maintenance of BP achieved. 
4.6 Conclusions 
The results in this chapter demonstrate that the cardiovascular stress of 
HD is capable of inducing significant global and segmental reductions in 
MBF. These changes in myocardial perfusion are repetitive and 
sufficient to result in reduced ventricular contraction. Such repetitive 
ischemic insults in patients with CAD are widely recognised to be 
important in the pathogenesis of cardiac failure. Stunning has been 
shown to be a powerful predictor of a dismal prognosis in patients with 
coronary artery disease 160. HD-induced RWMA are common in dialysis 
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patients. Dialysis-induced myocardial stunning may be an important and 
previously unappreciated factor in the development of cardiac failure in 
HD patients. Additional attention to the way in which we dialyse patients 
may not only be important in the subjective patient tolerability of the 
treatment but also a key therapeutic target to reduce the vast 
cardiovascular morbidity and mortality to which these patents are 
subjected. 
The following chapters aim to further knowledge into the extent of the 
problem of acute haemodialysis induced cardiac injury and functional 
decline in the haemodialysis population as a whole. 
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Chapter 5 
 
Results: 
Haemodialysis induced acute cardiac injury: prevalence and associated 
factors. 
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5 Results: Haemodialysis induced cardiac injury: 
prevalence and associated factors. 
5.1 Introduction 
The data contained in the previous chapter demonstrates that acute, 
dialysis-induced regional wall motion abnormalities are associated with 
a significant reduction in segmental myocardial blood flow, consistent 
with ischaemia. This was true even in the absence of significant 
macrovascular coronary artery disease. As previously mentioned, a 
number of small studies have described the phenomenon of HD 
induced myocardial stunning, as well as the potential (at least in the 
short term) to abrogate dialysis induced cardiac injury with dialysis 
techniques which improve haemodynamic tolerability 70,71. 
The details of the mechanisms involved in HD induced myocardial 
stunning are currently largely unresolved and unfortunately, little is 
known about the extent to which the haemodialysis population actually 
suffers from this phenomenon. What is known however is that during 
HD, patients are particularly susceptible to myocardial ischaemia and in 
the four patients studied in chapter 4, all had a reduction in myocardial 
blood flow during dialysis and all had some degree of functional 
impairment as measured by the development of RWMAs. That study 
was however not powered adequately to look for either the prevalence 
or associated factors of myocardial stunning. A deeper understanding of 
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the prevalence of acute haemodialysis induced myocardial stunning 
may help to identify patients at risk of intra-dialytic myocardial 
ischaemia, RWMAs and haemodynamic instability. This may in turn 
help to develop dialysis based interventions to combat these 
complications and improve mortality. 
This study was designed to ascertain the prevalence of myocardial 
stunning in the HD population to better understand the longer term 
consequences of this phenomenon on LV function, intradialytic 
haemodynamics and survival. In addition this study provided an 
opportunity to define the risk factors and their interactions in relation to 
the development of acute cardiac injury. 
5.2 Methods 
5.2.1 Patients 
Seventy prevalent HD patients were recruited for a 12-month 
observational cohort study from a single hospital based haemodialysis 
unit. Patients were excluded if they had pre-existing severe LV systolic 
dysfunction (NYHA IV) or inadequate echocardiographical windows to 
obtain images of sufficient quality. Only one patient was excluded on 
this basis.  
 As patients dialysed as part of a conventional thrice weekly treatment 
regime (four hour dialysis sessions), all studies were conducted after 
the first two-day interdialytic period, as arrhythmias and cardiac events 
 92 
are known to be increased after the 3-day interdialytic break. All 
patients were undergoing standard haemodialysis treatments with no 
sodium or biofeedback profiling. 
5.2.2 Study protocol 
After entry to the study, SDWLHQWV¶ ZHUH LQWHUYLHZHG ERWK WR FRQILUP
consent and for the purpose of taking a medical history and performing 
a physical examination. All medical details were then confirmed using 
SDWLHQWV¶QRWHV 
 After that initial meeting, all patients (n=70) subsequently underwent an 
initial (baseline) monitored haemodialysis session. During this 
monitored dialysis treatment, global and regional left ventricular function 
was measured using serial echocardiography at four separate time 
points: pre-dialysis; during treatment at both two and four hours; and 
again 30 minutes into the post-dialysis recovery phase. Non-invasive 
haemodynamic monitoring of blood pressure (BP) was undertaken 
every 15 minutes. Pre-dialysis blood tests were drawn immediately after 
insertion of access needles, and post levels were taken from the arterial 
line 10sec after reducing blood pump speed to 50ml/min. Single pool 
Kt/Vurea values were calculated from pre and post urea levels 144. 
The primary endpoint was to assess the prevalence of HD induced 
RWMAs in a standard HD population. Secondary endpoints included 
the identification of variables associated with the development of LV 
RWMAs. 
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Ethical approval for the project was granted by Nottingham Local 
Research Ethics Committee. 
5.2.3 Haemodialysis details 
Dialysis was performed as described in chapter 3 using Hospal Integra 
monitors (Hospal, Mirandola, Italy) using low-flux polysulfone dialysers, 
either 1.8 or 2.0 m2SHU LQGLYLGXDOSDWLHQWV¶XVXDOSUHVFULStions (LOPS 
18/20; Braun Medical Ltd, Sheffield, UK). 
Dialysate fluid contained sodium, 138 mmol/L; potassium, 1 mmol/L; 
calcium 1.25 mmol/L; magnesium, 0.5 mmol/L; bicarbonate, 32 mmol/L; 
glucose, 5.6 mmol/L; and acetate, 3 mmol/L. Dialysate sodium 
conductivity was set at 13.6 ms/cm. 
$OO WUHDWPHQWV ZHUH RI IRXU KRXUV¶ GXUDWLRQ DQG DQWLFRDJXODWLRQ ZDV
with unfractionated heparin. Dialysate flow was 500 mL/min, and 
dialysate temperature was set at 37°C. For each session, net fluid 
removal was set on an individual basis according to ideal dry weight. 
Blood pump speed varied between 250 and 450 mL/min, depending on 
WKHSDWLHQW¶VYDVFXODUDFFHVV 
5.2.4 Echocardiography 
Echocardiography and subsequent analysis were performed as 
described in chapter 3. Images were recorded prior to commencing 
dialysis (baseline); at 120 minutes and 240 minutes during dialysis; and 
30 minutes after dialysis was finished (recovery).  
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Ten regions of the left ventricle were assessed for the development of 
new regional wall motion abnormalities (RWMAs) at each time point. A 
wall motion abnormality was defined as a reduction in wall motion of 
>20% from baseline readings. Regions that showed a functional decline 
of >20% during HD compared to rest with evidence of functional 
recovery in the post-dialysis period were classed as stunned segments. 
The presence of three or more such RWMAs (out of a maximum of ten 
regions) in any individual patient was counted as evidence of clinically 
significant myocardial stunning.   
5.2.5 Measurement of blood pressure 
Non-invasive, serial blood pressure readings were taken as described 
in chapter 3. Blood pressure was measured pre-dialysis and then 
serially every 15 minutes during haemodialysis using an automated 
digital oscillometric device. Each value recorded was the mean of three 
individual readings. 
5.2.6 Measurement of haematological and biochemical variables 
Blood samples were analysed as detailed in chapter 3. Pre-dialysis 
blood tests were drawn immediately after insertion of access needles, 
and post-dialysis levels were taken from the arterial line 10 seconds 
after reduction of blood pump speed to 50 ml/min. 
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5.3 Statistical analysis 
This power calculation is based on detecting significant changes in 
LVEF using echocardiography between baseline and 12 months of 
3.6% 161 with a standard deviation of 8.987 162 for which the required 
sample size was 68 patients. This achieved a power of 90% at a 
significance level of 5%.  
Results are presented as the mean value ± SD or the median and 
interquartile range (IQR) unless otherwise stated. BP data were 
analysed using two-ZD\DQDO\VLVRIYDULDQFH$129$ZLWK%RQIHUURQL¶V
post tests for multiple comparisons. Categorical variables between the 
WZR JURXSV ZHUH DQDO\VHG XVLQJ )LVKHU¶V H[DFW WHVW Depending on 
Gaussian distribution (significant deviations from a normal distribution 
were excluded with the Kolmogorov-Smirnov test), all other data were 
analysed using either the paired or unpaired t tests or the Mann-
Whitney or Wilcoxon matched pairs tests. An alpha error at P<0.05 was 
judged to be significant. An alpha error at P<0.05 was judged to be 
significant. 
5.4 Results 
5.4.1 Prevalence of regional wall motion abnormalities 
64% of patients (45/70) developed a significant number of regional wall 
motion abnormalities during haemodialysis (figure 5.4.1a). There was 
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no significant difference between the number of regions affected at two 
hours compared to four hours (4.48±1.7 vs. 4.52±1.9, P=0.8). 
 
 
Figure 5.4.1a: Prevalence of haemodialysis induced left ventricular 
regional wall motion abnormalities (RWMAs). 
 
5.4.2 Severity of regional wall motion abnormalities 
In those regions affected, there was a significant reduction in 
percentage shortening fraction (%SF) at each timepoint compared to 
baseline (baseline 3.17±1.28%; two hours 1.75±0.67%, P<0.001; four 
hours 1.59±0.69%, P<0.001; recovery 2.3±0.94%, P<0.01). There was 
also a significant return towards pre-dialysis values for %SF between 
both timepoints during HD and the recovery period (P<0.001), 
confirming the presence of myocardial stunning. Although the mean 
Patients with >2 RWMAs 
Patients with <2 RWMAs
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%SF was lower in affected regions at four hours compared to two, this 
was only a trend and did not reach statistical significance (P=0.14). All 
of these data are represented in figure 5.4.2a. 
 
 
Figure 5.4.2a: Severity of regional wall motion abnormalities over time 
during haemodialysis. Percentage shortening fraction (%SF) was 
significantly lower compared to baseline at each timepoint. Post dialysis 
%SF was significantly higher than at both 2 and 4 hours during 
treatment, confirming at least partial recovery of function in those areas 
and consistent with myocardial stunning. 
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5.4.3 Patient characteristics and dialysis related factors 
associated with the presence of myocardial stunning 
Patient demographics and other dialysis related factors are shown in 
table 5.4.3a. Univariate analysis of these variables showed a number of 
factors associated with the development of haemodialysis induced 
myocardial stunning. These were advancing age (P=0.03); higher 
intradialytic ultrafiltration volumes (P=0.01) and the presence of 
diabetes mellitus as a co-morbid condition (RR=1.7; CI 1.2 to 2.4; 
P=0.002), see figures 5.4.3a and 5.4.3b. 
 
Figure 5.4.3a: Myocardial stunning and patient age. The development 
of HD-induced myocardial stunning was associated with a significantly 
higher age (P=0.03). 
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Characteristics All Patients (n=70) 
Patients with 
RWMAs 
(n=45) 
Patients 
without RWMAs 
(n=25) 
P 
value 
Age (mean, years) 63.1 ± 13.7 65.6 ± 1.9 59.4 ± 3 0.03 
Male:Female 47 : 23 28 : 17 19 : 6 0.29 
Dialysis vintage (mean, months) 45.2 ± 32.3 43.5 ± 31 48.1 ± 34.8 0.57 
Intradialytic UF volume (mean, L) 1.95 ± 0.83 2.13 ± 0.91 1.59 ± 0.75 0.01 
Kt/V urea 1.3 ± 0.2 1.3 ± 0.2 1.3 ± 0.3 0.88 
Smoker 11 (16%) 7 (16%) 4 (16%) 1 
Ethnicity (n) 
    
Caucasian 65 (93%) 43 (96%) 22 (88%) 0.34 
Afro-caribbean 1 (1%) 1 (2%) 0 (0%) 1 
Asian 4 (5%) 1 (2%) 3 (12%) 0.13 
Etiologies (n) 
    
Diabetic nephropathy 22 (31%) 18 (40%) 4 (16%) 0.06 
Glomerular disease 12 (17%) 8 (18%) 4 (16%) 1 
APKD 7 (10%) 5 (11%) 2 (8%) 1 
Urological 6 (9%) 3 (7%) 3 (12%) 0.66 
Unknown 9 (13%) 5 (11%) 4 (16%) 0.71 
Other 14 (29%) 6 (13%) 8 (32%) 0.12 
Co-morbidities (n) 
    
Ischaemic heart disease 24 (34%) 19 (42%) 5 (20%) 0.071 
Diabetes mellitus  28 (40%) 24 (53%) 4 (16%) 0.002 
Hypertension 42 (60%) 27 (60%) 15 (60%) 1 
Hyperlipidaemia 31 (44%) 21 (47%) 10 (40%) 0.62 
Left ventricular hypertrophy 42 (60%) 27 (60%) 15 (60%) 1 
 
Table 5.4.3a: Patient characteristics and dialysis related factors in all 
patients and in groups based on the presence (with) or absence 
(without) of dialysis induced regional wall motion abnormalities 
(RWMAs). APKD = adult polycystic kidney disease; UF = ultrafiltration. 
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Figure 5.4.3b: Myocardial stunning and ultrafiltration volume. The 
development of HD-induced myocardial stunning was associated with a 
significantly higher ultrafiltration volume (P=0.01). 
 
Patients with ischaemic heart disease (IHD) were more likely to develop 
HD-induced RWMAs but this was only a trend and did not reach 
statistical significance (P=0.07). 
There were no other statistically significant differences between those 
patients with or without HD-induced myocardial stunning with respect to 
underlying aetiology, dialysis vintage, drug therapies or other co-morbid 
conditions. 
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5.4.4 Haematological and biochemical variables associated 
with the presence of myocardial stunning 
Haematological and biochemical values are summarised in table 5.4.4a.  
Parameter 
Pre-dialysis blood testing Post-dialysis blood testing 
Patients with 
RWMAs 
Patients 
without 
RWMAs 
P 
value 
Patients with 
RWMAs 
Patients 
without 
RWMAs 
P 
value 
Haemoglobin 
(g/dL) 11 ± 1.3 11.5 ± 1 0.15 11.4 ± 1.4 12 ± 1.5 0.14 
Haematocrit 
(L/L) 0.36 ± 0.04 0.36 ± 0.02 0.35 0.36 ± 0.04 0.37 ± 0.04 0.44 
Na+ (mmol/L) 138 ± 3 139 ± 4 0.18 138 ± 2 139 ± 3 0.1 
K+ (mmol/L) 4.8 ± 0.8 4.7 ± 0.9 0.89 3.0 ± 0.4 3.0 ± 0.5 0.69 
Urea (mmol/L) 21.1 ± 5.4 19.8 ± 5.0 0.33 6.2 ± 2.2 6.3 ± 2.5 0.81 
Creatinine 
(ȝmol/L) 668 ± 192 746 ± 220 0.13 259 ± 88 301 ± 132 0.12 
Phosphate 
(mmol/L) 1.7 ± 0.4 1.6 ± 0.6 0.42 0.8 ± 0.2 0.8 ± 0.2 0.61 
Bicarbonate 
(mmol/L) 22.7 ± 3.0 22.8 ± 3.2 0.87 27.8 ± 2.8 28.4 ± 2.5 0.44 
Corrected 
Ca2+ (mmol/L) 2.42 ± 0.16 2.4 ± 0.15 0.58 2.36 ± 0.09 2.4 ± 0.11 0.84 
Albumin (g/L) 35 ± 4.1 37 ± 3.4 0.02 37 ± 5.2 39 ± 5.7 0.04 
hsCRP 11.02 ± 9.5 7.9 ± 6.3 0.13 - - - 
F7Q7ȝJ/ 0.098 ± 0.08 0.036 ± 0.04 0.001 - - - 
 
Table 5.4.4a: Baseline haematological and biochemical data stratified 
based on the presence (with) or absence (without) of haemodialysis 
induced myocardial stunning taken before and after HD. Post dialysis 
cardiac troponin-T (cTnT) levels were not taken due to an insufficient 
time lapse needed to detect a significant change. hsCRP = high 
sensitivity C-reactive protein. 
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Univariate analysis of these variables also showed a number of factors 
associated with the development of HD-induced myocardial stunning. 
These were lower albumin levels (p=0.02) and elevated cTnT 
concentration (P=0.001), see figures 5.4.4a and 5.4.4b.  
 
Figure 5.4.4a: Myocardial stunning and serum albumin. The 
development of HD-induced myocardial stunning was associated with a 
significantly lower serum albumin concentration (P=0.02). 
 
 
There were no other statistically significant differences between those 
patients with or without HD-induced myocardial stunning with respect to 
haematological or biochemical markers that were measured. 
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Figure 5.4.4b: Myocardial stunning and cardiac troponin-T. The 
development of HD-induced myocardial stunning was associated with a 
significantly higher serum cardiac troponin-T concentration (P=0.001). 
 
5.4.5 Intradialytic blood pressure and myocardial stunning 
There was a significant reduction in systolic blood pressure (SBP) 
during treatment in patients with HD-induced myocardial stunning 
(P<0.0001) compared to those without who had no such reduction in 
SBP (P=0.16), see figure 5.4.5a. 
 104 
 
Figure 5.4.5a: Reduction in systolic blood pressure (SBP) during 
haemodialysis (HD) in patients with and without HD-induced regional 
wall motion abnormalities (RWMAs) consistent with myocardial stunning 
(P<0.0001). 
 
The total number of episodes of intradialytic hypotension (as defined in 
chapter 3) was significantly higher in patients with myocardial stunning 
than those without (2.1 ± 3.5 episodes vs. 0.2 ± 0.5 episodes, P<0.01). 
Sub analysis revealed however that it was only asymptomatic 
intradialytic hypotension that was significantly different (1.9 ± 3.3 
episodes vs. 0.3 ± 0.9 episodes, P=0.02) between patient groups ± 
episodes of symptomatic IDH were not statistically different (0.2 ± 0.5 
episodes vs. 0.04 ± 0.2 episodes, P=0.1). 
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5.4.6 Factors associated with the severity of myocardial 
stunning 
Further analysis using Spearman univariate correlation revealed 
significant correlations between a number of these same variables 
mentioned above and the severity of myocardial stunning as measured 
by magnitude of reduction in %SF including: reduction in SBP (r2 0.4, 
P=0.001); higher UF volumes (r2 0.28, P=0.02); higher plasma cTnT 
concentration (r2 0.29, P=0.02) and increasing age (r2 0.29, P=0.014), 
see table 5.4.6a. 
 
Variable r2 P value 
Maximum SBP reduction 0.4 0.001 
Ultrafiltration Volume 0.28 0.02 
Asymptomatic IDH 0.28 0.02 
Cardiac troponin-T 0.29 0.02 
Age 0.29 0.014 
 
Table 5.4.6a: Independent factors associated with the severity of 
myocardial stunning. SBP, systolic blood pressure; IDH, intradialytic 
hypotension. 
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5.4.7 Multivariate analysis of factors associated with 
myocardial stunning 
 
Factor associated with development of 
myocardial stunning 
Odds 
Ratio 
P 
value 
UF volume during HD of 1L 5.1 
0.007 UF volume during HD of 1.5L 11.6 
UF volume during HD of 2L 26.2 
Maximum SBP reduction during HD of 10 mmHg 1.8 
0.002 Maximum SBP reduction during HD of 20 mmHg 3.3 
Maximum SBP reduction during HD of 30 mmHg 6.0 
 
Table 5.4.7a: The effect of increasing ultrafiltration (UF) volume and 
worsening intradialytic haemodynamics on the development of HD-
induced myocardial stunning. 
 
Stepwise multivariate analysis of those factors contributing to the 
presence of myocardial stunning revealed that the following were all 
independent variables associated with the development of HD-induced 
RWMAs: maximum reduction in SBP, per mmHg (OR 1.1, CI 1.02-1.1, 
P=0.002); UF volume per litre (OR 5.1, CI 1.33-19.7, P=0.007); age per 
year (OR 1.26, CI 1.04-1.54, P=0.004) and cTnT concentrations per 
ȝg/L (OR 1.07, 1.01-1.13, P=0.018) (Nagelkerke R2=0.6 of the model 
overall). The non linear increasing effects of UF volume and BP on risk 
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of developing HD induced cardiac injury are illustrated in table 5.4.7a. 
All other factors, including diabetes mellitus, albumin levels and IHD did 
not enter the final analysis. 
5.5 Discussion 
This chapter demonstrates for the first time that dialysis induced 
recurrent cardiac injury is common, and associated with a number of 
factors including reduction in myocardial contractile function. 
Furthermore we have identified specific elements of the dialysis process 
(and the patients¶ response to it) as previously unappreciated adverse 
factors and potential drivers of heart failure in HD patients.  
Almost two-thirds of patients had evidence of acute, dialysis induced LV 
dysfunction. This was present at both timepoints studied, but was more 
severe towards the end of the HD session as treatment time 
progressed. After HD had completed there was evidence of partial (but 
not complete) recovery. However recovery was assessed at 30 minutes 
post HD, largely determined by patient willingness to remain in the unit 
after termination of therapy. We have previously demonstrated that HD 
can directly induce RWMAs 70,71 and that these are associated with a 
corresponding decrease in segmental myocardial blood flow with 
recovery post-HD 107 consistent with myocardial stunning 
There was a significant association between the development of HD-
induced myocardial stunning and diabetes mellitus, but not for patients 
with a history of IHD. In the HD population, decline in LVEF is usually 
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progressive over time and often accelerated 163, and there is increasing 
evidence that this is not due to traditional cardiac risk factors or 
conventional atherosclerotic coronary artery disease 164,165. However, 
evidence suggests that HD patients with diabetes, but normal epicardial 
coronary anatomy, have significantly reduced coronary flow reserve 49, 
that predisposes to the development of demand ischaemia. It is 
therefore not surprising that the effects of diabetes and coronary artery 
disease per se on the development of HD-induced myocardial stunning 
might be dissociated from each other. 
Lower serum albumin levels were also associated with the development 
of dialysis induced myocardial stunning (on a univariate basis only). 
There is a large body of evidence linking malnutrition and inflammation 
to the development of atherosclerosis in patients with end-stage renal 
disease (ESRD) 37,166-169. Unfortunately, serum albumin in isolation 
(especially with no significant difference between high sensitivity C-
reactive protein levels) is a poor diagnostic marker. The role of other 
biochemical markers such as interleukin-6 and fetuin-A may provide 
additional information on the association between HD-induced 
myocardial stunning, malnutrition, calcification and inflammation 170,171 
but was outside the scope of this study.  
Higher ultrafiltration volumes, intradialytic haemodynamic instability and 
raised biochemical markers of myocardial damage (cTnT) were all 
associated with the development and severity of HD-induced 
myocardial stunning. Logistic regression analysis confirmed that each of 
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these factors were independent determinants of myocardial stunning 
and that the risk associated with higher UF volumes and greater drops 
in SBP increased disproportionately with each additional unit of 
measure. It is certainly not unusual in clinical practice for patients to 
have ultrafiltration volumes set at two litres or more and to experience a 
drop in SBP of more than 20 mmHg.  
It is well recognised that cardiac troponin-T (cTnT) levels are often 
elevated in dialysis patients and that elevated levels predict mortality 89-
91,95,172-175
. This study has shown a direct association between troponin-
T concentrations and the development and severity of myocardial 
stunning. A recent study of cardiac troponins and outcome in acute 
heart failure revealed associations with lower systolic blood pressure, 
lower left ventricular ejection fraction and higher mortality 88. However 
WKH LGHQWLILFDWLRQ RI µDW ULVN¶ SDWLHQWV ZKR PD\ EHQHILW IURP VSHFLILF
dialysis based interventions remains a clinical challenge. The 
usefulness of cTnT and other biochemical markers of cardiac damage 
(in conjunction with other clinical factors like left ventricular ejection 
fraction and systolic blood pressure) remains unknown but may in the 
future provide a useful tool to identify vulnerable patients who would 
benefit from modified therapies and additional treatments. 
Similarly, intradialytic hypotension (IDH) has also been shown to be an 
independent risk factor for mortality in HD patients 109,176,177. It is 
interesting to note that the number of episodes of IDH with symptoms 
was comparable between those patients with myocardial stunning and 
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those without but that asymptomatic IDH was significantly higher in the 
myocardial stunning group. This would suggest that the most vulnerable 
patients, most susceptible to dialysis induced cardiac injury could go 
undetected on the majority of haemodialysis units. There is currently no 
research showing that higher ultrafiltration rates during HD are 
associated with poor outcome. However, there is evidence that both 
larger inter dialytic weight gain between two subsequent HD treatment 
sessions and higher ultrafiltration rate are associated with worse 
survival 178. There are currently no available data to allow the potential 
differential effects of ultrafiltration volume and ultrafiltration rate on poor 
outcome to be appreciated. This finding of the effect of ultrafiltration 
requirements is crucially important as it represents a potential 
therapeutic target that might be pursued by a variety of means. More 
frequent daily or nocturnal HD therapies can improve cardiovascular 
outcome measures and quality of life 179,180. Such treatments have also 
been shown to improve intradialytic haemodynamics by reducing IDH 
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 and caused an improvement in plasma concentrations of 
biochemical markers of myocardial damage and dysfunction 121. We 
have already demonstrated that dialysis based  strategies such as 
cooled dialysate and the use of bio-feedback control can improve 
intradialytic haemodynamics and reduce HD-induced myocardial 
stunning 70. Targeting treatments that minimise ultrafiltration rates and 
improve IDH will prevent the acute development of myocardial stunning, 
and may improve long term cardiovascular outcomes. 
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5.6 Conclusions 
Conventional HD exerts significant acute stress upon the cardiovascular 
system. The results in this chapter support the contention that 
subclinical myocardial ischaemia causing myocardial stunning is 
commonly precipitated by dialysis. Such episodes of ischaemia are 
associated with higher ultrafiltration volumes, intradialytic 
haemodynamic instability and raised biochemical markers of ischaemic 
myocardial damage. These same variables are also associated with the 
severity of stunning as measured by the magnitude of reduction in 
regional shortening fraction. Unfortunately however, the most at risk 
and vulnerable patients remain asymptomatic and therefore difficult to 
identify, making it more challenging to target interventions to those 
patients who would most benefit. 
The results in the following chapters will highlight the potential acute 
and chronic consequences of repetitive haemodialysis induced 
myocardial injury. A deeper knowledge of these short and long-term 
sequelae will further help to appreciate the true nature of this 
phenomenon and its contribution to the appalling cardiovascular 
morbidity and mortality in chronic HD patients. 
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Chapter 6 
 
Results: 
Haemodialysis induced left ventricular dysfunction is associated with an 
increase in ventricular arrhythmias. 
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6 Results: Haemodialysis induced left ventricular 
dysfunction is associated with an increase in 
ventricular arrhythmias. 
6.1 Introduction 
As already discussed, the majority of haemodialysis patients die from 
cardiovascular causes and a significant proportion of that mortality is 
attributable to sudden cardiac death. As sudden cardiac death appears 
to correlate with the peri-dialytic period, a number of studies looking at 
the potential pro-arrhythmogenic effects of HD and the presence of both 
potentially life-threatening complex ventricular arrhythmias (CVAs) and 
premature ventricular complexes (PVCs) has been associated with 
increased morbidity and mortality. 
Separate to that, we have now shown that haemodialysis causes a 
reduction in regional ventricular function as seen in the form of regional 
wall motion abnormalities and that this is associated with a matched 
reduction in myocardial blood flow consistent with ischaemia. Other 
studies have linked the increase in ventricular ectopy and arrhythmias 
with alternative surrogate markers of ischaemia (e.g. the presence of 
coronary vessel stenoses) but no evidence exists to date of a link 
between dialysis induced acute left ventricular dysfunction (secondary 
to myocardial ischaemia) and cardiac arrhythmias. 
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We hypothesise that myocardial ischaemia may contribute to the 
development of both RWMAs and ventricular arrhythmias. As ischaemia 
induced RWMAs are potentially preventable 70,71, the identification of a 
common pathophysiological process connecting both sudden and 
ischaemic cardiac death in HD patients may offer single therapeutic 
targets to reduce both causes of mortality. The aim of this study was to 
investigate any association between the development of left ventricular 
RWMAs and arrhythmias. 
Additional aims included: the evaluation of the roles of co-morbid 
conditions such as diabetes, left ventricular hypertrophy and ischaemic 
heart disease (as well as other demographic variables) that may 
contribute to increased demand ischaemia; and any association 
between serum electrolyte concentrations and the presence of 
arrhythmias. 
6.2 Methods 
6.2.1 Patients 
Forty prevalent HD patients were recruited for an observational cohort 
study from a single hospital based haemodialysis unit. Patients were 
excluded if they had: a change in target weight in the preceding six 
weeks, pre-existing severe LV systolic dysfunction or inadequate 
echocardiographical windows to obtain images of sufficient quality. All 
patients haemodialysed thrice weekly for four hours. The study session 
was conducted after the first short inter-dialytic period as arrhythmias 
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and cardiac events are known to be increased after the long inter-
dialytic break. Medications remained unchanged.  
6.2.2 Study protocol 
After recruitment and consent SDWLHQWV¶ GU\ ZHLJKW DQG DQWL-
hypertensive as well as all other medications remained unchanged for 
the duration of the study. Patients were continued on standard thrice 
weekly haemodialysis. Patients were encouraged to continue daily 
activities as usual before the study session. In the event that the patient 
had suffered symptoms of angina or used their GTN spray within 24 
hours of commencement, the session was postponed as this may have 
affected the continuous ECG monitoring and the frequency of 
ventricular arrhythmias and ectopics. The session was then 
rescheduled for four weeks time at which point the same restrictions 
applied. 
For the monitored dialysis treatment, serial echocardiography was 
performed pre-dialysis, during treatment at two and four hours and 
again 30 minutes into the recovery. Non-invasive continuous ECG 
recordings were undertaken using a Holter monitor. Pre-dialysis blood 
tests were drawn immediately after insertion of access needles, and 
post levels were taken from the arterial line 10 seconds after reducing 
blood pump speed to 50 ml/min. Single pool Kt/Vurea values were 
calculated from pre and post urea levels 144.  
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The primary endpoint was the frequency of ventricular ectopics and 
complex ventricular arrhythmias during HD in relation to the 
development of ischaemia induced LV regional wall motion 
abnormalities. 
All patients gave informed consent prior to commencement, and ethical 
approval for the project was granted by Derbyshire Local Research 
Ethics Committee. 
6.2.3 Haemodialysis details 
Dialysis was performed as described in chapter 3 and is not repeated 
here. 
6.2.4 Continuous ECG monitoring (Holter) 
Continuous measurement of SDWLHQWV¶(&*XVLQJWKH+ROWHUPRQLWRUVLV
described in detail in chapter 3. Patients were connected to the 
monitoring equipment and 5 minutes of baseline data was collected 
before the commencement of dialysis. This enabled the Holter analysis 
software (NorthEast Monitoring Inc Holter LX Enhanced Software) to 
more accurately distinguish intradialytic changes in ECG morphology. 
The initiation of dialysis was marked as an event using the built in event 
recognition software. 
After 24 hours, the Holter device automatically stopped recording and 
patients were instructed on how to remove the monitors themselves. All 
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equipment was returned to the Haemodialysis Unit for data retrieval at 
their next treatment session 48 hours later. 
Frequency of ectopy was classified as a percentage of the total beats 
during the time period studied 142 UDUH  RFFDVLRQDO ! WR
1.0%), frequent (>1.0 to 10%) and very frequent (>10%). Ventricular 
arrhythmias were stratified according to the Lown classification 143 
(class 0, no VEs; class 1, unifocal VEs <30/hour; class 2, unifocal VEs 
>30/hour; class 3, multiform VEs; class 4a, 2 consecutive VEs; class 
4b, >3 consecutive VEs; class 5, R-on-T phenomenon). Classes 3 and 
above were accepted as complex ventricular arrhythmias. All patients 
who were classified as having a class 3 arrhythmia or above had all 
their abnormal complexes visually reviewed to exclude false positive 
results caused by artifact. 
6.2.5 Echocardiography 
Echocardiography and subsequent analysis were performed as 
described in chapter 3. Images were recorded prior to commencing 
dialysis (baseline); at 120 minutes and 240 minutes during dialysis; and 
30 minutes after dialysis was finished (recovery). Ten regions of the left 
ventricle were assessed for the development of new regional wall 
motion abnormalities (RWMAs) at each time point as before. 
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6.3 Statistical analysis 
Results are expressed as mean ± SD if normally distributed or median 
(interquartile range, IQR) if non-normally distributed unless otherwise 
stated. Categorical data was analysed using Fisher's exact test. Both 
echocardiographic and Holter data were analysed using the unpaired t-
test or the Mann-Whitney test for unpaired data depending on normality 
of the distribution. Similarly, for paired data the paired t-test or Wilcoxon 
signed rank test was used. An alpha error at P<0.05 was judged to be 
significant. 
6.4 Results 
6.4.1 Haemodialysis induced echocardiographic dysfunction 
67% (27) of the 40 patients developed significant RWMAs at peak 
stress on HD defined as a reduction in SF of >20% in >2 LV regions. Of 
these patients, 58% had shown recovery 30 minutes after HD, 
confirming the presence of myocardial stunning in this group. 
6.4.2 Prevalence and associations of ventricular ectopy 
Premature ventricular complexes (PVCs) were detected in 63% (25) of 
patients with 25% (10) being classed as frequent or very frequent 
(figure 4.4.2a. The total frequency of PVCs was higher during HD than 
in the post dialysis phase (0.26% (IQR 0.04 to 1.3) vs. 0.12% (IQR 0.01 
to 0.7), P<0.01). 
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Figure 6.4.2a: Frequency of premature ventricular complexes. 25% (10) 
were classed as frequent or very frequent. 
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Sub Groups 
/RZQ6FRUH 
66 ± 12.7 
14 : 10 
46.7 ± 32.5 
 
22 
2 
 
8 
4 
3 
2 
4 
3 
 
5 
1 
4 
0 
0 
Lown Score <3 
59.6 ± 13.8 
12 : 4 
57.2 ± 38.9 
 
16 
0 
 
5 
4 
1 
0 
5 
1 
 
3 
3 
3 
1 
2 
Frequent / very 
frequent PVCs 
69 ± 12 
12 : 2 
55.3 ± 28.9 
 
0 
2 
 
5 
2 
1 
1 
4 
1 
 
4 
2 
4 
0 
0 
Occasional / 
Rare PVCs 
62 ± 13.4 
16 : 10 
50 ± 37.9 
 
26 
0 
 
8 
6 
3 
1 
5 
3 
 
4 
2 
3 
1 
2 
All 
Patients 
(n=40) 
63.7 ± 13.2 
28 : 12 
50.6 ± 34.3 
 
38 
2 
 
13 
8 
4 
2 
9 
4 
 
8 
4 
7 
1 
2 
Characteristics 
Age (mean, years) 
Male:Female (n) 
Dialysis vintage (mean, months) 
Ethnicity (n) 
    Caucasian 
    Asian 
Etiologies (n) 
    Diabetes mellitus 
    Glomerular disease 
    APKD 
    HT / Renovascular disease 
    Other 
    Unknown 
Relevant medication (n) 
    ACEi / ARB 
    Ǻ-blocker 
    Calcium channel blocker 
    Digoxin 
    Amiodarone 
 121 
There were no statistically significant differences with respect to 
frequency of PVCs with any of the variables described (P>0.05). Of 
note, the frequency with which the two patients on amiodarone 
experienced PVCs was classified as rare and occasional. 
 
Table 6.4.2b: Biochemical data stratified according to frequency of 
PVCs (expressed as mean ± SD). Except for post dialysis K+ levels 
(*P<0.02), there were no significant differences between those patients 
with rare or occasional PVCs and those with frequent or very frequent 
PVCs. 
Parameter 
Patients with rare or occasional 
PVCs 
Patients with frequent or very 
frequent PVCs 
Pre-dialysis Post dialysis Pre dialysis Post dialysis 
Haemoglobin 
(g/dl) 11.4 ± 1.5 11.9 ± 1.8 10.6 ± 1.0 10.9 ± 1.0 
Na+ (mmol/L) 138.1 ± 3.4 137.9 ± 2.7 138.0 ± 3.6 138.1 ± 2.5 
K+ (mmol/L) 4.9 ± 0.8 3.1 ± 0.4* 4.4 ± 0.8 2.7 ± 0.3* 
Urea (mmol/L) 20.4 ± 5.4 6.1 ± 2.2 22.3 ± 4.7 6.2 ± 2.0 
Creatinine 
(ȝmol/L) 711 ± 169 275 ± 80 723 ± 241 257 ± 97 
Phosphate 
(mmol/L) 1.7 ± 0.4 0.8 ± 0.2 1.7 ± 0.5 0.7 ± 0.2 
Bicarbonate 
(mmol/L) 22.7 ± 2.7 27.0 ± 3.4 22.2 ± 3.3 29.3 ± 2.0 
Corrected Ca2+ 
(mmol/L) 2.4 ± 0.2 2.4 ± 0.1 2.4 ± 0.1 2.3 ± 0.1 
Albumin (g/L) 36.4 ± 3.8 38.9 ± 6.2 35.1 ± 5.3 36.2 ± 5.9 
F7Q7ȝJ/ 0.09 ± 0.1 - 0.08 ± 0.06 - 
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Laboratory data stratified according to frequency of PVCs are shown in 
table 6.4.2b. Lower post-dialysis potassium (K+) levels were associated 
with the development of PVCs (2.7 ± 0.3 mmol/L vs. 3.1 ± 0.4 mmol/L, 
P<0.02). There were no other significant differences between patients 
with rare or occasional PVCs and those with frequent or very frequent 
PVCs. 
 
Figure 6.4.2b: The effect of RWMA and HD on %PVCs ± The frequency 
of PVCs was significantly higher during HD than in the post dialysis 
phase in those patients who developed RWMAs (n=27). There was no 
such difference in those patients who did not develop RWMAs (n=13). 
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The frequency of PVCs was higher during HD in patients who 
developed RWMAs compared to the post dialysis period (0.26% (IQR 
0.07 to 1.82) vs. 0.16% (IQR 0.01 to 0.7), P<0.001). However, in those 
patients who did not develop RWMAs, there was no significant 
difference in the incidence of PVCs during and after HD (0.12% (IQR 0 
to 0.67) vs. 0.09% (IQR 0 to 1.2), P>0.7), see figure 6.4.2b. Although 
the median incidence of PVCs both during and after dialysis was higher 
in those patients who developed RWMAs compared to those who did 
not, this did not reach statistical significance (P>0.05). 
Patients with pre-existing ischaemic heart disease (IHD) (n=13) had an 
increased frequency of PVCs during HD compared to those without 
(1.19% (IQR 0.15 to 3.46) vs. 0.17% (IQR 0.02 to 0.48), P<0.03) as did 
patients with LVH (n=18) (0.87% (IQR 0.21 to 3.46) vs. 0.12% (IQR 
0.01 to 0.76), P<0.02). Post dialysis, there was no difference in the 
frequency of PVCs between either group (P>0.2), see figure 6.4.2c.  
There was also a difference in median values between the frequency of 
PVCs during and after HD within the cohorts of patients with IHD and 
LVH but this did not reach statistical significance (P>0.1). Only four 
patients had both IHD and LVH and no increased risk for both was 
observed. 
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Figure 6.4.2c:  The impact of IHD and LV morphology on PVCs ± the 
frequency of PVCs during HD in patients with IHD was significantly 
higher than those without (*P<0.02). Similarly, the frequency of PVCs 
was significantly higher in patients with LVH compared to those without 
(P<0.03). There was no difference between the groups post dialysis 
(ÁP>0.2). 
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6.4.3 Prevalence and associations of ventricular complexity 
(Lown Score) 
61% (24) of patients were classified as having CVAs with a Lown score 
of 3 or above (figure 4.4.3a). Of those patients with a Lown score of 4 (a 
or b), the total number of episodes of 2 consecutive PVCs was 
considerably higher during HD than in the follow up period (57 ± 5.3 vs. 
17 ± 7.6, P<0.004). 
 
Figure 6.4.2a: Patients stratified according to Lown score. 61% (24) had 
a score of 3 or above. No patients recorded a score of 5. 
 
Demographic data are shown above in table 6.4.2a. There were no 
statistically significant differences with respect to Lown score and any of 
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the variables described (P>0.05). Of note, the two patients on 
amiodarone had a Lown score of one and zero (i.e. no development of 
CVAs). 
 
Parameter 
Patients with Lown score <3 3DWLHQWVZLWK/RZQVFRUH&9$V 
Pre-dialysis Post dialysis Pre dialysis Post dialysis 
Haemoglobin 
(g/dl) 10.9 ± 1.3 11.5 ± 1.5 11.2 ± 1.4 11.7 ± 1.7 
Na+ (mmol/L) 138.7 ± 3.1 137.9 ± 2.9 137.8 ± 3.5 138.0 ± 2.5 
K+ (mmol/L) 4.7 ± 0.8 3.1 ± 0.5* 4.8 ± 0.8 2.9 ± 0.3* 
Urea (mmol/L) 19.5 ± 5.4 6.1 ± 2.5 21.9 ± 5.0 6.2 ± 1.9 
Creatinine 
(ȝmol/L) 721 ± 164 282 ± 85 711 ± 209 261 ± 86 
Phosphate 
(mmol/L) 1.6 ± 0.4 0.9 ± 0.2 1.7 ± 0.5 0.7 ± 0.2 
Bicarbonate 
(mmol/L) 22.4 ± 3.2 26.5 ± 4.3 22.6 ± 2.7 28.5 ± 2.1 
Corrected Ca2+ 
(mmol/L) 2.4 ± 0.1 2.4 ± 0.05 2.4 ± 0.2 2.4 ± 0.1 
Albumin (g/L) 36.1 ± 4.0 38.4 ± 5.8 36.0 ± 4.5 37.7 ± 6.5 
F7Q7ȝJ/ 0.1 ± 0.13  0.08 ± 0.06  
 
Table 4.3.3a: Biochemical data stratified according to Lown score 
(expressed as mean ± SD). Except for post dialysis K+ levels (*P<0.04), 
there were no significant differences between patients with a Lown 
score of <3 and those with a Lown score of 3 representing complex 
ventricular arrhythmias (CVAs). 
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Laboratory data stratified according to Lown score are shown in table 
4.4.3a. Lower post-dialysis potassium (K+) levels were associated with 
a Lown score 3 (2.9 ± 0.3 mmol/L vs. 3.1 ± 0.5 mmol/L, P<0.04). 
There were no other significant differences between patients with a 
Lown score <3 and those with a Lown score 3. 
There were no correlations between Lown score and the development 
of RWMAs (P>0.7) or change in %SF between any of the time points. 
3DWLHQWVZLWK ,+'ZHUHPRUH OLNHO\ WRKDYHD/RZQVFRUH3 although 
this was only a trend and did not reach statistical significance (P<0.08). 
There was no significant association between LVH and Lown score 
(P>0.4). Again, no increased risk in patients with both IHD and LVH was 
observed. 
There was no evidence of significant ST segment change associated 
with either the development of CVAs, PVCs or RWMAs (P>0.05). 
6.5 Discussion 
This study demonstrates a significant number of new, reversible left 
ventricular RWMAs occurred during HD, consistent with our previous 
findings 70,71. We have also confirmed the arrhythmogenicity of HD. 
Ventricular ectopy in the form of PVCs and CVAs is increased during 
HD, which is consistent with previously published evidence 181,182. More 
significantly, we have demonstrated a significantly higher frequency of 
PVCs during HD in those patients who develop dialysis induced acute 
cardiac injury (in the form of RWMAs). 
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We found no significant association between PVCs or arrhythmias and 
demographic variables including concomitant medication. Previous 
evidence has suggested that the high incidence of ventricular 
arrhythmias detected in previous studies could be due to differences in 
patient recruitment and variables including age, disease aetiology, 
dialysis vintage and duration, and concomitant medication 103. We found 
no such association between these variables and the frequency of 
PVCs or arrhythmias. Furthermore, the use of digoxin in patients on 
maintenance HD has been shown to increase the incidence of occult 
and potentially serious ventricular ectopy 183,184 and also potentially 
contribute to the high incidence of PVCs and CVAs in HD patients. Only 
one (2.5%) out of the 40 patients recruited to this study was on digoxin 
and they had no evidence of ectopic ventricular activity, with a Lown 
score of zero. 
Lower post dialysis potassium concentrations were associated with a 
higher incidence of PVCs and an increased Lown score. The evidence 
relating to the association of end-dialysis potassium concentration with 
ventricular ectopy is somewhat contradictory. The largest study looking 
at the use of potassium profiling, designed to avoid rapid shifts in 
plasma potassium during HD did show a reduction in the 
arrhythmogenic effect of HD with this technique 185. However, another 
study showed no increase in arrhythmias with empirical reductions in 
fixed dialysate potassium concentration, even when using a dialysate 
solution containing no potassium at all 186. There was no association 
between post-dialysis potassium concentration and the development of 
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RWMAs. Whilst the association between the development of ischaemia 
related functional decline and arrhythmias is clear, it is not so easy to 
clearly define the role of potassium within that relationship. 
The incidence of new RWMAs and the prevalence of dialysis induced 
myocardial stunning  were both in keeping with previous work  187. 
RWMAs have been shown to develop in response to a decrease in 
myocardial blood flow 107. This work has shown a direct correlation 
between HD induced functional decline of the left ventricular 
myocardium at a segmental level and falling myocardial blood flow 
within the corresponding regions. 
The incidence of cardiac arrhythmias manifesting as PVCs and CVAs 
stratified according to Lown score was also consistent with previous 
published work 24. We confirmed that these arrhythmias were higher 
during HD than in the subsequent monitored period post-dialysis 60. Our 
results did not show an association between the development of 
RWMAs and Lown score however there is evidence that increasing 
Lown scores do not predict mortality in HD patients 188. 
Patients who developed RWMAs on HD had a significantly higher 
incidence of PVCs during HD than in the following 20 hour period. 
Patients who did not develop left ventricular RWMAs displayed no 
difference in the incidence of PVCs during and after HD. As mentioned 
above, the development of RWMAs and myocardial stunning are linked 
with both global and regional myocardial ischaemia. In this study, IHD 
and LVH were also associated with an increased frequency of PVCs 
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during HD. Both of these pathological processes pre-dispose our 
patients to demand myocardial ischaemia. 
There is to date, no published work on the potential link between HD 
induced myocardial ischaemia and the development of ventricular 
arrhythmias. In this study, the numbers of intra-dialytic PVCs were 
significantly increased in patients with evidence of HD induced 
myocardial ischaemia. This strengthens the hypothesis that HD induces 
ischaemic damage and that sudden death in HD patients may also be 
linked to an underlying ischaemic process. Unfortunately, patient 
numbers did not allow for multivariate analysis to understand in more 
detail the exact role of each of these variables so no further conclusions 
are derived from these results. However, this still has important clinical 
implications.  
Thus far, only pharmacological strategies directly targeting the 
increased incidence of CVAs and PVCs in HD patients have been 
utilised. Beta blockade, with carvedilol, has been shown to be beneficial 
in reducing CVAs and heart failure in patients with dilated 
cardiomyopathy 189. Furthermore carvedilol is associated with a 
significant reduction in total PVCs and episodes of ventricular 
tachycardia in HD patients 190. Unfortunately, the association of intra-
dialytic hypotension (IDH) and poor outcome 109 militate against 
widespread usage of such vasoactive medication. The use of 
implantable defibrillators in HD patients surviving cardiac arrest has 
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also been evaluated 191 and shown to be beneficial. However their use 
as a preventative treatment is yet to be confirmed. 
Conversely, modifying HD using such methods as cooled dialysate can 
improve haemodynamics and has been shown to reduce the incidence 
of HD induced RWMAs 71. If the development of PVCs and CVAs is 
also driven by an ischaemic pathophysiological process, then these 
therapeutic strategies may help to reduce morbidity and mortality not 
just from ischaemia but also from sudden cardiac death related to 
malignant ventricular arrhythmias. 
6.6 Conclusions 
The data within this chapter demonstrate that haemodialysis induced 
myocardial ischaemia may lead to the development of both functional 
LV abnormalities and ventricular arrhythmias, potentially playing a role 
in the development of the two commonest causes of cardiovascular 
death in chronic HD patients. Underlying risk factors for demand 
myocardial ischaemia could contribute to this phenomenon. Therapeutic 
strategies targeting improved haemodynamics during dialysis may 
reduce HD induced ischaemia and the life-threatening arrhythmias that 
go alongside it. This in turn may reduce the incidence of sudden death 
in our HD population. Further work is needed to look at the long term 
consequences of HD induced myocardial ischaemia with respect to 
both function and arrhythmogenicity and to see whether or not potential 
modifications (e.g. cooled dialysate) that reduce the number of RWMAs 
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during the HD procedure have any impact on left ventricular function 
and the incidence of PVCs or CVAs. 
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Chapter 7 
 
Results: 
Haemodialysis induced repetitive myocardial stunning results in global 
and regional reductions in left ventricular function. 
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7 Results: Haemodialysis induced repetitive 
myocardial stunning results in global and 
regional reductions in left ventricular function 
7.1 Introduction 
Data above have shown that haemodialysis can induce reductions in 
myocardial blood flow that precipitate ischaemia and cause regional left 
ventricular dysfunction consistent with myocardial stunning. This 
phenomenon is common and associated with a number of potentially 
modifiable factors including ultrafiltration volume and intradialytic 
haemodynamic instability. So far, it has been demonstrated that 
myocardial stunning is associated with an increase in ventricular ectopy 
but nothing is currently known about the long term consequences of 
such repetitive cardiac injury. 
In the non-dialysis population, repeated episodes of demand ischaemia 
and stunning can result in chronic reduction in left ventricular function 
72,78
. This led to the hypothesis that repeated episodes of myocardial 
ischaemia lead to a spectrum of disease encompassing myocardial 
stunning through to myocardial hibernation 79 and ending in myocardial 
remodeling and scarring 192. Standard conventional thrice weekly 
haemodialysis as a cause of repetitive myocardial stunning may lead to 
chronic myocardial hibernation and eventually to myocardial scarring 
resulting in left ventricular dysfunction. Although myocardial hibernation 
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may represent a functional adaptation to chronic hypoperfusion that can 
be reversed with resWRUDWLRQ RI UHJLRQDO 0%) WKH µVPDUW KHDUW¶
hypothesis) 82, there is evidence to suggest that hibernating 
myocardium is still highly vulnerable to increases in demand or 
reductions in oxygen supply 83 such as further haemodynamic stress 
during HD. Therefore, ongoing recurrent episodes of ischaemia 
precipitated by HD may have negative consequences on this adaptive 
balance leading to further myocardial injury and eventual non-viable 
myocardium with irreversible reduction in left ventricular function. 
The aim of this analysis was to look for evidence of chronic myocardial 
dysfunction in haemodialysis patients precipitated by repeated episodes 
of HD induced myocardial stunning over a 12 month period. 
7.2 Methods 
7.2.1 Patients 
Recruitment of patients is covered in chapter 5 section 5.2.1. Of the 70 
prevalent HD patients who were consented for this 12-month 
observational cohort, nineteen patients were censored from the follow 
up analysis: patients who had died (n=9), patients who had received 
kidney transplant (n=6), those who changed dialysis modality (n=3) and 
withdrawal of consent (n=1). 
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7.2.2 Study protocol 
Shortly before the 12-month anniversary of their baseline study, 
patients were approached on the haemodialysis unit to verbally confirm 
their consent to remain in the study. As mentioned above, one patient 
withdrew consent at that time. 
As near to 12 months as practicable, patients underwent an identical 
study session to that at baseline. Patients were re-interviewed for the 
purpose of reviewing their medical history and performing a physical 
examination. All medical details were then again confirmed using 
SDWLHQWV¶QRWHV 
During the follow-up monitored haemodialysis session, the following 
variables were collected: details of dialysis treatment; global and 
regional left ventricular function was using serial echocardiography at 
four separate time points: pre-dialysis; during treatment at both two and 
four hours; and again 30 minutes into the post-dialysis recovery phase; 
non-invasive haemodynamic monitoring of blood pressure (BP) was 
undertaken every 15 minutes; pre-dialysis blood tests were drawn 
immediately after insertion of access needles, and post levels were 
taken from the arterial line 10 seconds after reducing blood pump speed 
to 50ml/min and single pool Kt/Vurea values were calculated from pre 
and post urea levels 144.  
The primary endpoints at this stage were to understand the longer term 
consequences of this phenomenon on LV function and to assess 
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whether HD induced myocardial stunning would progress over time to 
the development of fixed systolic dysfunction, consistent with the 
continuum of myocardial hibernation. In addition, we sought to identify 
the haemodynamic consequences of this with respect to intradialytic 
haemodynamics. Secondary endpoints included: the potential role of 
haematological and biochemical variables (as well as dialysis 
adequacy, Kt/V) and the use of troponin-T as a risk marker for the 
progression of regional myocardial dysfunction. 
7.2.3 Haemodialysis details 
Dialysis was performed as described in chapter 3 and is not repeated 
here. 
7.2.4 Follow-up collection of study data 
Measurement of regional and global LV function (using 
echocardiography), blood pressure, haematological and biochemical 
variables is outlined in full in sections 5.2.4 ± 5.2.6 and not repeated 
here. 
7.2.5 Definitions of HD-induced cardiac dysfunction and 
rationale 
Based on segmental performance, the following definitions of HD-
induced cardiac dysfunction were applied. 
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Myocardial stunning: regions that showed a functional decline of >20% 
during HD compared to rest with evidence of functional recovery in the 
post-dialysis period were classed as stunned segments. Previous work 
using PET has demonstrated a corresponding reduction in MBF with 
post stress recovery in function and perfusion in those areas. 
Myocardial hibernation / fibrosis: a reduction in resting systolic function 
of >60% within previously stunned myocardial segments that remained 
fixed during HD was taken to represent chronically dysfunctional 
myocardium within the disease spectrum of myocardial hibernation / 
fibrosis. A value of 60% was used based on animal studies showing a 
similar reduction in wall motion score between chronically stunned and 
hibernating myocardial segments 193. 
7.3 Statistical analysis 
Descriptive analyses are presented as mean ± standard deviation. The 
paired Student t test was used for comparison of continuous variables 
within each cohort. The Student t test was used for comparison of 
continuous variables between the two cohorts. Repeated analysis of 
variance was used for multiple comparisons of a continuous variable 
within a group. Linear correlation was used to investigate potential 
associations between variables of interest. For other data, either the 
paired t-test or Wilcoxon rank sum test was used depending on 
normality of the distribution. Significant deviations from a normal 
distribution were excluded with the Kolmogorov-Smirnov test. All 
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statistical tests were two-tailed with a P value less than 0.05 taken to 
indicate significance. 
7.4 Results 
7.4.1 Prevalence of regional wall motion abnormalities after 12-
months 
Of the 51 patients who entered follow-up, 74% (38/51) had significant 
RWMAs during HD. Of the 31 follow-up patients with evidence of 
myocardial stunning at baseline, 94% (29/31) continued to have 
evidence of significant RWMAs during HD and 45% (14/31) had an 
increase in the number of affected regions. Two patients had a 
reduction in the number of RWMAs below significance.  
7.4.2 Incidence of new regional wall motion abnormalities after 
12-months 
Of the 20 follow-up patients who did not have evidence of myocardial 
stunning at baseline, 45% (9/20) showed development of significant 
RWMAs; however 55% (11/20) continued to be unaffected. 
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7.4.3 Effect of myocardial stunning on global left ventricular 
function after 12-months 
 
Figure 7.4.3a: Change in left ventricular ejection fraction at rest over 12 
months in patients with and without evidence of myocardial stunning at 
baseline. 
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At baseline, LVEF at rest (LVEFrest) was not significantly different 
between patients who did, and did not, develop HD-induced RWMAs 
(62.1±11.4% vs. 60.1±7.7%, P=0.4). After 12 months, LVEFrest had 
significantly deteriorated in patients with RWMAs (62.1±11.4% vs. 
54.7±10.1%, P<0.0008) but remained unchanged in those patients 
without (60.1±7.7% vs. 55.8±5.5%, P=0.09), see figure 7.4.3a. 
 
Figure 7.4.3b: Change in left ventricular ejection fraction during 
haemodynamic stress of HD over 12 months in patients with and 
without evidence of myocardial stunning at baseline. 
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Baseline LVEF at peak dialytic stress (LVEFHD) was significantly lower 
in patients who had RWMAs compared to those who did not (67±6.8% 
vs. 57.3±10.1%, P<0.0001). Although there was a reduction in LVEFHD 
after 12 months in both those patients with HD-induced RWMAs and 
those without (57.3±10.1% vs. 50.9±8.9, P<0.001 and 67±6.8% vs. 
61.3±9.3, P=0.007 respectively), the difference in LVEFHD between the 
two groups remained significant (61.3±9.3 vs. 50.9±8.9, P<0.0001), see 
figure 7.4.3b. 
7.4.4 Effect of myocardial stunning on systolic blood pressure 
over 12 months 
After 12-months both groups of patients (with and without evidence of 
HD-induced RWMAs) exhibited a significant deterioration in SBP during 
HD. Mean reduction was greater in patients with RWMAs at both 
timepoints (-18.6±6.9 mmHg to -23.3±7.2 mmHg, P<0.01 and -7±3.6 
mmHg to -14±4.8 mmHg, P<0.001 respectively). However, the 
separation remained between patients developing RWMAs versus 
those who did not (-23.3±7.2 mmHg vs. -14±4.8 mmHg, P<0.001). 
7.4.5 Progression of myocardial stunning to fixed systolic 
dysfunction (myocardial hibernation) 
In order to assess for the progression of myocardial stunning to fixed 
reductions in segmental functional (myocardial hibernation), a separate 
analysis of those patients who exhibited signs of HD-induced 
myocardial stunning at baseline was performed. As stated above, a 
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reduction in resting systolic function of >60% within previously stunned 
myocardial segments that remained fixed during HD was classified as a 
hibernating segment. 
 
Table 7.4.5a: Demographic characteristics and dialysis related factors - 
based on the presence (with) or absence (without) of new fixed 
segmental systolic reduction of >60% after 12 months. APKD, adult 
polycystic kidney disease; HT, hypertension. 
 
Of the 45 patients with evidence of myocardial stunning at baseline, 30 
entered follow up. The clinical characteristics of this sub-group are 
shown in table 7.4.5a. Patients were divided into two groups; patients 
Parameters Patients without Patients with P 
Age (mean, years) 65 ± 14.5 64.8 ± 11.8 >0.9 
Male : Female (n) 6 : 5 13 : 6 >0.6 
Dialysis vintage (mean, months) 31.9 ± 21.6 41.6 ± 28.5 >0.9 
Etiologies (n)    
Diabetes mellitus 4 (36%) 10 (53%) >0.4 
Glomerular disease 2 (18%) 2 (11%) >0.5 
APKD 1 (9%) 3 (16%) >0.9 
Other 3 (27%) 1 (5%) >0.2 
Unknown 1 (9%) 3 (16%) >0.1 
Ischaemic heart disease (n) 6 (45%) 5 (25%) >0.2 
Smoker (n) 3 (27%) 5 (25%) >0.9 
Intradialytic weight gain (mean, 
kg) 1.6 ± 0.7 1.84 ± 0.7 >0.9 
Ultrafiltration volume (mean, L) 2.03 ± 0.6 2.3 ± 0.9 >0.6 
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with evidence of fixed segmental reduction after 12 months in 
previously stunned myocardial regions and those without. There were 
no statistically significant differences between the 2 groups with respect 
to underlying aetiology, co-morbid conditions (including diabetes 
mellitus and ischaemic heart disease) or dialysis vintage. 
At baseline a total of 146 regions (48.7%) developed myocardial 
stunning out of a maximum of 300 in 30 patients. The mean resting SF 
of those regions that developed myocardial stunning on HD was 
significantly higher than those that did not (3.19 ± 1.18% vs. 2.07 ± 
0.75%, P<0.01). At follow-up, 47 of the 146 stunned regions (32.2%) 
had developed a fixed reduction in systolic function of >60% that did not 
show an increase on HD. There was a significant decline in resting SF 
over 12 months in all regions that developed HD-induced myocardial 
stunning at baseline (3.19 ± 1.18% vs. 1.87 ± 0.7%, P<0.0001). 
However there was no significant change over 12 months in those 
regions that were unaffected by HD at baseline (2.07 ± 0.75% vs. 2.06 
± 0.78%, P=0.99), see figure 7.4.5a. 
In terms of the effect on EF at rest and on HD, patients who developed 
myocardial segments with fixed systolic reduction of >60% (n=19) 
showed a significant decline in EF over 12 months both at rest and at 
peak stress during HD (61.5 ± 10.1% vs. 52.9 ± 8.6%, P<0.007 and 
59.5 ± 10% vs. 49.9 ± 6.5%, P<0.003 respectively). 
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Figure 7.4.5a: Change in regional SF over time - there was a significant 
reduction in SF over 12 months in those segments that developed 
RWMAs at baseline (index) compared to those that did not. 
 
In comparison, patients who did not develop such abnormalities showed 
no significant reduction in these values either at rest or during HD (63.3 
± 14.8% vs. 56.2 ± 13.1%, P>0.1 and 53.9 ± 10.4% vs. 52.4 ± 12.4% 
P>0.7 respectively). These results are summarised in figure 7.4.5b. 
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Figure 7.4.5b: Change in EF at rest and during HD over 12 months in 
patients with fixed reductions in segmental function of >60% - the 
development of fixed segmental reduction in previously stunned 
myocardial segments was associated with a significant reduction in 
LVEF both at rest and during HD. There was no significant reduction in 
LVEF in patients who did not develop fixed reductions in segmental 
function. 
 
Looking at Intradialytic changes in blood pressure, using a two-way 
ANOVA, there was a significant reduction in SBP during HD and over 
12 months in the patient group that developed fixed segmental systolic 
dysfunction of >60% (F(16,336) = 4.71; MSE = 227; P<0.0001). This 
was not true in the other group who had no significant change in their 
SBP during HD over 12 months (F(16,820) = 0.25; MSE = 655; P>0.9), 
see figure 7.4.5c. 
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Figure 7.4.5c: Changes in SBP during HD over 12 months - after 12 
months there was a significant difference in SBP during HD in those 
patients with new fixed reductions of >60% in previously stunned 
myocardial segments. 
 
In this sub group, haematological, biochemical and dialysis details gave 
the following results: both at baseline and follow-up, 83% of patients 
had a significantly raised plasma cTnT concentration (0.03 ȝg/L), 
consistent with the presence of repetitive acute myocardial injury. 
However, there were no significant differences among any of the 
haematological or biochemical measurements (including cTnT) within or 
between either of the groups at baseline or over the 12 month follow-up 
period. There were also no significant differences between the groups 
with respect to dialysis adequacy (Kt/Vurea) or ultrafiltration volumes. 
These data are summarised in table 7.4.5b. 
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Patients without fixed reduction in 
segmental systolic reduction 
Patients with  fixed reduction in 
segmental systolic reduction 
Parameter 
Baseline Follow-up Baseline Follow-up 
Pre-HD Post-HD Pre-HD Post-HD Pre-HD Post-HD Pre-HD Post-HD 
Haemoglobin 
(g/dl) 10.8±1.1 11.3±1.0 11.8±1.7 12.2±1.8 11.2±1.5 11.7±1.6 11.9±1.6 12.2±1.7 
Na+ (mmol/L) 137±3 137±2 136±4 137±2 138±3 138±2 137±4 137±3 
K+ (mmol/L) 4.3±0.5 2.8±0.5 4.4±0.8 2.8±0.4 4.9±1.0 2.9±0.4 4.6±0.1 3.0±0.7 
Urea (mmol/L) 19.6±4.7 5.8±2.1 17.8±5.6 5.4±2.4 21±4.6 6.5±2.2 23.3±8.7 7.0±2.9 
Creatinine 
(ȝmol/L) 665±165 258±74 618±165 250±87 658±213 267±107 725±257 300±148 
Phosphate 
(mmol/L) 1.8±0.4 0.8±0.1 1.7±0.5 0.7±0.2 1.5±0.5 0.8±0.3 1.8±0.6 0.8±0.3 
Bicarbonate 
(mmol/L) 23.8±1.9 27.1±4.1 22.8±2.2 27±1.6 23.1±2.5 27.9±2.4 24.2±2.6 26.8±1.7 
Corrected Ca2+ 
(mmol/L) 2.42±0.2 2.34±0.1 2.43±0.13 2.31±0.1 2.4±0.1 2.4±0.1 2.4±0.19 2.3±0.14 
Albumin (g/L) 34.4±2.9 35.8±3.8 30.6±6.2 32.3±7.4 35.3±4.7 36.6±5.5 35.2±4.4 37.1±4.9 
F7Q7ȝJ/ 0.07±0.05 - 0.12±0.12 - 0.09±0.06 - 0.08±0.05 - 
Kt/V urea 1.3±0.2 - 1.4±0.2 - 1.3±0.3 - 1.3±0.4 - 
 
 
Table 7.4.5b: Pre- and Post-HD haematological and biochemical values 
for both groups at baseline and follow-up - there were no significant 
differences between different or within the same groups at either time 
point (P>0.1). 
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7.5 Discussion 
We have previously demonstrated that HD can directly induce RWMAs 
and that these are associated with a corresponding decrease in 
segmental MBF with recovery post-HD consistent with myocardial 
stunning. This chapter demonstrates for the first time that repetitive 
haemodialysis induced cardiac injury can lead to chronic reduction in 
LV function and also, that LV segments which develop myocardial 
stunning during HD can progress over time into areas of fixed systolic 
dysfunction that have distinct systemic haemodynamic consequences. 
These manifest as reductions in LVEF at rest and a reduced ability to 
increase LV contractile function to maintain BP during HD with fluid 
removal. This could potentially create a vicious cycle for further HD-
induced cardiac injury. 
At baseline, both groups of patients had similar LVEFrest. During HD, 
patients with myocardial stunning were unable to maintain cardiac 
contractile performance, and had a significant drop in their LVEFHD. 
After 12 months, LVEFrest had fallen in patients with HD induced 
myocardial stunning and their ability to respond to the challenge of HD 
was even further compromised. Patients without myocardial stunning at 
baseline maintained their LVEFrest, but LVEFHD was significantly 
reduced. This is entirely consistent with the pattern of injury associated 
with ischaemic cardiomyopathy in the non-dialysis population. 
Repetitive ischaemic injury initially causes a loss of contractile reserve 
that may lead to myocardial fibrosis and resting dysfunction 194. In HD 
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patients, repetitive HD-induced myocardial stunning led to a reduction in 
contractile reserve and then resting LV systolic dysfunction. This 
process of deterioration has already begun in patients unaffected by 
HD-induced myocardial stunning at baseline, as almost half now have 
evidence of HD-induced RWMAs and reduced contractile reserve. This 
also has major potential clinical implications. In the non-dialysis 
population timely revascularisation can lead to an improvement in 
LVEF, heart failure and prognosis 195. In addition to modifications to the 
HD procedure, treatment of underlying coronary artery disease may 
slow progression of heart failure and improve outcome. 
Looking specifically at patients with myocardial stunning at baseline, 
over the period of 12 months, a number of these abnormal regions had 
progressed to areas of fixed systolic dysfunction. That is to say that not 
only was there a significant reduction in resting shortening fraction in 
that region after 12 months compared to baseline (>60% reduction in 
%SF) but that this did not improve during the haemodynamic stress 
associated with haemodialysis. This would be wholly consistent with 
progression to segmental myocardial hibernation or even fibrosis.  
Within the cohort of patients that developed myocardial stunning at 
baseline, there was no significant association between the progression 
of LV regional wall dysfunction and demographic variables. It is not 
possible to identify patients experiencing HD induced cardiac injury on 
the basis of known co-morbidities. In the HD population decline in LVEF 
is usually progressive over time and often accelerated 163 but there is 
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increasing evidence that this is not due to traditional cardiac risk factors 
or conventional atherosclerotic coronary artery disease 165. It is 
therefore not surprising that the presence or absence of IHD and 
diabetes mellitus were not different between the two groups. Similarly, 
no significant difference in dialysis vintage (time on dialysis in months) 
was observed, however both groups had been receiving HD for a 
considerable time (>2 years). There is currently no evidence as to 
whether a critical time period on dialysis exists after which the process 
of irreversible myocyte damage begins and the potential for 
improvement in LVEF is lost. In reality this is likely to differ considerably 
from patient to patient and be determined by a complex interrelationship 
between a number of underlying factors that affect cardio-renal 
performance. Some of these pathological processes associated with 
HD that predispose to demand cardiac ischaemia (coronary and 
peripheral arterial calcification 196, impaired microcirculation and 
increased pulse wave velocity 22) are now more clearly understood but 
there are an equal number of humoral and genetic factors whose roles 
are very poorly defined 197.  
At baseline within patients who developed myocardial stunning, around 
half of all LV regions developed RWMAs on HD. At rest these regions 
had a significantly higher regional SF than those unaffected by HD. This 
may reflect vulnerability to demand ischaemia in more kinetic areas of 
the LV in response to haemodynamic stress in HD patients with 
reduced CFR. At follow up, these regions had significantly reduced their 
SF in comparison to unaffected regions at baseline. The magnitude of 
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that reduction varied but a considerable number (32.2%) showed a 
reduction of >60% that remained fixed during HD. 
As a result of these areas of fixed systolic dysfunction, affected patients 
showed a decline in both resting and demand EF (on HD) after 12 
months, which was not seen in the unaffected group. This is in keeping 
with other published work looking at the effect of chronic myocardial 
stunning and myocardial hibernation on LV function in patients with 
IHD. In our dialysis patients however, this reduction in EF seems to 
have a direct impact on intradialytic haemodynamics.  
This sub-group as a whole represents patients with HD-induced cardiac 
dysfunction. Both individual study groups had some reduction in 
absolute SBP during HD. However, the only patients that had a 
significant deterioration in their SBP during HD after 12 months were in 
the group that developed regional fixed systolic reductions of >60%. 
This is not attributable simply to volume overload. A small subset of 
patients with below average UF volumes had significant reductions in 
SBP. In addition, SBP at the end of HD is primarily determined by 
cardiac output 198 and therefore it is likely that the absolute reduction in 
SBP seen here is secondary to the reduction in LVEF. Intradialytic 
hypotension (IDH) is known to be associated with increased mortality. 
Given the underlying vulnerability of hibernating myocardium to 
increases in demand 78 coupled with decreased CFR in HD patients it 
may be that this adaptive process actually leads to further segmental 
injury by exacerbating intradialytic instability. This may be one of the 
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reasons that prevalence of heart failure is so high and survival so poor 
in HD patients. 
This hypothesis is supported by evidence that a continuation of HD 
results in a significant increase in cardiovascular events as well as 
myocyte fibrosis and death compared to uraemic patients not on HD 199. 
A study by Wali et al 84 looking at the effects of renal transplantation in 
patients with heart failure demonstrated that a longer duration of 
dialysis in months prior to transplantation was the only significant factor 
associated with a decreased likelihood of achieving a normal LVEF in 
the post-transplantation period. They attributed this to prolonged 
exposure to potentially negatively inotropic factors and other toxins that 
are present in uraemic plasma, which may be decreased after 
transplantation 200. Whilst these potential uraemic toxins may play a part 
we assert that the observed changes related to the removal of dialytic 
stress. 
Previous studies in our centre have shown that myocardial segments 
which develop stunning during HD have normal resting blood flow but a 
reduction in blood flow during treatment. Conventional definitions of 
myocardial hibernation suggest that resting MBF in these areas would 
be reduced, but this was beyond the scope of this current study. 
Although MBF has not been measured, repeated myocardial stunning 
has been shown in animal models to precede myocardial hibernation 
and remodeling 201. Such fixed reductions in systolic function in those 
regions undergoing chronic myocardial stunning would be consistent 
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with myocardial hibernation but may also potentially represent areas 
that have already undergone fibrosis and remodeling. Therefore, these 
chronically stunned segments may well have deteriorated over 12 
months and lie somewhere along the continuum of disease classified as 
myocardial hibernation and remodeling. 
Dialysis sessions that are complicated by episodes of IDH are 
associated with a significant rise in cardiac troponin I and T levels 100 
suggesting underlying sub-clinical myocardial damage. A significant 
amount of work has been done looking at the clinical significance of 
biochemical markers of cardiac injury including cardiac troponins but 
their value as long-term prognostic markers is as yet undetermined. We 
observed no difference in cTnT levels between the two groups of 
patients however this may in part be due to the fact that a number of the 
most potentially unstable patients died before 12 months and were not 
included in the analysis. More work is needed to assess the use of 
ELRFKHPLFDOPDUNHUVDVDVFUHHQLQJWRROIRUWKHLGHQWLILFDWLRQRIµDWULVN¶
patients. 
The process of myocardial stunning in HD has been shown to be 
modifiable in a number of ways (apart from transplantation) that 
improve intradialytic haemodynamics. These include biofeedback 
mechanisms and cooled dialysate 70,71 although there are as yet no long 
term data looking at improvements in LVEF as a result of the longer 
term applications of these interventions. Other dialysis treatment such 
as nocturnal haemodialysis have been shown to result in an 
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improvement in LVEF 180 which may also be in part due to abrogation of 
HD induced myocardial stunning, through modifications to ultrafiltration 
rates and IDH. Given the current shortage of donor organs for kidney 
transplantation these other dialysis options may offer treatment 
strategies that can minimise / avoid HD induced myocardial stunning, 
myocardial hibernation and remodeling, improve LV function and 
thereby reduce heart failure and mortality. 
7.5.1 Study limitations 
Echocardiography was the only method used to quantify functional 
decline however this method is repeatable and quantitative. Also, the 
use of other imaging techniques such as magnetic resonance imaging 
to assess functional change while the patient was receiving HD would 
be technically impossible. 
There was no angiography or perfusion imaging available to quantify 
epicardial CAD in these patients. However, HD induces myocardial 
ischaemia even in the absence of epicardial CAD and myocardial 
scintigraphy is an imperfect technique for the evaluation of CAD in 
patients with end-stage renal disease 202. Although the mechanism of 
HD driven myocardial stunning and hibernation would still apply in this 
case, it may be that coronary revascularisation is a potential 
intervention that will improve LVEF and heart failure in this group. That 
question is outside the scope of this study. 
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7.5.2 Conclusions 
The results in this chapter demonstrate that HD-induced cardiac injury 
is associated with a reduction in segmental and global LV function. The 
cycle of intra-dialytic instability resulting in repetitive cardiac injury leads 
to a potential for yet more dialysis induced hypotension. This fits well 
with the observation that heart failure is associated with very poor 
outcome in HD patients. However, haemodynamic instability during HD 
is a potentially avoidable phenomenon. This raises the possibility that 
addressing HD-induced repetitive injury might prevent the development 
of myocardial stunning, hibernation and fibrosis which lead to LV 
systolic dysfunction in these patients and potentially prevent the 
development of heart failure. How much such interventions may 
improve outcome is not yet known and the next chapter will investigate 
any potential associations between haemodialysis induced cardiac 
injury and mortality. 
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Chapter 8 
 
Results: 
Haemodialysis induced repetitive myocardial stunning and the 
associations with increased hazard of death and time to first 
cardiovascular event. 
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8 Results: Haemodialysis induced repetitive 
myocardial stunning is associated with an 
increased hazard of death and time to first 
cardiovascular event 
8.1 Introduction 
In the previous chapters, results have shown that haemodialysis 
induced myocardial stunning is common and associated with a number 
of negative predictors of outcome including intradialytic hypotension, 
ventricular arrhythmias and elevated serum cardiac troponin-T 
concentrations. Potentially more serious however is the observation 
that, over time, this phenomenon leads to a reduction in global and 
segmental left ventricular function, both at rest and during 
haemodialysis. 
Records from the US Renal Data System have shown that HD is an 
independent risk factor for the development of both de novo and 
recurrent heart failure with a two-year mortality after a diagnosis of 
congestive heart failure as high as 51% 124, making it one of the most 
common causes of cardiovascular mortality in this patient group. 
The aim of this chapter was to evaluate the impact of chronic 
haemodialysis induced myocardial stunning on patient survival and time 
to first cardiovascular event. 
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8.2 Methods 
8.2.1 Study protocol 
Recruitment of the 70 initial patients is covered in chapter 5 section 
5.2.1 and is not repeated here. 
After 12 months, mortality data was collected for all patients, as well as 
time to first cardiovascular event. Cause of death was obtained from 
SDWLHQWV¶ KRVSLWDO QRWHV ,Q WKH HYHQW WKDW D SDWLHQW GLHG LQ WKH
community, their General Practitioner was contacted and asked to 
provide a cause of death. In one case where the patient died out-of-
hospital, a post mortem examination was conducted and the final cause 
RIGHDWKZDVREWDLQHGIURPWKH&RURQHU¶V2IILFH 
Defined cardiovascular events included: a new diagnosis of coronary 
artery or cerebrovascular disease; myocardial infarction; 
cerebrovascular and peripheral vascular events. All hospital admissions 
were identified using the PAS system and subsequently confirmed 
XVLQJ SDWLHQWV¶ KRVSLWDO UHFRUGV $Q\ RI WKH DERYH FRQGLWLRQV ZHUH
recorded including date of first diagnosis. 
At this final stage, the primary endpoints were to understand the longer 
term consequences of this phenomenon with respect to mortality and 
cardiovascular morbidity. Secondary endpoints included: the potential 
role of haematological and biochemical variables (cardiac troponin-T) 
as a potential marker to identify the most at risk patients. 
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8.2.2 Haemodialysis details 
Dialysis was performed as described in chapter 3 using Hospal Integra 
monitors (Hospal, Mirandola, Italy) using low-flux polysulfone dialysers, 
either 1.8 or 2.0 m2SHU LQGLYLGXDOSDWLHQWV¶XVXDOSUHVFULSWLRQV/236
18/20; Braun Medical Ltd, Sheffield, UK). Exact prescriptions and 
treatment regimes for these 70 patients are detailed in section 5.2.3 and 
not repeated here.  
8.2.3 Collection of study data 
Measurement of regional and global LV function using 
echocardiography (to define the presence of myocardial stunning), 
blood pressure, haematological and biochemical variables is outlined in 
full in sections 5.2.4 ± 5.2.6 and not repeated here. 
8.3 Statistical analysis 
The Wilcoxon rank sum test was used to investigate potential 
associations between variables of interest (cTnT) over time. Descriptive 
analyses are presented as median (interquartile range) unless 
otherwise stated. Significant deviations from a normal distribution were 
evaluated with the Kolmogorov-Smirnov test. Survival data was 
analysed using a logrank test to create Kaplan-Meier curves for both 
mortality and the combined endpoint of mortality and time to first 
cardiovascular event. Cox regression analysis was used to investigate 
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the association between variables of interest. All statistical tests were 
two-tailed with a P value less than 0.05 taken to indicate significance. 
8.4 Results 
8.4.1 Myocardial stunning is associated with a decreased 12 
month survival 
Of the 70 patients who were consented for the study, nine had died 
within the 12 month follow-up period. Of these nine patients, all of them 
(100%) had evidence of haemodialysis induced myocardial stunning 
during the baseline study session. Causes of death were: six from 
cardiac disease, two from sepsis and one stroke. As a result of this the 
presence of haemodialysis induced myocardial stunning was 
associated with increased relative mortality at 12 months (P=0.019), 
see figure 8.4.1a. 
8.4.2 Myocardial stunning is associated with an increased 
cardiovascular event rate  
Similarly, a composite end point of mortality and time to first 
cardiovascular event confirmed the association between myocardial 
stunning and such events. 
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Figure 8.4.1a: The association of haemodialysis induced myocardial 
stunning with mortality. The development of HD-induced RWMAs was 
associated with increased relative mortality at 12 months. 
 
Of the 70 patients who were consented for the study (and in addition to 
the nine who had died), a further five had a non-fatal cardiovascular 
event within the 12 month follow-up period. These events consisted of: 
two strokes, two peripheral vascular events and one new diagnosis of 
ischaemic heart disease confirmed by angiography. Of these additional 
five patients, four had evidence of haemodialysis induced myocardial 
stunning at baseline and only one did not. So, survival to a composite 
end point of mortality and first cardiovascular event also demonstrated 
almost complete separation in events, and mortality, between patients 
with and without HD induced myocardial injury; with only one patient in 
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the unaffected group, compared to 13 in the myocardial stunning group 
(P=0.017, hazards ratio of 8, 95% CI 1.264 to 10.99), see figure 8.4.2a. 
 
Figure 8.4.2a: The association of haemodialysis induced myocardial 
stunning with mortality and time to first cardiovascular event. The 
development of HD-induced RWMAs was associated with reduced 
survival to a composite end point of mortality and time to first 
cardiovascular event. 
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8.4.3 Baseline troponin-T concentrations were associated with an 
increased mortality 
As reported, baseline cTnT levels were associated with the presence 
and severity of myocardial stunning on univariate and multivariate 
analyses (sections 5.4.4 and 5.4.6-7). After 12 months, the mean cTnT 
levels for the cohort as a whole had increased significantly (0.06 ȝJ/ 
[IQR 0.02 to 0.1] vs. 0.07 ȝJ/ [IQR 0.03 to 0.1], P<0.03) and there 
remained a significant separation in cTnT levels between patients who 
developed haemodialysis induced myocardial stunning and those who 
did not (0.04 ȝJ/ [IQR 0.02 to 0.07] vs. 0.08 ȝJ/ [IQR 0.05 to 0.14], 
P<0.002) figure 8.4.3a).  
 
Figure 8.4.3a: Cardiac troponin-T concentrations in patients with and 
without myocardial stunning at both baseline and after 12 months. A 
significant difference remained between the groups at both timepoints. 
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There was no significant increase in cTnT within groups (those with 
myocardial stunning or those without, P=ns). Baseline cTnT levels were 
significantly higher in those patients who died compare to those who 
survived to 12 months (0.14 ȝJ/ [IQR 0.1 TO 0.16] vs. 0.05 ȝJ/ [0.02 
TO 0.09], P<0.001, figure 8.4.3b).  
 
 
Figure 8.4.3b: Baseline cardiac troponin-T levels were significantly 
higher in patients who died within 12 months (P<0.001). 
 
Cox regression analysis showed an increased hazard of death in 
patients with myocardial stunning and an elevated cTnT than in patients 
with elevated cTnT alone (P<0.02). 
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8.5 Discussion 
These data demonstrates for the first time that dialysis induced 
recurrent cardiac injury is associated with not only with reductions in 
myocardial contractile function but also with patient survival. 
To date, only surrogate markers of myocardial ischaemia in 
haemodialysis patients have been used to investigate the long term 
effects of myocardial ischaemia precipitated by the dialysis process. 
Studies looking at silent myocardial ischaemia using 12-lead Holter 
monitoring have yielded conflicting results. One study of 67 dialysis 
patients who underwent a single 12-hour period of Holter monitoring 
reported that 16 (23%) displayed evidence of silent ST depression. 
After two years, there was no difference between in mortality and 
cardiac event rates between those who did and did not display ST 
depression at baseline 58. In a separate study of 62 haemodialysis 
patients who were studied for six months, of the two patients who died, 
both had experienced ST depression at baseline leading the authors to 
believe that silent ST depression was associated with a negative 
prognosis 62. In reality, it is most likely that these studies were 
inadequately powered to detect a difference in mortality and in any 
case, relying solely on Holter monitoring alone has been shown to 
underestimate the true incidence of silent ischaemia which would have 
patients being wrongly classified at the outset 65. This chapter has 
shown that myocardial stunning, which is known to be associated with 
reductions in myocardial blood flow consistent with ischaemia, is 
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associated with increased mortality. Given that myocardial stunning in 
present in over 60 per cent of haemodialysis patients, it is likely that the 
true incidence of haemodialysis induced ischaemia has, up until this 
point, been greatly underappreciated. Although the mortality 
observations are derived from a small number of patient deaths and the 
study is clearly underpowered in this respect. However statistical 
significance was achieved and the clear separation for cardiovascular 
events and mortality between the two groups is compelling. 
The association between myocardial stunning and the combined 
endpoint of all cause mortality and first cardiovascular event is also of 
importance. Studies have shown that increased levels of biomarkers 
which indicate cardiac damage are associated with not just 
cardiovascular death but also from other causes (e.g. sepsis) 90 
Specifically, it is well recognised that cTnT levels are often elevated in 
dialysis patients and that elevated levels predict mortality 89. This would 
suggest that patients with repetitive cardiac injury and leak of such 
biomarkers into the plasma are less capable of mounting a response to 
the increased cardiovascular demands at the time of systemic insult 
from other causes. This is entirely consistent with the results in this 
thesis. Myocardial stunning results in a fall in systolic cardiac function, 
firstly during the systemic stress of haemodialysis but then at rest 
causing a reduction in LVEF. This is associated with a significantly 
higher troponin-T level, both at baseline and after 12 months. Such 
patients are at continuous risk from the repetitive damage caused by 
myocardial ischaemia and over time become less and less able to cope 
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with the haemodynamic demands put upon them from systemic illness 
of any cause. 
So, in addition to the association with presence and severity of 
myocardial stunning, elevated plasma cTnT levels were also associated 
with an increased hazard of death. A recent study of cardiac troponins 
and outcome in acute heart failure revealed associations with lower 
SBP, lower LVEF and higher mortality 88.  
The fact the Cox regression analysis showed that elevated cTnT 
concentrations in patients with haemodialysis induced myocardial 
stunning is more predictive of mortality than elevated cTnT alone shows 
that it is those patients with functional abnormalities who are most 
vulnerable. This may help to develop strategies to identify those 
patients most at risk. Individuals who display any evidence of cardiac 
dysfunction (e.g. intradialytic hypotension or cardiac abnormalities on 
routine clinical echocardiography) in conjunction with a raised random 
cTnT level (not done in response to a clinical episode) may represent 
an at risk section of the haemodialysis population. As such cTnT and 
other biochemical markers of cardiac damage (e.g. BNP) may provide 
useful tools to identify vulnerable patients who might benefit from 
modified dialysis therapies. 
8.6 Conclusions 
The results summarised within this chapter demonstrate for the first 
time that HD-induced myocardial stunning is associated with poor 
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outcomes. Despite the small numbers, these findings are consistent 
with evidence linking other cardiovascular abnormalities with increased 
mortality (e.g. left ventricular hypertrophy, intradialytic hypotension and 
left ventricular systolic dysfunction). This supports the hypothesis that 
haemodialysis induced myocardial ischaemia and myocardial stunning 
is intrinsically linked with these pathological conditions and may in fact 
represent a unifying pathophysiological process. If so, then dialysis 
based interventions aimed at reducing the incidence and prevalence of 
myocardial stunning may reduce the impact on the cardiovascular 
system and help to improve outcomes. 
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9 Conclusions 
Cardiovascular death remains grossly elevated in haemodialysis 
patients with very little change in mortality over the last decade despite 
extensive research into the field of cardio-renal medicine. In the future, 
as the dialysis population continues to expand (and whilst donor 
kidneys remain scarce), this excess of mortality is becoming an 
increasingly important issue. Haemodialysis patients are subject to a 
grossly elevated rate of cardiovascular attrition and it is becoming 
apparent that the current prevailing paradigm of considering this as a 
result of a particularly severe form of the cardiovascular risk factors 
seen in the general population is not true. This results in the well 
appreciated failure of Framingham risk models to predict events in this 
group, and the almost universal failure of attempts to successfully apply 
interventions that are well proven to be effective in the general 
population.  
There are many different factors that impact negatively on the 
cardiovascular system in haemodialysis patients and it is likely that any 
solution to this growing problem will have to be multi-faceted in nature. 
However, our results suggest that the haemodialysis procedure itself 
may be central to this process by inducing a reduction in myocardial 
blood flow sufficient to induce subclinical myocardial ischaemia. 
Previous small studies have demonstrated the development of dialysis 
induced LV regional wall motion abnormalities 70,71 and now these 
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results have confirmed that such abnormalities are associated with 
changes in myocardial blood flow consistent with current definitions of 
myocardial stunning. Although there are other reports of silent 
ischaemia occurring during dialysis 43,56-65 our work is the first to shown 
a direct association between the process of haemodialysis and changes 
in myocardial blood flow (which has subsequently been reproduced in 
other studies 134). Although it was inadequately powered to show a true 
difference between the two dialysis modalities (standard haemodialysis 
and biofeedback dialysis) our study suggested that biofeedback dialysis 
was associated with an improvement in myocardial blood flow at rest 
and better recovery in the post-dialysis period. Cooled dialysate has 
also been shown to reduce the number of stunned myocardial 
segments 70 and these two widely available treatment options may 
represent a simple, cost effective therapeutic intervention aimed at 
reducing myocardial stunning and ischaemia. Other modifications to the 
dialysis treatment regime have shown to have benefit. Short daily 
dialysis treatments were associated with a reduction in LVMI, 
extracellular fluid volume and better control of blood pressure 203. 
Similarly, frequent nocturnal haemodialysis has been shown to improve 
left ventricular ejection fraction, LVMI and cause regression of LVH 
179,180,204
 with a reduction in biochemical markers of cardiac damage 205. 
Unfortunately, the estimated reduction in cost needed to make these 
therapies cost neutral with current thrice weekly practises is likely to be 
prohibitive at present 206, making other dialysis modifications mentioned 
above more practicable. 
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In a large group of haemodialysis patients, we have now demonstrated 
that the prevalence of myocardial stunning is significantly higher than 
previously thought. This is important as repeated episodes of ischaemia 
and myocardial stunning may be cumulative and contribute to the 
genesis of chronic heart failure in patients with ischaemic heart disease 
77
. Therefore, we postulated that thrice weekly haemodialysis and the 
resulting repetitive dialysis induced myocardial stunning may contribute 
to chronic cardiac dysfunction. It is perhaps logical that myocardial 
stunning would be associated with an increased troponin-T 
concentration given that the mechanism underlying this phenomenon is 
ischaemic cardiac injury. However, the observation that increased 
intradialytic ultrafiltration volumes and poor intradialytic haemodynamics 
are associated with myocardial stunning is of crucial importance as 
these both represent potential modifiable risk factors and therapeutic 
targets.  
Mirroring the published literature, we found an increase in ventricular 
ectopy and complexity during haemodialysis compared to the post 
dialysis period however, these ventricular abnormalities were 
significantly higher in patients with haemodialysis induced regional left 
ventricular dysfunction. Also, these electrophysiological abnormalities 
were higher in those patients in whom there were additional factors 
associated with demand ischaemia (left ventricular hypertrophy and 
ischaemic heart disease). These results demonstrated for the first time 
that haemodialysis induced myocardial ischaemia may lead to the 
development of both functional LV abnormalities and ventricular 
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arrhythmias, potentially playing a role in the development of the two 
commonest causes of cardiovascular death in chronic HD patients. 
Therapeutic strategies targeting the mechanisms of myocardial 
stunning during dialysis may reduce HD induced ischaemia and the life-
threatening arrhythmias that go alongside it. This in turn may reduce the 
incidence of sudden death in our HD population as well as any long-
term benefit seen with respect to improvements in left ventricular 
function. 
After 12-months, these results confirmed the hypothesis that repetitive 
dialysis induced cardiac injury leads to a reduction in left ventricular 
function and may be a driving force behind the development and 
progression of heart failure in this group. Those patients with 
myocardial stunning at baseline got worse, developing areas of fixed 
systolic dysfunction consistent with myocardial hibernation and scarring 
with a corresponding reduction in left ventricular function on and off 
dialysis. Those patients without myocardial stunning at baseline had 
evidence of regional wall motion abnormalities and had also developed 
evidence of demand associated systolic decline. All of this was in the 
context of elevated biochemical markers of myocardial injury (cardiac 
troponin-T levels). 
Mortality was significantly higher in patients with dialysis induced 
myocardial stunning, as was time to mortality combined with 
cardiovascular events. This demonstrates for the first time that dialysis 
induced myocardial stunning is associated with poor outcomes. Despite 
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the small numbers, these findings are consistent with evidence linking 
other cardiovascular abnormalities with increased mortality (e.g. left 
ventricular hypertrophy, intradialytic hypotension and left ventricular 
systolic dysfunction). This supports the hypothesis that haemodialysis 
induced myocardial ischaemia and myocardial stunning is intrinsically 
linked with these pathological conditions and may in fact represent a 
unifying pathophysiological process. Raised troponin-T levels were also 
associated with an increased mortality at 12-months which is entirely in 
keeping with current literature 90. However, there was an increased 
hazard of death in those patients with a raised troponin-T and 
myocardial stunning compared to those with myocardial stunning alone. 
It could be speculated that these patients with myocardial stunning and 
a troponin-T leak represent those patients with the most clinically 
significant reductions in myocardial blood flow during dialysis and hence 
are the most at risk. This would also fit with our observation that 
troponin-T level is an independent determinant of both the presence 
and severity of myocardial stunning and provides an exciting possibility 
for the early detection of the most vulnerable patients in whom dialysis 
based interventions may have the most positive outcomes. 
In final conclusion, the results of this thesis describe a potentially highly 
significant, common and previously unappreciated direct effect of the 
dialysis process itself in producing recurrent cumulative myocardial 
injury. Furthermore, this the studies contained within this thesis define 
the characteristics of conventional thrice weekly haemodialysis 
treatment that drive this process, and the longer term severe effects on 
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cardiac function and overall patient survival. All of the findings within it 
are consistent with recently published small scale, short term 
mechanistic studies of this phenomenon, confirming this process is 
related to dialysis induced changes in myocardial blood flow and can be 
abrogated acutely by modification of the dialysis technique. The findings 
of this thesis suggest several novel, potentially modifiable mechanisms 
related to the short and long-term effects of dialysis that are potentially 
implicated in the development of uraemic cardiomyopathy. It remains to 
be seen whether improving the haemodynamic tolerability of dialysis 
would be an effective intervention to reduce the development of heart 
failure in this patient group. 
9.1 Limitations 
The principle limitation of these results (aside from the limitations of 
each individual aspect which are mentioned above) is the use of 
echocardiography as the sole imaging technique for the detection of 
myocardial stunning. Echocardiography is the predominant technique 
used for evaluation of left ventricular function and for the assessment 
and quantification of valvular heart lesions and in conjunction with flow 
Doppler is well established as a safe, non-invasive, and versatile 
diagnostic modality. However, assessment of regional cardiac 
dysfunction at rest and during stress remains subjective and semi-
quantitative, with high inter-observer variability 207-209. 
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The limitations of the conventional echocardiographical evaluation of LV 
function have been attributed to its two-dimensional nature, which 
reveals only partial information about cardiac anatomy and function 
contained in specific cross sectional planes. Alternative techniques 
based on three-dimensional reconstruction from multiple two-
dimensional planes (as we have done) are time consuming and 
therefore not clinically practical. To minimise these factors, a single 
operator acquired all echocardiographical images to minimise inter-
observer variability. 
Cardiac magnetic resonance (CMR) imaging, whilst an extremely 
powerful tool for looking at myocardial structure and would have been 
superior in measuring indices such as LVMI and LVH as well as cardiac 
dimension. However, CMR is increasingly recognised as a less than 
ideal reference for LV functional measurements because of several 
limitations that include poor endocardial definition near the apex and the 
use of gadolinium as a contrast medium is now extremely limited in the 
CKD population. In any case, the use of intradialytic CMR would be 
impossible. However, the use of real-time three-dimensional 
echocardiography has been shown to be as accurate as using CMR 
images for measuring volumetric indices of regional LV function and for 
the detection of regional wall motion abnormalities 210 and this 
technique would be available to use during haemodialysis. Other more 
up-to-date forms of cardiac imaging include tissue Doppler and strain 
Doppler imaging which depict local myocardial motion and may enable 
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quantification of myocardial function and measurement of regional 
myocardial dysfunction 211,212.  
Unfortunately, we had no data pertaining to myocardial blood flow, 
coronary flow reserve or coronary artery anatomy in any significant 
number of the long term cohort of patients. The use of PET to assess 
these would have been impracticable and the use of non-routine 
angiography would have been a challenge both ethically and for the 
purposes of recruitment. Ideally, another surrogate marker for 
myocardial perfusion or coronary anatomy would have been used as 
angiographic data for coronary anatomy was only available for patients 
in the study investigating myocardial perfusion (chapter 4). High 
resolution CT scanning is available to image significant proximal 
coronary vessel lesions and two-dimensional speckle tracking is also 
validated for the detection of significantly diseased coronary arteries 
using altered diastolic deformation at rest 213. All of these techniques 
are becoming more widely available and would have made the results 
more robust. 
Unfortunately due to these factors, the observational nature of each of 
the studies and the lack of perfusion data for patients, we have 
extrapolated results that imply but do not implicitly prove myocardial 
stunning as the mechanism for long term injury. Whilst each of the 
steps outlined from one chapter to the next seems plausible the exact 
link remains unproven. However, the association with ischaemia, 
regional dysfunction and RWMA development is well established even if 
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the pathophysiological link with stunning and fibrosis remains 
controversial and efforts to reduce the mechanisms behind HD induced 
ischaemia should be a focus for future therapeutic targets. 
9.2 Future work 
This thesis explores the mechanisms, prevalence and consequences 
(both short and medium term) of haemodialysis induced myocardial 
stunning. However, there remain several unanswered questions. 
Further work is required to prove the underlying pathophysiological 
model that has been proposed. Although the concept of myocardial 
stunning (persistent myocardial dysfunction after a return to normal 
underlying blood flow) has been demonstrated in a small number of 
patients on HD, the effect of repetitive HD induced ischaemia and 
associated myocardial hibernation and fibrosis has yet to be 
scientifically proven. The results in this thesis show a deterioration that 
would fit with a progression along the continuum of stunning-
hibernation-fibrosis but in order for that link to be confirmed, prospective 
data would be needed to establish not only a reduction in function but 
also a corresponding reduction in myocardial blood flow. 
With regard to the potential effect of modifications to the dialysis 
process on short and long term outcomes, a number of issues remain. 
To examine whether cooled temperature and biofeedback dialysis 
techniques would have the same positive effects on a larger scale, 
further work is now needed to investigate if such measures translate to 
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improved long term outcomes. Using grant monies awarded from the 
British Renal Society based on these results, data is already being 
collected looking at the effects of isothermic dialysis on intradialytic 
haemodynamic tolerability and ventricular ectopy. This pilot work has 
been used to design a study looking at the long term benefits on 
outcome (including survival, cardiovascular event rate, left ventricular 
geometry and function, troponin-T concentrations amongst others) 
using these dialysis based techniques. 
The logistics of testing the hypothesis that longer dialysis regimes 
(either short daily or nocturnal dialysis) may improve outcome is difficult 
given the current pressures in haemodialysis units in the UK. However, 
despite this ethical approval has been granted for a collaborative study 
in the United States in a centre with an active daily dialysis programme 
to look at the positive associations of daily dialysis and improved 
haemodynamics, lower ultrafiltration requirements through smaller 
interdialytic weight gains and improved electrolyte homeostasis. 
Similarly, timely renal transplantation has been shown to improve 
cardiac function in previously dialysis dependent patients. There exists 
the possibility of the future follow up of this cohort of patients for a 
longer period of time to look at not only the progression of 
cardiovascular decline but also for potential improvements in donor 
recipients. 
Each of these may reveal mechanisms by which we can reduce acute 
haemodialysis induced cardiac injury. If so, then dialysis based 
interventions aimed at reducing the incidence and prevalence of 
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myocardial stunning may reduce the impact on the cardiovascular 
system and help to improve patient outcomes. 
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10 Abbreviations 
ACEi Angiotensin-II converting enzyme inhibitor 
ANOVA Analysis of variance 
APKD Adult polycystic disease 
ARB Angiotensin-II receptor blocker 
BD Twice daily 
BFD Biofeedback dialysis 
BNP Brain naturietic peptide 
BP Blood pressure 
BV Blood volume 
CAD Coronary artery disease 
CAPD Continuous ambulatory peritoneal dialysis 
CFR Coronary flow reserve 
CKD Chronic kidney disease 
CO Cardiac output 
COREC Central Office of Research Ethics Committees 
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CRP C-reactive protein 
cTnI cardiac troponin-I 
cTNT cardiac troponin-T 
CVA Complex ventricular arrhythmia 
Cx Circumflex 
DICOM Digital imaging and communication in medicine 
ECG Electrocardiograph 
EF Ejection fraction 
eGFR Estimated glomerular filtration rate 
ESRD End stage renal disease 
ETT Exercise tolerance test 
GFR Glomerular filtration rate 
GTN Glyceryl trinitrate 
Hct Haematocrit 
HD Haemodialysis 
HDF Haemodiafiltration 
HF Haemofiltration 
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hsCRP High sensitivity C-reactive protein 
HT Hypertension 
IDH Intradialytic hypotension 
IHD Ischaemic heart disease 
IL-6 Interleukin-6 
IQR Interquartile range 
ISMN Isosorbide mononitrate 
KDOQI Kidney Disease Outcomes Quality Initiative  
LMS Left main stem 
LV Left ventricular 
LVEF Left ventricular ejection fraction 
LVEFHD Left ventricular ejection fraction during haemodialysis 
LVEFrest Left ventricular ejection fraction at rest 
LVH Left ventricular hypertrophy 
LVMI Left ventricular mass index 
MAP Mean arterial pressure 
MBF Myocardial blood flow 
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MICS Malnutrition-inflammation complex syndrome  
NHANES National Health and Nutrition Examination Surveys  
NYHA New York Heart Association 
OD Once daily 
PC Personal computer 
PET Positron emission tomography 
pmp per million population 
PVC Premature ventricular complex 
RCA Right coronary artery 
RPP Rate pressure product 
RR Relative risk 
RRT Renal replacement therapy 
RWMA Regional wall motion abnormality 
SBP Systolic blood pressure 
SD Standard deviation 
SF Shortening fraction 
Sfmean Mean shortening fraction 
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SFWMA Shortening fraction of wall motion abnormality 
SPECT Single photon emission computed tomography 
SV Stroke volume 
TPR Total peripheral resistance 
UF Ultrafiltration 
US United States 
USRDS United States Renal Data System 
VE Ventricular ectopic 
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